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IN THE UTAH COURT OF APPEALS

HEIDI PETERSON on behalf
of MARKELLE FREI-PETERSON,
Petitioner and Appellant,
vs.

Case No. 98-0078-CA

UTAH DEPARTMENT OF HEALTH,
DIVISION OF HEALTH CARE
FINANCING,

Category No. 14

)

Respondent and Appellee.

i

BRIEF OF APPELLEE

JURISDICTION
In accordance with Rule 410-14-2, Utah Administrative Code,
a hearing requested by Petitioner Peterson was conducted as a
formal hearing before the Division of Health Care Financing.

The

provisions of Chapter 4 6b of Title 63, Utah Administrative
Procedures Act, are applicable ana pursuant to § 63-46b-16(l)
"all final agency action[s] resulting from formal adjudicative
proceedings" fall under the jurisdiction of either the Supreme
Court or the Court of Appeals.

In this instance, under § 78-2a-

3(2) (a), Utah Code Ann. (1997), the Court of Appeals has
appellate jurisdiction over this matter.
STATEMENT OF NATURE OF PROCEEDINGS BELOW
This appeal is taken from the Final Agency Order of the
Division of Health Care Financing (Division/DHCF) adopting the

Recommended Decision issued by the Administrative Law Judge
denying Medicaid funds for growth hormone to treat Markelle FreiPeterson for short bowel syndrome.

In the time leading up to the

administrative hearing, Markelle had received growth hormone for
a few months, paid for by Primary Children's Medical Center
charitable funds.

Her treating physician wanted to treat

Markelle for a period of time with the growth hormone, prompting
the request for Medicaid coverage.

The Division issued its

denial dated July 16, 1997, from which the petitioner sought a
hearing.

The hearing was conducted December 8, 1997, resulting

in the Recommended Agency Decision dated January 7, 1998.

The

Final Agency Order, adopting the Recommended Decision, was dated
January 15, 1998.

Petitionei timely filed her notice of appeal

with this court February 11, 1998.
STATEMENT OF THE ISSUE PRESENTED FOR REVIEW
Whether the use of growth normone to treat short-bowel
syndrome is properly categorj zed as experimental and therefore
properly denied coverage under the Medicaid program.
STANDARD OF REVIEW
In an instance requiring the reviewing court to consider a
mixed question of law and fact, the court will review the
question of law for correctness but apply some degree of
deference to the agency's determination in its application of the
law to the facts.

Drake

v.

Industrial

2

Commission,

939 P.2d 177,

181 (Utah 199*7) .

The degree of discretion granted to the agency

must be evaluated in light of the particular circumstances.

Some

reasons which support a broader grant of discretion are when (1)
the facts to which the rule are to be applied are "complex and
varying [and] no rule [would] adequately address the relevance of
all . . . [the] facts . . . ; (2) the matter to be decided is
sufficiently new that a reviewing court would not be able to
"anticipate and articulate definitively what factors should be
outcome determinative;" and (3) the witnesses' demeanor is
relevant and the record cannot adequately reflect those factors.
State

v.

Pena,

869 P.2d 932, 939 (Utah 1994).

The listing in

Pena is not exhaustive and additional factors would also be
considered under the particular situation of a specific case.
Given the nature of the legal rule and the grant of discretion
accorded the Division by statute to administer the Medicaid
program to meet the objectives, see

§ 26-18-3, Utah Code Ann.

(1995), this court should grant a degree of discretion to the
Division m
Drake,

its application of the rule to the set of facts.

939 P.2d at 182, citing Pena,

869 P.2d at 939.

Whether

the decision to deny Medicaid coverage for the Petitioner was
proper "is a mixed question of law and fact. [A] . . .
determination of the law is reviewed for correctness, while . . .
findings of fact are reviewed for clear error. [The agency's]
application of the law to the facts is reviewed for abuse of any

3

discretion granted the [agency] in applying the stated rule . . .
to the facts of the case."

Woodhaven

942 P.2d 918, 924, citing Pena,

Apartments

v.

Washington,

869 P.2d at 937.

DETERMINATIVE STATUTES AND RULES
1.

42 U.S.C. § 1396a(a)(5)

2.

42 U.S.C. § 1396(a) (10) (A)

3.

42 U.S.C. § 1396d(a)(4)(B)

4.

42 U.S.C. § 1396d(r)

5.

Utah Code Ann. §§ 26-18-3; 26-18-4

6.

Utah Administrative Code R414-1A-200

7.

Utah Administrative Code R414-1A-300

8.

Utah Administrative Code R414-10-6

9.

Utah Administrative Code R414-13x-l.(5)(a)
STATEMENT OF THE CASE
Appellant, Markelle Frei-Peterson, diagnosed with short

bowel syndrome, receives parenteral nutrition.

Her treating

physician wanted to try a regimen of growth hormone, hoping it
would induce increased function of the intestines thereby
reducing or eliminating parenteral nutrition.

The associated

problems of short bowel syndrome include the risk of central line
catheter infections, the loss of intravenous access sites, and,
potentially, liver dysfunction.

The Medicaid program requires

prior authorization for certain treatments, including the
treatment proposed for Markelle.

The application for Medicaid

coverage for the growth hormone was submitted to DHCF.

Upon the

initial review, the factors of the case did not meet the
applicable criteria.

Because the proposed use for the drug did

not meet: the usual criteria, additional documentation supporting
the use was requested from the physician.

The documentation

received was reviewed and submitted to the Check Utilization
Review Committee.
experimental.

The Committee determined the proposed use was

Accordingly, the Health Program Manager of the

Utilization Management staff in DHCF notified the parents of
Markelle that the request for growth hormone therapy was denied
on the basis the procedure was experimental.

The Notice of

Denial, dated July 16, 1997, included information of the right to
a hearing if the applicant for Medicaid disagreed with the
decision.

Thereafter, Appellant filed a request for hearing on

July 28, 1997.

During the time from the request for hearing to

the date the hearing was conducted on December 8, 1997, Markelle
received growth hormone therapy paid by charitable funds of the
Primary Children's Medical Center.

At the hearing, testimony was

presented by witnesses for Markelle and on behalf of DHCF as well
as documentation and exhibits in support of the parties'
positions.

Thereafter, the Administrative Law Judge made the

Recommended Decision to uphold DHCF's denial of Medicaid coverage
on the basis it was experimental.

This Decision dated January 7,

1998, was adopted as the Final Agency Order on January 15, 1998.
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STATEMENT OF FACTS
Markelle Frei-Peterson, at the time of the Formal Hearing in
December 1997, was described as a 24-month old child with short
bowel syndrome.

To briefly acquaint this court with the nature

of the condition, as described more fully in the articles
submitted by Markelle's physician and made a part of the formal
hearing record, it is a disorder characterized by "diarrhea,
dehydration, electrolyte disturbances, malabsorption, and
progressive malnutrition" resulting from "extensive loss or
dysfunction of the intestinal absorptive surface area."

The

severity "depends upon the length, location, and absorptive
function of the remaining bowel and its ability to accommodate
the reduced absorptive surface area."

Compensatory function can

occur; meanwhile, parenteral nutrition is often necessary.
Parenteral nutrition may be total (TPN) or partial and may be
temporary or permanent.-

Also at the time of the hearing,

Markelle received parenteral nutrition for approximately 90
percent of her needs (T-126-10):.

For perhaps the three- to

*This short definition is taken from Theresa A. Byrne, et

al.,
Growth Hormone, Glutamine,
Nutrient
Absorption
in Patients

and a Modified Diet Enhance
With Severe Short Bowel Syndrome,

Journal of Parenteral and Enteral Nutrition (1995) (R-41-47).
For additional description of the syndrome, articles submitted by
Petitioner's physician to DHCF and included in the record are
found at R-21 to 66.
References to the transcript of the formal hearing before
the Utah Department of Health, Division of Health Care Financing,
shall be designated by the initial "T"; references ro other
6

four-month period prior to the hearing, Markelle's enteral
feedings had been increasing but she remained dependent upon
parenteral nutrition.

(T-126-10, 11). One of the concerns

expressed by Markelle's physician, Dr. William D. Jackson, was
the condition of her liver because the syndrome is characterized
by progressive liver disease (T-126-31).

Liver tests in

approximately June 1997 showed some marked abnormalities which
subsequently normalized (T-126-19) independent of the growth
hormone therapy which had been initiated late in 1997 (T-126-29,
30).

The impetus to the growth hormone therapy was concern for

the potential of liver disease (T-126-31); however, the basic
objective of any treatment was to stimulate the ability of the
intestinal tract to tolerate increasing enteral nutrition, this
in turn providing the natural protection for the liver function.
(T-126-31).

At the time the growth hormone therapy was

considered, Markelle was having health problems necessitating
hospitalization and the liver tests with marked abnormalities
concerned Dr. Jackson.

A few things in her treatment were

changed in addition to adding growth hormone.

(T-126-19).

The

factors changed were not specified and were not definitively
related to any improvement in enteral feedings; the maturation
process may have played a role in adapting to increased enteral

portions of the record before the Division shall be designated by
the letter "R."
7

feeding or the growth hormone may have provoked a change.
126-19).

(T-

Markelle had begun to tolerate increasing enteral

feedings.

(T-126-19, 21). The progress in Markelle's condition

admittedly did not prove the efficacy of the therapy.

(T-126-

38) .
In addition to describing Markelle's condition, Dr. Jackson,
board certified in pediatrics and pediatric gastroenterology and
nutrition, made reference to recent articles on the topics of
short bowel syndrome and growth hormone studies published in
professional journals.

The studies reported were small and short

term, consisting of eight to 47 study patients in three- to fourweek trials.

(R-41; R-28; R-25).

Dr. Jackson referred to the

study results demonstrating some increased measures for
absorption and function, but over very short terms, with small
groups of adults.

(T-126-28).

This is an area of new therapy

generating active work and controversy.

(T-126-15, 16, 28).

Asked to comment on the therapy as experimental, Dr. Jackson
elaborated as follows:
I think there's a lot of therapies that we use that are
rightfully considered experimental which in terms of -if you think of it in terms of data being accumulated
and evaluating the efficacy, the appropriate dosage,
the appropriate indications, things like that. And
this one particularly as early a therapy as this is, as
young a therapy I guess as this is would definitely I
think have to be considered that.
(T-126-35).

Dr. Jackson's continuing testimony on this point

addressed his interpretation of his use of the growth hormone fcr
8

Markelle as not being an experiment in the strict sense inasmuch
as no protocol were being followed and a study of one patient
wouldn't constitute an experiment in his mind.

(T-126-35).

Dr.

Jackson likened his decision to the "art of medicine" wherein
available data is applied to a "desperate clinical situation" and
in "adding up pluses and minuses" a judgment is made which "could
be deemed erroneous by peers or other people," but on the other
hand other peers agree with trying this as a therapy.

He stated

that as Markelle's physician it was his "judgment . . . that [he]
would like to try this."

Further, he stated he had a certain

idea about its use but certainly did not have all the information
. . . and "we often don't in making practice decisions and making
clinical decisions. . . .

We don't know that this indeed is what

cured the patient or this indeed is what did anything."
36).

(T-126-

Further questioning elicited testimony that Markelle did

not have growth hormone deficiency.

(T-126-41).

The theory

presented was that growth hormone would be given to "stimulate
growth factor production in the body, including epidermal growth
factors, things like that work on the lining of the intestine to
stimulate growth."

Experimental animal studies in which

excessive amounts of growth hormone are given have produced
animals expressing hyperplasia (tumors) in the small bowel.
126-42).

(T-

The theory is to use the growth hormone as a

pharmacological agent to "actually stimulate the kind of growth

9

factors that would be required to try to make the small bowel
develop and grow more."
recognized.

(T-126-43).

No known level of dosage is

(T-126-43) .

Upon receipt of the request for Medicaid coverage for the
growth hormone, DHCF reviewed the information presented and
applied the applicable criteria; at this point Markelle did not
meet the criteria.

(T-126-47, 48). Specifically, Markelle did

not have documented failure of growth nor of insufficiency caused
by kidney failure.

(T-126-49).

The proposed use was not a

common use for the drug, therefore, DHCF requested additional
documentation, including any supporting literature, as well as
liver function tests, clinical records, parenteral and enteral
nutrition information.

(T-126-48).

This information was

reviewed and submitted to the Check Utilization Review Committee.
The Committee, composed of physicians, nurses, consultants,
social workers,

reviewed the documentation and

proposed was not typical but was experimental.

found the use
(T-126-48, 49).

The Notice of Decision denying Medicaid coverage stated it was
based on Utah Administrative Code R414-10-5, Physician's Covered
Services, wherein it provides that "[e]xperimental or medically
unproven physician services or procedures are excluded from
coverage."

(T-126-51).

Duane Park, a registered pharmacist with

a master's degree in health administration, testified on behalf
of DHCF concerning effective drug utilization as required by the

10

Medicaid law.

Mr. Park develops and coordinates the drug

utilization review process for the State as mandated by federal
law.

(T-126-52).
Dr. John Hylen testified on behalf of DHCF.

He stated he

had a doctorate in medicine, a master's degree in public health,
and was board certified in internal, cardiovascular, and
geriatric medicine.

Dr. Hylen's statements reiterated issues

raised previously and particularly indicated his concerns that
growth hormone used as proposed had not yet been proven effective
in preventing liver disease nor were data available concerning
toxicities for children.

Dr. Hylen's testimony centered on

concerns that since side effects were unknown, its efficacy in
preventing progressive liver disease or the need for a liver
transplantation remained undocumented, and it is an expensive
medication and alternative cost-effective means exist to address
the nutritional concerns, that he found many unanswered questions
weighed against the therapy.

(T-126-60, 61).

SUMMARY OP THE ARGUMENT
At issue is the proposed use of a drug, humatrope, a
recombinant human growth hormone, to stimulate gastrointestinal
function for a child suffering from short bowel syndrome.

Under

applicable Medicaid rules, the drug is approved for use under
circumstances where a person is deficient in the growth hormone.
The Appellant Markelle has no growth hormone deficiency.

11

Rather,

her treating physician proposes to use growth hormone in the hope
it will stimulate gastrointestinal function.

However, the use

proposed in the instant case is considered experimental.

Under

Medicaid law, coverage is not permitted for experimental
procedures.

This approach is justifiable because the Medicaid

program's objectives are not directed toward research.

In

compliance with federal law, Utah, by its designated agency
charged with the efficient and effective administration of the
Medicaid program, has established rules addressing Medicaid
payment policy for experimental or unproven medical practices and
treatments.
The agency has defined an "experimental or unproven medical
practice" as one

not proven medically efficacious.

Medically

efficacious practices have been determined effective and widely
utilized as a standard practice.

These practices are approved as

a covered Medicaid service on the basis of medical necessity.
Proven effective treatments widely utilized are covered services
when medically necessary.

The determination of medically

necessary is a proper exercise of agency discretion.

A medically

necessary service must be reasonably calculated to effectively
address the patient's situation.

This entails a consideration of

the treatment for its preventive, diagnostic or curative use for
the patient's condition as well as for its effectiveness and
suitability.

12

The Division has essentially defined "necessary treatment"
as used in the Medicaid Act to exclude experimental treatments.
This is a valid interpretation by the Division fulfilling its
role in meeting the objectives of the Act.

Absent proven

effectiveness for a treatment necessary for the patient's medical
condition, the Division reasonably may deny funds.
ARGUMENT
POINT I:
THE MEDICAID PROGRAM, A COOPERATIVE FEDERAL-STATE
ENDEAVOR, CREATED TO ASSIST PARTICIPATING STATES BY
PROVIDING FEDERAL FINANCIAL ASSISTANCE, PROVIDES
MEDICAL ASSISTANCE TO NEEDY INDIVIDUALS WHO ARE
ELIGIBLE UNDER THE STATE'S APPROVED PLAN.
In 1965 Congress established the Medicaid program by
enacting Title XIX of the Social Security Act.

The program is a

cooperative federal-state endeavor by which federal grants are
paid to states enabling them to provide medical assistance to
persons otherwise unable to pay for necessary medical care.
Although Medicaid is entirely optional, once a state elects to
participate, the state must comply with all the federal statutory
and regulatory requirements.

Harris

100 S.Ct. 2671, 2680 (1980).

Participating states must have a

State plan approved by the Secretary.

v.

McRae,

448 U.S. 297, 301,

See 42 U.S.C. § 1396.

single agency must be selected to administer the plan.
U.S.C. § 1396a(a)(5).

A

See 42

Although states must comply with the

federal requirements, they retain broad discretion in determining
13

which medical services will be covered under their plans.
However, to qualify for federal funds the state plan must include
the seven mandatory medical services referenced at 42 U.S.C. §
1396a (a) (10) (A), which include inpatient hospital services,
various outpatient hospital services, laboratory and X-ray
services, specified nursing facility services, early and periodic
screening, diagnostic, and treatment services for eligible
individuals under 21, (42 U.S.C. § 1396d(r)) various physician
services, nurse-midwife services, and services of certified
pediatric or family nurse practitioners.

42 U.S.C. §

1396d(a)(4)(B).
Utah is a participating Medicaid state having opted to
participate by adopting the Medical Assistance Act in 1981.
Utah Code Ann. §§ 26-18-1 to -11 (1995 and Supp. 1997).

See

Having

opted into the federally created medical assistance program, Utah
assumes complete administration of its program.

Utah designated

the Division of Health Care Financing as the single
administrative agency for the state.

As the designated agency,

the Division is responsible for administering the Medicaid
program m

accordance with federal and state law.

The Utah

legislature granted the Division broad authority to develop
standards and to develop and administer policies in implementing
the state's plan.

Utah Code Ann. §§ 26-18-3(2), -4(1) (1995).

Utah has complied with federal requirements by creating a state

14

Medicaid plan which has received approval by the Secretary of
Health and Human Services.

Utah Admin. Code R414-1-4.

A.
A state's medical assistance plan must be
consistent with the objectives of Title XIX; the plan
must employ reasonable standards for determining
eligibility for and extent of medical assistance.
Title XIX's overarching objective is to enable participating
states, "as far as practicable, to furnish medical assistance to
individuals whose income and resources are insufficient to meet
the costs

of necessary medical services."

2366, 2371, 432 U.S. 438 (1977^.

Beal

v.

Doe,

97 S.Ct.

Title XIX does not specify

particular medical procedures to be provided; although
participating states must provide financial assistance for five
(the Medicaid statute now mandates seven categories) broad
categories of medical treatment, states are not required to fund
every medical procedure falling within the general categories.
Indeed, the statute expressly provides: "A State plan
for medical assistance must . . . include reasonable
standards . . . for determining eligibility for and the
extent of medical assistance under the plan which . . .
are consistent with the objectives of this [Title]. . .
." 42 U.S.C. § 1396a(a)(17) (1970 ed., Supp. V ) .
Beal

v.

Doe,

97 S.Ct. at 2370-71; A.M.L.

v.

Department

of

Health,

863 P.2d 44, 47 (Utah App. 1993).
To retain the integrity of the program, each participating
state must submit and receive approval for its state plan.
However, receiving approval does not mean the state plan is
minutely managed by federal oversight.

15

In fact, the Beal

Court

goes on to state, "[t]his language confers broad discretion on
the States to adopt standards for determining the extent of
medical assistance, requiring only that such standards be
^reasonable' and ^consistent with the objectives' of the Act."
Bealr

97 S.Ct. at 2371.
B.
Utah's standards of eligibility and coverage are
reasonable and in conformance with the objectives of
the Act.
In conformance with Title XIX and by the authority granted

under § 26-18-3(2), Utah Code Ann. (1995), Utah's designated
Medicaid office has established standards enabling the Division
to administer its Medicaid program.

The specific standards

applicable to this case provide in pertinent part:
R414-1A-300.

Policy.

(1) Experimental or unproven medical practices are not
covered Medicaid services.
(2) Division staff and physician consultants shall
establish criteria to determine whether a service or
procedure is a covered Medicaid service.
(3) Procedures or services proven to be medically
efficacious for specific medical conditions may be provided
as covered Medicaid services only for the conditions
specified.
Such procedures or services are not covered for
any other conditions or for experimental trials
The issue before this court concerns DHCF's denial of Medicaid
coverage for an experimental use of a drug.

The policy excludes

experimental or unproven medical practices; it does not exclude
procedures or services proven to be medically efficacious.
Furthermore, the criteria applied to a given situation is the
result of the combined efforts of Division staff and physician
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consultants.

This is an important issue on which the agency

should be permitted broad discretion to fashion rules which
promote the objectives of the Medicaid program.

Medicaid was not

created to promote research for new treatments.

In fact, using

the population of Medicaid-covered individuals as a potential
pool of research subjects would raise public policy and ethics
concerns.

This population of persons is already vulnerable

because of lack of sufficient personal funds to obtain needed
medical services.

While the concept of public funding of medical

research is not a foreign or repugnant one, it would be
unacceptable to combine the dual purpose of needed medical
treatment and experimental medical treatment within the single
program of Medicaid.

The Medicaid program is not a research

program.
In addition to the rule establishing the Medicaid payment
policy for experimental or unproven medical practices, the agency
has by rule defined certain terms which govern the agency in its
assessment of the set of facts applicable to the particular
individual.

The definitions established by rule provide in

pertinent part:
R414-1A-2 00.
Definitions.
(1) Terms used in this rule [R414-1A. Medicaid Policy
for Experimental or Unproven Medical Practices.] are defined
in R414-1-1.
(2) In addition:
(a) "experimental or unproven medical practice"
means any procedure, medication product, or service
that is:
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(i) not proven to be medically efficacious
for a given procedure; or
(ii) performed for or in support of purposes
of research, experimentation, or testing of new
processes or products; or
(iii) both;
(b) "medically efficacious" means a medical
practice that:
(i) has been determined effective and is
widely utilized as a standard medical practice for
specific conditions; and
(ii) has been approved as a covered Medicaid
service by division staff and physician
consultants on the basis of medical necessity, as
defined in R414-13x-l.(5)(a),. . . .
When determining the application of "experimental medical
practice" to the facts of the case, the question of "medical
necessity" may arise because of the specific circumstances.

A

service is "medically necessary" if it is:
(1) reasonably calculated to prevent, diagnose, or cure
conditions in the recipient that endanger life, cause
suffering or pain, cause physical deformity or
malfunction or threaten to cause a handicap; and
(2) there is no other equally effective course of
treatment available or suitable for the recipient . . .
which is more conservative or substantially less
costly.
Utah Admin. Code R414-13x-l.(5)(a).
Under both the Medicaid Act and Utah law, the Division has
been granted discretion to establish and implement a program
designed to furnish medical assistance within the scope and
intent of the law.
those objectives.

The Division has designed a program to meet
Nothing in federal or state law prevents the

state from denying coverage for medical practices or services
which do not satisfy reasonable criteria designed to achieve the
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program's objectives.

As the Beal

Court noted, u[a]lthough

serious statutory questions might be presented if a state
Medicaid plan excluded necessary medical treatment from its
coverage, it is hardly inconsistent with the objectives of the
Act for a State to refuse to fund unnecessary
desirable

medical services."

Beal,

though perhaps

97 S.Ct. at 2371.

The

terminology of "unnecessary" is not precisely the correct
question in the instant case.
in Beal

Rather, the reference to the quote

helps clarify the determination in this case.

The

agency's decision denied the request because the proposed use was
experimental.

The medical procedure is unproven; and without a

certain quantum of reliable authority establishing a procedure's
safety and effectiveness, the agency is justified in exercising
its discretion not to fund a questionable medical service.
POINT II:
UTAH'S STANDARD GOVERNING EXPERIMENTAL
MEDICAL PRACTICES IS REASONABLE AND AS
APPLIED TO THE FACTS OF THE CASE WAS A
REASONABLE EXERCISE OF AGENCY DISCRETION.
The rule applied in this case denied Medicaid coverage for
an experimental use of growth hormone to treat short bowel
syndrome.

In essence, if the practice or service is determined

experimental, then it has not been proven medically efficacious
for that purpose.

In Rush

v.

Parham,

625 F.2d 1150, 1156 (5th

Cir. 1980), that court had occasion to consider the question
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presented when applying the standard of experimental within the
definition of medically necessary services.

The case concerned a

request for transsexual surgery and presented that court with the
problem of whether the Georgia Medicaid program's definition of
medically necessary services could exclude experimental
treatments.

The court concluded that it was a valid exercise of

the agency's discretion to exclude experimental treatments.

Its

support was found in a letter Medicare3 uses to explain why
certain services are ineligible for reimbursement.

The

supportive information contained in the opinion at footnote 11
states:
The clearest articulation of the considerations
that go into determining whether a particular service
is experimental is found in a letter Medicare uses to
explain to its clients and providers why a service is
ineligible for reimbursement:
In making such a decision [whether to provide
payment for a particular service], a basic
consideration is whether the service has come to be
generally accepted by the professional medical
community as an effective and proven treatment for the
condition for which it is being used. If it is,
Medicare may make payment. On the other hand, if the
service or treatment is not yet generally accepted, is
rarely used, novel or relatively unknown, then
authoritative evidence must be obtained that it is safe
and effective before Medicaid may make payment.
Enclosure # 2 to Intermediary Letters Nos. 77-4 & 77-5,

3

The Medicare program, which is administered directly by the
federal government on a nationwide basis, shares similarities
with the Medicaid program, including the relationship between the
private physician and the federal government wherein the
physician's judgment plays a central role yet the physician must
operate within the reasonable limits established by the state.
20

[1976 Transfer Binder] Medicare & Medicaid Guide (CCH)
1 28,152 (1976).
Rush

v.

Parnam,

625 F.2d at 1156 n. 11.

Following Rush,

the question of experimental treatment has

been considered in a variety of settings, not all of which
actually turn on the application of that standard to the facts of
the case.

A number of cases cited by Appellant as having

followed -Rush's lead on this point are, in fact, distinguishable.
In Weaver

v.

Reagan,

886 F.2d 194 (8th Cir. 1989), a class

of Medicaid-eligible individuals were denied coverage for AZT to
treat their AIDS.

The Missouri Department of Social Services

defended their action claiming the coverage was limited to only
those patients whose condition met the FDA labeling statement
and, secondarily, any use outside the labeling statement was
se experimental.

per

Not only did an FDA bulletin refute the

Department's position with respect to the controlling nature of
the labeling statement, out the Weaver

court applying the Rusn

definition found the use of AZT beyona the labeled uses was not
experimental masmucn as it was commonly prescribed for the use
requested by plaintiffs and was generally accepted in the medical
community as an effective treatment.

In sum, Missouri's action

was arbitrary since the rule created an irrebuttable presumption.
Such is not the case with Utah's standard which takes into
consideration factors such as acceptance in the medical community
as an efficacious treatment.
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In Montoya

v.

Johnston,

654 F.Supp. 511 (W.D.Tex. 1987), the

Texas Department of Human Services placed a cap of $50,000 on the
amount Medicaid would pay for inpatient hospital services during
any 12-month period.

This effectively precluded the liver

transplants, costing approximately $200,000, sought by two young
children otherwise eligible for Medicaid.

In support of the

request, the children's physicians submitted affidavits stating
that liver transplants were not considered experimental.
Additionally, the court found the Texas Medicaid cap was
arbitrary and unreasonable.

The cap was contrary to Medicaid

regulations which prohibit restrictions which "arbitrarily deny
or reduce the amount, duration or scope of a required service . .
. to an otherwise eligible recipient solely because of the
diagnosis, type of illness or condition." Montoya
654 F.Supp. at 513.

While the Montoya

v.

Johnston,

court cited to Rush

the definition of experimental treatment, the facts of
distinguish it from the instant case.

and

Montoya

Appellant Markelle did nor

come up against an arbitrary cap or restriction nor did the
evidence submitted state unequivocally the procedure was not
experimental.

Rather, the contrary situation exists in that

there is no unequivocal statement that the use of growth hormone
for the use requested is not experimental.
In Miller

by Miller

v.

Whitburn,

10 F.3d 1315 (7th Cir.

1993), the issue of experimental is framed in a somewhat
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different manner.

The question decided was that the district

court could review Wisconsin's Department of Health and Social
Services' definition of experimental to ensure it complied with
federal mandates that standards applied by states be reasonable.
The court took care to reiterate that states retained significant
discretion in deciding which treatments to cover.

The actual

determination of whether the liver-bowel transplantation at issue
was covered by Medicaid remained to be considered.

The court

noted the record did not contain facts addressing matters such as
efficacy or the opinion of the medical community.
Rush,

the Miller

In citing to

court cited the definition of experimental in

its entirety; it then made further comments on the term.
stated

It

x>

[c]learly, the best indicator that a procedure is

experimental is its rejection by the professional medical
community as an unproven treatment."
Whitburn,

10 F.3d at 1320.

Miller

by Miller

v.

This would be correct if the

scientific studies had been properly conducted and confirmed the
conclusion the treatment was worthless.

As it stands, it perhaps

states too much until the confirming results; therefore, it is of
dubious use in analyzing the instant matter.
the Miller

However, further on

court states that "certain procedures may be so new

and . . . relatively unknown, that the medical community may not
yet have formed an opinion as to their efficacy."
Miller

v.

Whitburn,

Id.

Miller

The court then stated "[i]f
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'authoritative evidence' exists that attests to a procedure's
safety and effectiveness, it is not ^experimental.'" Miller
Miller

v.

Whitburn,

Id.

by

Taken together these statements indicate

that experimental determinations

require authoritative evidence

establishing safety and effectiveness.

Therefore, DHCF's

determination in the present case is reasonable if the same
factors are applied.
And, finally, in McLaughlin

v.

Will ia.iu.Sf 801 F.Supp. 633

(S.D. Fla. 1992), the court considered Florida's denial of
Medicaid for a liver-small bowel transplantation because it was
deemed experimental.
Rush

The definition of experimental found in

was applied as binding precedent as the McLaughlin

court

considered a possibly fatal situation and so the court found
useful the determination that a relatively new procedure can be
found medically necessary if "authoritative evidence" established
it was "safe and effective."
at 639, citing from Rush.

McLaughlin

v.

Williams,

801 F.Supp.

Of concern to the court were factors

of safety and effectiveness where new procedures are considered.
Risks and benefits must be balanced.

Rapid medical advances made

determinations difficult and rigid standards applied by the state
compounded the problem.

The court identified in some detail that

"simple demarcation" was not a workable means of defining
experimental.

McLaughlin

v.

Williams,

801 F.Supp. at 638-40.

Such is not the case in the instant matter.
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The standard applied

by DHCF permits evaluation of the effectiveness of the procedure
and its utilization in the medical community along with the
physician's determination of medical necessity.

Appellant argues

that DHCF's definition of experimental should include specific
demarcation to define "how widely used" a practice should be to
avoid the same fate as the court identified in McLaughlin.

In

point of fact, this would not benefit the decision making
process.

In these cases the Division needs to be able to

exercise its discretion so that a reasoned and reasonable
decision is made.
The Recommended Decision, adopted as the Final Agency Order,
(R-109-114), sets forth the decision to deny on the basis of
experimental treatments not being covered by Medicaid.

In her

findings, the administrative law judge (ALJ) identified
Markelle's diagnosis and prior and current condition.

She also

identified the proposed treatment as still controversial
notwithstanding a number of reputable physicians were motivated
to prescribe the treatment.

She also alluded to the fact growth

hormone was not included in the package labeling statement.

The

record transcript and exhibits and submitted articles when taken
as a whole justify the ALJ's conclusion even though the findings
are somewhat cursory.

Further, the reasoning given by the ALJ

identifies those additional factors necessary to support the
conclusion.

Of importance is the recognition that the testimony
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does not refute the experimental nature of the treatment and that
it remains controversial.

(R-113).

Also, while the ALJ writes

"Dr. Jackson made compelling arguments for the medical necessity
of using growth hormone" (R-113), that is not the same as stating
he established the medical necessity.

A careful reading of the

transcript and the recommended decision shows the ALJ did not
reject the treating physician's testimony.

Her decision weighed

all the evidence and finding the treatment remained controversial
even by Dr. Jackson's own testimony gave reason and credibility
to the decision.

Frey

v.

Bowen,

816 F.2d 508 (10th Cir. 1987).

In fact, nowhere in the record does Dr. Jackson unequivocally
state the treatment is medically necessary.
Even assuming the Division has applied the wrong standard to
the facts of this matter, Appellant's position is not supported
upon a review of the entire record.

Assuming the review standard

applied by Appellant is to succeed in claiming that the ALJ's
decision should fail for lack of sufficient evidence, Appellant
must marshall all the evidence presented and show that
notwithstanding the evidence contrary to the decision there is
insufficient evidence to adequately support the conclusion.
A.M.L.

v.

Department

Tax Comm'n of

Utah,

of

Health,

863 P.2d at 46-47; Zissi

842 P.2d 848, 852-53 (Utah 1992).

v.

State

The record

as a whole provides sufficient evidence which a reasonable person
could accept as adequate to support the conclusion reached by the
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administrative law Judge.

Appellant's position is that even if

the procedure is not widely utilized as a standard medical
practice, novel or relatively unknown procedures can be found
medically necessary if authoritative evidence shows the treatment
is safe and effective.

Appellant claims the authoritative

evidence to be relied upon in this case is the "testimony of Dr.
Jackson, together with extensive medical literature" (Appellant's
Br. at 20). Appellant's summary of Dr. Jackson's testimony
identifies eight points as determinative.
indicated" use of the drug]

Point 1: ["higher

While using a drug to possibly save

a life could reasonably be classified as a "higher indication"
for the drug than its approved use for short statured persons,
this does not equate with effectiveness.

Point 2: [cost

effective alternative] While the limited data suggests growth
hormone treatment costs

less than either TPN or a liver

transplant, the critical factor is whether the drug effectively
eliminates or prevents either of the alternative treatments and
the attendant costs; and, the evidence does not establish that
fact.

(T-126-26, 27, 29-31). Point 3: [studies by "mainstream"

professionals supporting use] While Dr. Jackson testified the
proposed use found support among "mainstream" professionals, the
fact remains that these studies describe limited trials which
remain in the investigational stage and are still controversial.
(T-126-27-28) .

Point 4: [short-term studies show some increase
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in absorption and amino acid uptake] While study trial results
may show some of the hoped-for benefits, the results obtained
suggested to those conducting the trials that additional trials
should be undertaken to determine effectiveness.
37-38).

(R-25, 28-29,

Point 5: [apparent improvement in Markelle's enteral

nutrition while taking growth hormone]

While testimony indicated

some increased ability to tolerate oral feedings, Dr. Jackson
testified he could not tie that change to any treatment and it
could be the result of the maturation process.

(T-126-18, 19).

Point 6: [use of growth hormone reasonably calculated to prevent
death, improve quality of life] While Dr. Jackson did testify
that his goals with respect to the use of growth hormone would be
to achieve the definitional elements contained in the "medically
necessary" rule read at the hearing, he further testified that it
was a new therapy, still controversial and it may not turn out to
be effective.

(T-126-26). Point 7: [growth hormone would lessen

suffering] While eliminating the need for TPN would also
eliminate suffering caused by infections, and so forth, this
would only occur if the treatment proved safe and effective and
in fact eliminated the parenteral nutrition; that was one of Dr.
Jackson's goals but that is different than stating the proposed
experimental use will achieve that goal.

Point 8: [no

alternative treatment for less cost] Assuming the proposed growth
hormone treatment worked as hoped and was of limited duration,
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the testimony supports this conclusion.

As further testimony

indicates, Markelle receives TPN which is expensive; however, her
oral feedings have increased.

(T-126-18).

Four published studies, previously referred to generally,
were submitted at the time of the administrative hearing; and,
unfortunately and inexplicably, the literature had not been
received for the Division's medical expert to review and comment
upon during testimony.

Whether this legitimately constitutes

extensive, authoritative evidence which proves safety and
effectiveness is questionable.

If Appellant's standard should

apply, one question to be addressed is what constitutes
authoritative evidence.

It is not unreasonable to require a

certain quantum of such evidence such that a person would
reasonably believe it established the safety and effectiveness of
the experimental procedure.
the proposed standard.

Are these studies sufficient to meet

The studies submitted for support contain

statements of reservation and these reservations are acknowledged
by Dr. Jackson in his testimony.

The studies state their initial

results suggest a potential alternative treatment and therefore
further trials are required to determine matters such as timing,
dosage, combinations for optimal effect, and safety and
effectiveness.

The studies were very small and conducted over

very short periods of time using adult subjects.

One reference

is made to a group of 12 children having received treatment (R-
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17); however, the details of treatment and results are limited
and cannot reasonably justify finding the treatment proposed for
Markelle is not experimental.

The study size and duration,

participant composition, and multiple factors (growth hormone,
glutamine and specialized diet) administered to the participants
in the clinical trials combine to raise significant concerns
justifying the Division's decision.

Since the elements of the

proposed standard of "safe and effective" require a factual
analysis, this should be left to the agency's discretion and the
reviewing court should grant deference to the agency's expertise.
CONCLUSION
The Medicaid program is a publicly funded program designed
to assist individuals who lack sufficient funds to obtain needed
medical services.

Since it is a public program, it must function

according to rules and regulations to ensure efficient and
effective use of limited resources.
considered a research program.

Medicaid never has been

While new, evolving treatments in

medical research are anticipated, it is unacceptable to
contemplate using a vulnerable population as potential research
subjects.

To protect both the individuals needing the Medicaid

services necessary and appropriate to the specific condition and
the integrity of the Medicaid program, the Division should have
policies in place to prevent unintended as well as intended
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abuses.

It is entirely appropriate for the Division to exclude

experimental medical services.
The agency's application of the rule to the facts of the
case resulted in a final agency order denying Medicaid coverage
for an experimental treatment.

In reviewing the record as a

whole, and in the absence of an abuse of the discretion granted
the agency to establish and administer the State's Medicaid
program, the agency's decision is reasonable and should be
affirmed.
Respectfully submitted this

day of June, 1998.
JAN GRAHAM
Attorney General/
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288 North 1460 West
Box 142901
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Executive Director
DIVISION OF HEALTH
CARE FINANCING

Michael J. Deily
Division Director

MARKELLE FREI-PETERSON
Petitioner
FINAL AGENCY ORDER
Case No. 97-209-11

vs.
UTAH DEPARTMENT OF HEALTH
DIVISION OF HEALTH CARE FINANCING,
Respondent.

IF YOU ARE NOT SATISFIED WITH THIS DECISION, YOU MAY REQUEST A
RECONSIDERATION FROM THE DIRECTOR OF HEALTH CARE FINANCING
WITHIN TWENTY (20) DAYS AFTER THIS DECISION IS SIGNED. IF YOU WOULD
LIKE TO APPEAL THIS DECISION, YOU MAY FILE A PETITION IN THE UTAH
COURT OF APPEALS WITHIN THIRTY (30) DAYS AFTER THIS DECISION IS
SIGNED. IF YOU DECIDE TO APPEAL, YOU ARE NOT REQUIRED TO ASK FOR A
RECONSIDERATION FIRST, BUT YOU MAY DO SO IF YOU WISH. IF YOU HAVE
QUESTIONS, CALL (801) 538-6576.
The enclosed Recommended Decision has been reviewed pursuant to Section 63-46b-12
Utah Code Ann. 1953, as amended, entitled "Agency Review - Procedure," and Department
of Health Administrative Rule R410-14, entitled "Division of Health Care Financing
Administrative Hearing Procedures for Medicaid/UMAP Applicants, Recipients, and
Providers."
I hereby adopt Recommended Decision No. 97-209-11 in its entirety.
RIGHT TO JUDICIAL REVIEW
Within twenty (20) days after the date that this Final Agency Order is issued, you may file a
written request for reconsideration with the Director of the Division of Health Care Financing.
Any request for reconsideration must state the specific grounds upon which relief is requested.
The filing of such a request is not a prerequisite for seeking judicial review.
Judicial review may be secured by filing a petition in the Utah Court of Appeals within thirty
(30) days of the issuance of this Final Agency Action or, if a request for reconsideration is

ihC\

filed and denied, within thirty (30) days of the denial for reconsideration. The petition shall
be served upon the Director of Health Care Financing and shall state the specific grounds upon
which review is sought. Failure to file such a petition within the 30-day time limit may
constitute a waiver of any right to appeal the Final Agency Order.
A copy of this Final Agency Order shall be sent to Petitioner or representative at the last
known address by certified mail, return receipt requested.

DATED this

/r

day of January 1998

BY:
Michael Deily, D
lare Financing
Division of Heal
UTAH DEPAR' 1ENT OF HEALTH
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BEFORE THE UTAH DEPARTMENT OF HEALTH
DIVISION OF HEALTH CARE FINANCING
STATE OF UTAH

MARKELLE FREI-PETERSON
Petitioner,
RECOMMENDED DECISION
vs.
UTAH DEPARTMENT OF HEALTH
DIVISION OF HEALTH CARE
FINANCING,
Respondent.

Case No. 97-209-11
Margaret J. Clark
Administrative Law Judge

Pursuant to Rule R410-14 of the Utah Department of Health and the Utah Administrative
Hearing Procedures Act, Title 63, Chapter 46b, Utah Code Annotated, 1953, as amended, a
formal administrative hearing for the above captioned case was held on December 8, 1997, at
8:00 a.m., in Room 344, Cannon Health Building, 288 North 1460 West, Salt Lake City,
Utah 84116, Margaret J. Clark, Administrative Law Judge, presiding. Daniel Jackson, M.D.,
testified on behalf of the petitioner. The petitioner's mother was present at the hearing. Steven
Gatzemeier represented the Division of Health Care Financing ("DHCF"). John C. Hylen,
M.D., and Duane Parke testified on behalf of DHCF.

ISSUE
SHOULD UTAH MEDICAID COVER GROWTH HORMONE TO TREAT SHORT
BOWEL SYNDROME FOR MARKELLE FREI-PETERSON?

FINDINGS OF FACT
1. Markelle Frei-Peterson is approximately twenty four months old, suffers from short bowel
syndrome, and is dependent on parenteral nutrition for approximately 90% of her nutritional
needs.
2. In the past three or four months she has begun to tolerate some oral feedings, but remains
dependent on parenteral nutrition.
3. Short bowel syndrome requires expensive technology and possibly a lifetime of parenteral
nutrition.
4. The goal of Markelle's treating physician is to accelerate her gastrointestinal adaptation
by administering the growth hormone for about one year.
5. Because she has short bowel syndrome, Markelle is at risk of central line catheter
infections, eventual loss of intravenous access sites, and progressive liver dysfunction.
6. Markelle has been receiving growth hormone for approximately three months. The
hormone has been supplied by a Primary Children's Hospital charity.
7. Usage of growth hormone for short bowel syndrome is considered an "off-label" use by the
Federal Food and Drug Administration.
8. The data is sufficient to motivate a number of reputable physicians to prescribe growth
hormone for short bowel syndrome, but it is still considered to be controversial.

RECOMMENDED CONCLUSIONS OF LAW
The use of growth hormone to treat small bowel syndrome is "experimental" as defined in:
Utah Administrative Code R414-1A-200, and is therefore not covered by Utah Medicaid [see
R414-1A-300(1)].

REASONS FOR PRESIDING OFFICER'S DECISION
DHCF denied reimbursement for growth hormone for Markelle because it contended that the
drug is experimental for usage in treating short bowel syndrome, and it has not been approved
by the Federal Drug Administration for that purpose.
DHCF's policy regarding experimental or unproven medical practices is contained in Utah
Administrative Code R410A. R410A-300 states in relevant part:
(1) Experimental or unproven medical practices are not covered Medicaid

services.
R410A-200 defines "experimental or unproven medical practice" as "(2)(i) not proven to be
medically efficacious for a given procedure." "Medically efficacious" is defined in R410-1A200(iii)(b) as "a medical practice that has been determined effective and is widely utilized as a
standard medical practice for specific conditions."
W. Daniel Jackson , M.D., Markelle's treating physician testified on her behalf. Dr.
Jackson is board certified in pediatrics and pediatric gastroenterology and nutrition. He is an
Assistant Professor of Pediatrics at the University of Utah School of Medicine, and Medical
Director of Nutrition Support Services at Primary Children's Hospital.
Dr. Jackson testified that growth hormone for short bowel syndrome is being used by a
number of reputable physicians in the United States. He testified that it was controversial, but
it had promise.
Dr. Jackson testified that growth hormone is commonly used in many children to treat short
stature, and since Medicaid covers the drug for that use, it should also cover its usage for
short bowel syndrome, which he believes has a "higher indication."
Dr. Jackson made compelling arguments for the medical necessity of using growth hormone
for Markelle. He testified that he thought that use of growth hormone in this case would be a
cost effective approach when compared to the potential cost of lifetime parental nutrition or
liver transplantation, both of which could result from small bowel syndrome. He testified
that more conservative approaches to treat Markelle were not successful, and as her treating
physician, he had weighted the pluses and minuses of using the growth hormone.
Dr. Jackson testified that the impetus for trying the growth hormone was the fact that Markelle
was showing signs of accelerated liver disease. Upon cross examination, John C. Hylen,
M.D., and Physician Consultant for DHCF asked Dr. Jackson if he could provide
documentation of whether or not Markelle's liver function had normalized as a result of
receiving the growth hormone. Dr. Jackson replied that he did not know why her liver
functions had improved, but he thought that it had normalized "independent of growth
hormone." He testified that Markelle had improved after receiving growth hormone, but that
improvement could also have come from the maturation process and the oral feedings Markelle
has recently begun to tolerate.
Dr. Jackson conceded that the use of growth hormone for short bowel syndrome is an area
where there is active work and controversy, and, "The indications are not in your code for
using it this way."
As the expert witness for the moving party, the burden of proof was on Dr. Jackson to prove
by the preponderance of the evidence that the growth hormone should be covered. Despite his
convincing testimony regarding the medical necessity of using the drug for Markelle, he was
not able to overcome DHCF's evidence that the use of growth hormone to treat short bowel
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syndrome is an off-label usage of the drug, and it has not yet been proven to be effective for
that usage. Although treatment of short bowel syndrome with growth hormone might be more
highly indicated than its usage for children of short stature, the law prohibits the use of
experimental treatments, and Dr. Jackson's testimony clearly indicated that the use of growth
hormone to treat short bowel syndrome was not "widely utilized as a standard medical
practice," and therefore meets the criteria for an "experimental procedure."

RECOMMENDED AGENCY ACTION
I recommend that DHCF's action be UPHELD.

RIGHT TO REVIEW
This Recommended Decision will be automatically reviewed by the Department of Health,
Division of Health Care Financing, prior to its release. Both the Recommended Decision and
a Final Agency Action, which represent the results of that review, will be released
simultaneously by the Department of Health, Division of Health Care Financing.
DATED this

7

day of January 1998

Ma*g£fct J. Cttrk
Administrative Law Judge

The following exhibits were admitted into evidence:
RESPONDENT'S EXHIBIT 1: Off-Label Drug Policy
PETITIONER'S EXHIBIT 1: Medical Literature Regarding Short Bowel Syndrome and
Growth Hormone
PETITIONER'S EXHIBIT 2: Billing Records for Markelle

No: 97-209-11
CERTIFICATE OF MAILING
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day of January 1998,1 mailed a true and correct copy of
the foregoing FINAL AGENCY ORDER AND RECOMMENDED DECISION, to the following parties:
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SALT LAKE CITY, UTAH 84113-1100
EVY SMITH, PEDIATRIC CONTINUUM CARE MANAGER
IHC ACCESS
MEMORIAL CLINIC
20 T H SOUTH 900 EAST
SALT LAKE CITY, UTAH 84105
JULIE RICH
IHC HOME CARE
MCKAY-DEE HOSPITAL CENTER
P. O. BOX 9370
OGDEN, UTAH 84409-9980
INTER-DEPARTMENTAL MAIL
STEVE GATZEMEJER
HEALTH PROGRAM MANAGER
COVERAGE & REIMBURSEMENT POLICY
DIVISION OF HEALTH CARE FINANCING
UTAH DEPARTMENT OF HEALTH

MICHAEL DEILY, DIRECTOR
DIVISION OF HEALTH CARE FINANCING
UTAH DEPARTMENT OF HEALTH

DR. JOHN HYLEN
COVERAGE & REIMBURSEMENT POLICY
DIVISION OF HEALTH CARE FINANCING
UTAH DEPARTMENT OF HEALTH
PENNI NAHLEY
COVERAGE & REIMBURSEMENT POLICY
DIVISION OF HEALTH CARE FINANCING
UTAH DEPARTMENT OF HEALTH

CHRIS SMITH

DUANE PARKE
COVERAGE & REIMBURSEMENT POLICY
DIVISION OF HEALTH CARE FINANCING
UTAH DEPARTMENT OF HEALTH
*
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Note 2
When state voluntarily elects to participate m
Medicaid program, it must comply with requirements of the Act and applicable regulations.
& ? J ; ^ £ t l H ^ d W * ^
Idaho 1991,813 P.2d 345,120 Idaho d.
3. Eligibility
Omnibus Budget Reconciliation Act does not
prevent otherwise eligible pregnant women who
are not permanently residing in this country
under color of Uw (PRUCOL) from receiving
M^d
^^red j ^ ^ ^ ^ where ^r
^ U ^ ^ c t ^ ^ l i ^ t ' G ^
CA2 (NT.) 1992.965 F2A1206.

State and federal regulations arbitrarily and1
capriciously limited to $1,500 the automobile eleelusion m calculating family resources for purPoses of eligibility for Aid to Families with
Dependent Children (AFDC) and Medicaid in
that reason initially offered for automobile asset
limitation, in allowing recipients to retain pos*
session of a car, could no longer provide rational
basis for the regulation in light of inflation, even
though Congress did not mandate review to
^mt
g^^
for mflation
Hazard v
S J « « F % U » » - l l :
F
** 899-

§ 1396a. State plans for medical assistance
(a) Contents
A State plan for medical assistance must—
(1) provide that it shall be in effect in all political subdivisions of the State, and, if
administered by them, be mandatory upon them;
(2) provide for financial participation by the State equal to not less than 40 per
centum of the non-Federal share of the expenditures under the plan with respect to
which payments under section 1396b of this title are authorized by this subchapter;
and, effective July 1, 1969, provide for financial participation by the State equal to
all of such non-Federal share or provide for distribution of funds from Federal or
State sources, for carrying out the State plan, on an equalization or other basis
which will assure that the lack of adequate funds from local sources will not result
in lowering the amount, duration, scope, or quality of care and services available
under the plan;
(3) provide for granting an opportunity for a fair hearing before the State agency
to any individual whose claim for medical assistance under the plan is denied or is
not acted upon with reasonable promptness;
(4) provide (A) such methods of administration (including methods relating to the
establishment and maintenance of personnel standards on a merit basis, except that
the Secretary shall exercise no authority with respect to the selection, tenure of
office, and compensation of any individual employed in accordance with such
methods, and including provision for utilization of professional medical personnel in
the administration and, where administered locally, supervision of administration of
the plan) as are found by the Secretary to be necessary for the proper and efficient
operation of the plan, (B) for the training and effective use of paid subprofessionai
staff, with particular emphasis on the full-time or part-time employment of recipients and other persons of low income, as community service aides, in the administration of the plan and for the use of nonpaid or partially paid volunteers in a social
service volunteer program in providing services to applicants and recipients and in
assisting any advisory committees established by the State agency, and (C) that
each State or local officer or employee who is responsible for the expenditure of
substantial amounts of funds under the State plan, each individual who formerly
was such an officer or employee, and each partner of such an officer or employee
shall be prohibited from committing any act, in relation to any activity under the
plan, the commission of which, in connection with any activity concerning the United
States Government, by an officer or employee of the United States Government, an
individual who was such an officer or employee, or a partner of such an officer or
employee is prohibited by section 207 or 208 of Title 18;
(5) either provide for the establishment or designation of a single State agency to
administer or to supervise the administration of the plan; or provide for the
establishment or designation of a single State agency to administer or to supervise
the administration of the plan, except that the determination of eligibility for
medical assistance under the plan shall be made by the State or local agency
administering the State plan approved under subchapter I or XVI of this chapter
(insofar as it relates to the aged) if the State is eligible to participate in the State
plan program established under subchapter XVI of this chapter, or by the agency
or agencies ad^ninistering the supplemental security income program established
under subchapter XVI or the State plan approved under part A of subchapter IV of
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this chapter if the State is not eligible to participate in the State plan program
established under subchapter XVI of this chapter;
(6) provide that the State agency will make such reports, in such form and
containing such information, as the Secretary may from time to time require, and
comply with such provisions as the Secretary may from time to time find necessary
to assure the correctness and verification of such reports;
(7) provide 3afeguards which restrict the use or disclosure of information concerning applicants and recipients to purposes directly connected with the administration of the plan;
(8) provide that all individuals wishing to make application for medical assistance
under the plan shall have opportunity to do so, and that such assistance shall be
furnished with reasonable promptness to all eligible individuals;
(9) provide—
(A) that the State health agency, or other appropriate State medical agency
(whichever is utilized by the Secretary for the purpose specified in the first
sentence of section 1395aa(a) of this title), shall be responsible for establishing
and mamtaining health standards for private or public institutions in which
recipients of medical assistance under the plan may receive care or services,
(B) for the establishment or designation of a State authority or authorities
which shall be responsible for establishing and mamtaining standards, other
than those relating to health, for such institutions, and
(C) that any laboratory services paid for under such plan must be provided
by a laboratory which meets the applicable requirements of section 1395x(e)(9)
of this title or paragraphs (13) and (14) l of section 1395x(s) of this title, or, in
the case of a laboratory which is in a rural health clinic, of section
1395x(aaX2)(G) of this title;
(10) provide—
(A) for making medical assistance available, including at least the care and
services listed in paragraphs (1) through (5), (17) and (21) of section 1396d(a) of
this title, to—
(i) all individuals—
(I) who are receiving aid or assistance under any plan of the State
approved under subchapter I, X, XIV, or XVI of this chapter, or part
A or part E of subchapter IV of this chapter (including individuals
eligible under this subchapter by reason of section 602(a)(37), 606(h),
or 673(b) of this title, or considered by the State to be receiving such
aid as authorized under section 682(e)(6) of this title),
(II) with respect to whom supplemental security income benefits
are being paid under subchapter XVI of this chapter or who are
qualified severely impaired individuals (as defined in section 1396d(q)
of this title),
(HI) who are qualified pregnant women or children as defined in
section 1396d(n) of this title,
(IV) who are described in subparagraph (A) or (B) of subsection
(I )(1) of this section and whose family income does not exceed the
minimum income level the State is required to establish under subsection (I )(2)(A) of this section for such a family;1
(V) who are qualified family members as defined in section
1396d(m)(l) of this title;1
(VI) who are described in subparagraph (C) of subsection (I )(1) of
this section and whose family income does not exceed the income level
the State is required to establish under subsection (I )(2)(B) of this
section for such a family, or
(VII) who are described in subparagraph (D) of subsection (Z )(1) of
this section and whose family income does not exceed the income level
the State is required to establish under subsection (I )(2)(C) of this
section for such a family;
(ii) at the option of the State, to any group or groups of individuals
described in section 1396d(a) of this title (or, in the case of individuals
described in section 1396d(a)(i) of this title, to any reasonable categories of
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Note 32
Undocumented alien whose chronic alcoholism
had so compromised her liver and central nervous system before she appeared at hospital
that lack of immediate medical attention would
not have resulted in more serious jeopardy to
her health did not possess "emergency medical
condition," such that would be eligible for assistance under Medical Care and Assistance Program. Norwood Hosp. v. Commissioner of Public Welfare, Mass.1994, 627 N.E.2d 914, 417
Mass. 64.
Statute which states that Medicaid payment
shall be made for care and services to alien
who is not lawfully admitted for permanent
residence, only if such care and services are
necessary for treatment of emergency medical
condition and alien otherwise meets eligibility
requirements for medical assistance of a State
plan, is exception to rule that prohibits Medicaid not only to nonresident aliens, but also to
resident aliens whose residency is unlawful; it
does not affect status of nonresident aliens.
Salem Hosp. v. Commiasioner of Public Welfare, Mass. 1991. 574 N.E.2d 385, 410 Mass.
625.
33. Relief from judgment or order
State of New York was entitled to relief from
consent decree establishing Medicaid pharmacy
reimbursement methodology, where Secretary
of Health and Human Services had subsequently
established reimbursement cap on Medicaid reimbursements for certain denned medications,
creating risk that state would lose federal financial participation if it did not comply. Pharmaceutical Soc of the State of New York, Inc. v.
§ 1396c.

Cuomo, S.D.N.Y.1991, 774 F.Supp. 826, affirmed
in part, reversed in part 981 F.2d 632.
34. Similarly situated individuals—Generally
Under federal Medicaid statute pursuant to
which federal payment for organ transplant will
not be made unless state plan provides for written standards and such standards provide that
similarly situated individuals are treated alike,
"similarly situated" means all patients who can
be treated effectively by same organ transplant
procedure. Salgado v. Kirschner, Ariz.1994,878
P.2d 659, 179 Ariz. 301, certiorari denied 115
a c t 1102,130 L.EcL2d 1069.
35.
Other necessary services
Provision of state Medicaid plan that allowed
state to deny life-sustaining over transplant coverage to otherwise eligible Medicaid recipient
solely because she was over 21 years of age.
violated requirement of federal Medicaid statute
that state standards for organ transplants treat
similarly situated individuals alike; recipient
was within class of all patients who could be
treated effectively by liver transplant, and catchall provision of Medicaid statute dealing with
federal early and periodic health screening diagnostic and treatment services (EPSDT) did not,
as state apparently contended, define substantive scope of medically necessary procedures
and draw distinction for such procedures between children and adults. Salgado v. Kirschner, Ariz.1994, 878 PJ2d 659, 179 Ariz. 301,
certiorari denied 115 S.Ct 1102, 130 L.EA2d
1069.

Operation of State plans

NOTES OF DECISIONS
compliance with federal Medicaid requirements
is discretionary. Phoenix Baptist Hosp. and
Decision of Secretary of Health and Human
Medical Center, Inc. v. UJS., CA9 (Ariz.) 1991,
Services (HHS) as to whether to hold hearing on 937F.2d452.
9. Hearing

§ 1396d.

Definitions

For purposes of this subchapter—
(a) Medical assistance
The term 'inedical assistance" means payment, of part or all of the cost of the
following care and services (if provided in or after the third month before the month in
which the recipient makes application for assistance or, in the case of medicare costsharing with respect to a qualified medicare beneficiary described in subsection (p)(l) of
this section, if provided after the month in which the individual becomes such a
beneficiary) for individuals, and, with respect to physicians, or dentists' services, at the
option of the State, to individuals (other than individuals with respect to whom there is
being paid, or who are eligible, or would be eligible if they were not in a medical
institution, to have paid with respect to them a State supplementary payment and are
eligible for medical assistance equal in amount, duration, and scope to the medical
assistance made available to individuals described in section 1396a(a)(10)(A) of this title)
not receiving aid or assistance under any plan of tfie State approved under subchapter I,
X, XIV, or XVI, or part A of subchapter IV, and with respect to whom supplemental
security income benefits are not being paid under subchapter XVI of this chapter, who
are—
(i) under the age of 21, or, at the option of the State, under the age of 20, 19, or
18 as the State may choose,
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(ii) relatives specified in section 606(b)(1) of this title with whom a child is living
if such child is (or would, if needy, be) a dependent child under part A of subchapter
IV of this chapter,
(iii) 65 years of age or older,
(iv) blind, with respect to States eligible to participate in the State plan program
established under subchapter XVI of this chapter,
(v) 18 years of age or older and permanently and totally disabled, with respect to
States eligible to participate in the State plan program established under subchapter XVI of this chapter,
(vi) persons essential (as described in the second sentence of this subsection) to
individuals receiving aid or assistance under State plans approved under subchapter
I, X, XTV, or XVI of this chapter,
(vii) blind or disabled as defined in section 1382c of this title, with respect to
States not eligible to participate in the State plan program established under
subchapter XVI of this chapter,
(viii) pregnant women,
(ix) individuals provided extended benefits under section 1396r-6 of this title,
(x) individuals described in section 1396a(u)(l) of this title, or
(xi) individuals described in section 1396a(z)(l) of this title,
but whose income and resources are insufficient to meet all of such cost—
(1) inpatient hospital services (other than services in an institution for mental
diseases);
(2) (A) outpatient hospital services, (B) consistent with State law permitting such
services, rural health clinic services (as defined in subsection (I )(1) of this section)
and any other ambulatory services which are offered by a rural health clinic (as
defined in subsection (I )(1) of this section) and which are otherwise included in the
plan, and (C) Federally-qualified health center services (as defined in subsection
(I )(2) of this section) and any other ambulatory services offered by a Federallyqualified health center and which are otherwise included in the plan;
(3) other laboratory and X-ray services;
(4) (A) nursing facility services (other than services in an institution for mental
diseases) for individuals 21 years of age or older; (B) early and periodic screening,
diagnostic, and treatment services (as defined in subsection (r) of this section) for
individuals who are eligible under the plan and are under the age of 21; and (C)
family planning services and supplies furnished (directly or under arrangements
with others) to individuals of child-bearing age (including minors who can be
considered to be sexually active) who are eligible under the State plan and who
desire such services and supplies;
(5) (A) physicians' services furnished by a physician (as defined in se<!tion
1395x(r)(l) of this title), whether furnished in the office, the patient's home, a
hospital, or a nursing facility, or elsewhere, and (B) medical and surgical services
furnished by a dentist (described in section 1395x(r)(2) of this title) to the extent
such services may be performed under State law either by a doctor of medicine or
by a doctor of dental surgery or dental medicine and would be described in clause
(A) if furnished by a physician (as defined in section 1395x(r)(l) of this title);
(6) medical care, or any other type of remedial care recognized under State law,
furnished by licensed practitioners within the scope of their practice as defined by
State law;
(7) home health care services;
(8) private duty nursing services;
(9) clinic services furnished by or under the direction of a physician, without
regard to whether the clinic itself is administered by a physician, including such
services furnished outside the clinic by clinic personnel to an eligible individual who
does not reside in a permanent dwelling or does not have a fixed home or mailing
address;
(10) dental services;
(11) physical therapy and related services;
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(12) prescribed drugs, dentures, and prosthetic devices; and eyeglasses prescribed by a physician skilled in diseases of the eye or by an optometrist, whichever
the individual may select;
(13) other diagnostic, screening, preventive, and rehabilitative services, including
any medical or remedial services (provided in a facility, a home, or other setting)
recommended by a physician or other licensed practitioner of the healing arts
within the scope of their practice under State law, for the maximum reduction of
physical or mental disability and restoration of an individual to the best possible
functional level;
(14) inpatient hospital services and nursing facility services for individuals 66
years of age or o"er in an institution for mental diseases;
(15) services in an intermediate care facility for the mentally retarded (other
than in an institution for mental diseases) for individuals who are determined, in
accordance*with section 1396a(a)(31)(A) of this title, to be in need of such care;
(16) effective January 1,1973, inpatient psychiatric hospital services for individuals under age 21, as defined in subsection (h) of this section;
(17) services furnished by a nurse-midwife (as defined in section 1395x(gg) of this
title) which the nurse-midwife is legally authorized to perform under State law (or
the State regulatory mechanism provided by State law), whether or not the nursemidwife is under the supervision of, or associated with, a physician or other health
care provider, and without regard to whether or not the services are performed in
the area of management of the care of mothers and babies throughout the
maternity cycle;
(18) hospice care (as defined in subsection (o) of this section);
(19) case-management services (as defined in section 1396n(g)(2) of this title) and
TB-related services described in section 1396a(z)(2)(F) of this title;
(20) respiratory care services (as defined in section 1396a(e)(9)(C) of this title);
(21) services furnished by a certified pediatric nurse practitioner or certified
family nurse practitioner (as defined by the Secretary) which the certified pediatric
nurse practitioner or certified family nurse practitioner is legally authorized to
perform under State law (or the State regulatory mechanism provided by State
law), whether or not the certified pediatric nurse practitioner or certified family
nurse practitioner is under the supervision of, or associated with, a physician or
other health care provider;
(22) home and community care (to the extent allowed and as defined in section
1396t of this title) for functionally disabled elderly individuals; and
(23) community supported living arrangements services (to the extent allowed
and as defined in section 1396u of this title);
(24) personal care services furnished to an individual who is not an inpatient or
resident of a hospital, nursing facility, intermediate care facility for the mentally
retarded, or institution for mental disease that are (A) authorized for the individual
by a physician in accordance with a plan of treatment or (at the option of the State)
otherwise authorized for the individual in accordance with a service plan approved
by the State, (B) provided by an individual who is qualified to provide such services
and who is not a member of the individual's family, and (C) furnished in a home or
other location; and
(25) any other medical care, and any other type of remedial care recognized
under State law, specified by the Secretary.
except as otherwise provided in paragraph (16), such term does not include—
(A) any such payments with respect to care or services for any individual who is
an inmate of a public institution (except as a patient in a medical institution); or
(B) any such payments with respect to care or services for any individual who
has not attained 65 years of age and who is a patient in an institution for mental
diseases.
For purposes of clause (vi) of the preceding sentence, a person shall be considered
essential to another individual if such person is the spouse of and is living with such
individual, the needs of such person are taken into account in determining the amount of
aid or assistance furnished to such individual (under a State plan approved under
subchapter I, X, XTV, or XVI of this chapter), and such person is determined, under
such a State plan, to be essential to the well-being of such individual. The payment
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In the case of any State which is providing medical assistance to its residents under a
waiver granted under section 1315 of this title, the Secretary shall require the State to
meet the requirement of section 1396a(a)(10)(E) of this title in the same manner as the
State would be required to meet such requirement if the State had in effect a plan
approved under this subchapter.
(q) Qualified severely impaired individual
The term "qualified severely impaired individual" means an individual under age 65—
(1) who for the month preceding the first month to which this subsection applies
to such individual—
(A) receded (i) a payment of supplemental security income benefits under
section 1382(b) of this title on the basis of blindness or disability, (ii) a
supplementary payment under section 1382e of this title or under section 212 of
Public Law 93-66 on such basis, (iii) a payment of monthly benefits under
section 1382h(a) of this title, or (iv) a supplementary payment under section
1382e(c)(3) of this tide, and
(B) was eligible for medical assistance under the State plan approved under
this subchapter; and
(2) with respect to whom the Commissioner of Social Security determines that—
(A) the individual continues to be blind or continues to have the disabling
physical or mental impairment on the basis of which he was found to be under
a disability and, except for his earnings, continues to meet all non-disabilityrelated requirements for eligibility for benefits under subchapter XVI of this
chapter,
(B) the income of such individual would not, except for his earnings, be
equal to or in excess of the amount which would cause him to be ineligible for
payments under section 1382(b) of this title (if he were otherwise eligible for
such payments),
(C) the lack of eligibility for benefits under this subchapter would seriously
inhibit his ability to continue or obtain employment, and
(D) the individual's earnings are not sufficient to allow him to provide for
himself a reasonable equivalent of the benefits under subchapter XVI of this
chapter (including any federally administered State supplementary payments)*
this subchapter, and publicly funded attendant care services (including personal
care assistance) that would be available to him in the absence of such earnings.
In the case of an individual who is eligible for medical assistance pursuant to section
1382h(b) of this title in June, 1987, the individual shall be a qualified severely impaired
individual for so long as such individual meets the requirements of paragraph (2).'
(r) Early and periodic screening, diagnostic, and treatment services
The term "early and periodic screening, diagnostic, and treatment services" means the
following items and services:
(1) Screening services—
(A) which are provided—
(i) at intervals which meet reasonable standards of medical and dental
practice, as determined by the State after consultation with recognized
medical and dental organizations involved in child health care and, with
respect to immunizations under subparagraph (B)(iii), in accordance with
the schedule referred to in section 1396s(c)(2)(B)(i) of this title for pediatric
vaccines, and
(ii) at such other intervals, indicated as medically necessary, to determine the existence of certain physical or mental illnesses or conditions;
and
(B) which shall at a niinimum include—
(i) a comprehensive health and developmental history (including assessment of both physical and mental health development),
(ii) a comprehensive unclothed physical exam,
(iii) appropriate immunizations (according to the schedule referred to in
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(iv) laboratory tests (including lead blood level assessment appropriate
for age and risk factors), and
(v) health education (including anticipatory guidance).
(2) Vision services—
(A) which are provided—
(i) at intervals which meet reasonable standards of medical practice, as
determined by the State after consultation with recognized medical organizations involved in child health care, and
(ii) at such other intervals, indicated as medically necessary, to determine th? existence of a suspected illness or condition; and
(B) which shall at a minimum include diagnosis and treatment for defects in
vision, including eyeglasses.
(3) Dental services—
(A) which are provided—
(i) at intervals which meet reasonable standards of dental practice, as
determined by the State after consultation with recognized dental organizations involved in child health care, and
(ii) at such other intervals, indicated as medically necessary, to determine the existence of a suspected illness or condition; and
(B) which shall at a minimum include relief of pain and infections, restoration of teeth, and maintenance of dental health.
(4) Hearing services—
(A) which are provided—
(i) at intervals which meet reasonable standards of medical practice, as
determined by the State after consultation with recognized medical organizations involved in child health care, and
(ii) at such other intervals, indicated as medically necessary, to determine the existence of a suspected illness or condition; and
(B) which shall at a minimum include diagnosis and treatment for defects in
hearing, including hearing aids.
(5) Such other necessary health care, diagnostic services, treatment, and other
measures described in subsection (a) of this section to correct or ameliorate defects
and physical and mental illnesses and conditions discovered by the screening
services, whether or not such services are covered under the State plan.
Nothing in this subchapter shall be construed as limiting providers of early and periodic
screening, diagnostic, and treatment services to providers who are qualified to provide
all of the items and services described in the previous sentence or as preventing a
provider that is qualified under the plan to furnish one or more (but not all) of such
items or services from being qualified to provide such items and services as part of early
and periodic screening, diagnostic, and treatment services. The Secretary shall, not
later than July 1, 1990, and every 12 months thereafter, develop and set annual
participation goals for each State for participation of individuals who are covered under
the State plan under this subchapter in early and periodic screening, diagnostic, and
treatment services.
(s) Qualified disabled and working individual
The term "qualified disabled and working individual" means an individual—
(1) who is entitled to enroll for hospital insurance benefits under part A of
subchapter XVIII of this chapter under section 1395i-2a of this title;
(2) whose income (as determined under section 1382a of this title for purposes of
the supplemental security income program) does not exceed 200 percent of the
official poverty line (as defined by the Office of Management and Budget and
revised annually in accordance with section 9902(2) of this title) applicable to a
family of the size involved;
(3) whose resources (as determined under section 1382b of this title for purposes
of the supplemental security income program) do not exceed twice the maximum
amount of resources that an individual or a couple (in the case of an individual with
a spouse) may have and obtain benefits for supplemental security income benefits
under subchapter XVI of this chapter; and

237

MEDICAL ASSISTANCE ACT

26-18-3

(c) mandatory outpatient, rather than inpatient, surgery in appropriate
cases;
(d) second surgical opinions;
(e) procedures for encouraging the use of outpatient services;
(f) coordination of benefits; and
(g) review and exclusion of providers who are not cost effective or who
have abused the Medicaid program, in accordance with the procedures and
provisions of federal law and regulation.
(3) The director of the division shall periodically assess the cost effectiveness and health impUcations of the existing Medicaid program, and consider
alternative approaches to the provision of covered health and medical services
through the Medicaid program, in order to reduce unnecessary or unreasonable utilization.
History: C. 1953, 26-18-2.3, enacted by L.
1988, ch. 21, § 4.
Federal Law. — Title XIX of the federal

Social Security Act, cited in Subsection (1), is
compiled as 42 U.S.C. § 1396 et seq.

NOTES TO DECISIONS
ANALYSIS

Discretion of division.
Resource preservation.
Discretion of division.
The legislature has, by virtue of Subsection
(1), explicitly granted the Division of Health
Care Financing (DHCF) discretion to establish
criteria concerning medical reimbursement.
When a hospital failed to submit a physician
certification before admission of a Medicaideligible patient and never obtained physician
recertification at any time during the patient's
three-month stay in acute care, the DHCF
reasonably denied reimbursement to the hospital. South Davis Community Hosp. v. Department of Health, 860 R2d 979 (Utah Ct. App.
1994).

Resource preservation.
Utah does not have a "resource spend down*
provision in its Medicaid plan, nor any statement of policy expressing a desire to preserve
the resources of potential beneficiaries. Utah's
statutes seem to evince a legislative concern for
economy and efficiency in the Medicaid program, not the preservation of applicants' assets.
Allen v. Utah Dep't of Health, 829 R2d 122
(Utah Ct. App. 1992), affd, 850 P.2d 1267 (Utah
1993).
It is not unreasonable for the division to
apply a fixed asset limit forbidding persons to
adjust their assets to become eligible for Medicaid benefits. Allen v. Utah Dep't of Health, 850
P.2d 1267 (Utah 1993).

26-18-3. Administration of Medicaid program by department — Disciplinary measures and sanctions —
Funds collected.
(1) The department shall be the single state agency responsible for the
administration of the Medicaid program in connection with the United States
Department of Health and Human Services pursuant to Title XIX of the Social
Security Act.
(2) The department shall develop implementing policy in conformity with
this chapter, the requirements of Title XIX, and applicable ^federal regulations.
(3) The department may, in its discretion, contract with the Department of
Human Services or other qualified agencies for services in connection with the
administration of the Medicaid program, including but not limited to the
determination of the eligibility of individuals for the program, recovery of
overpayments, and enforcement of fraud and abuse laws to the extent
permitted by law and quality control services.
141
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(4) The department shall provide, by rule, disciplinary measures and
sanctions for Medicaid providers who fail to comply with the rules and
procedures of the program, provided that sanctions imposed administratively
may not extend beyond:
(a) termination from the program;
(b) recovery of claim reimbursements incorrectly paid; and
(c) those specified in Section 1919 of Title XIX of the federal Social
Security Act.
(5) Funds collected as a result of a sanction imposed under Section 1919 of
Title XIX of the federal Social Security Act shall be deposited in the General
Fund as nonlapsing dedicated credits to be used by the division in accordance
with the requirements of that section.
History: C. 1953, 26-18-3, enacted by L.
1981, ch. 126, § 17; 1988, ch. 21, § 5; 1989,
ch. 165, § 1; 1990, ch. 183, § 9.
Federal Law. — Title XDC of the federal

Social Security Act is compiled as 42 U.S.C.
§ 1396 et seq. Section 1919 of Title XDC is 42
U.S.C. § 1396r.

NOTES TO DECISIONS
ANALYSIS

ent. By these standards, a child's temporary
absence from home will not qualify him or her
for benefits independent of parental resources.
Bleazard v. Utah Dep't of Health Care Fin., 861
P.2d 1048 (Utah Ct. App. 1993).

Children.
_
,
,
r
—Tempoi
Temporary absence from home.
Federal law.

Children
Federal law.
—Temporary absence from home.
Medicaid is not intended to provide benefits
Federal law requires that eligibility for "med- to the medically needy in circumstances where
ically needy" Medicaid benefits be determined financial need is not fully demonstrated and
consistently with the methods of the Aid to where benefits would be inconsistent with reFamilies with Dependent Children program quirements for the higher priority classification
and the Supplemental Security Income Pro- of the categorically needy. Bleazard v. Utah
gram. In the case of an unemancipated child, Dep't of Health Care Fin., 861 P.2d 1048 (Utah
resources include those available from a par- Ct. App. 1993).
COLLATERAL REFERENCES
C.J.S. — 81 C.J.S. Social Security and Public
Welfare § 126.

26-18-3.1.

Key Numbers. — Social Security and Public
Welfare «=» 241 et seq.

Medicaid e x p a n s i o n .

(1) The purpose of this section is to expand the coverage of the Medicaid
program to persons who are in categories traditionally not served by that
program.
(2) Within appropriations from the Legislature, the department may amend
the state plan for medical assistance to provide for eligibility for Medicaid:
(a) on or after July 1, 1994, for children 12 to 17 years old who live in
households below the federal poverty income guideline; and
(b) on or after July 1, 1995, for persons who have incomes below the
federal poverty income guideline and who are aged, blind, or disabled.
(3) (a) Within appropriations from the Legislature, on or after July 1,1996,
the Medicaid program may provide for eligibility for persons who have
incomes below the federal poverty income guideline.
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26-18-5

26-18-4. Department standards for eligibility under Medicaid — Funds for abortions.
(1) The department may develop standards and administer policies relating
to eligibility under the Medicaid program. An applicant receiving Medicaid
assistance may be limited to particular types of care or services or to payment
of part or all costs of care determined to be medically necessary.
(2) The department shall not provide any funds for medical, hospital, or
other medical expenditures or medical services to otherwise eligible persons
where the purpose of the assistance is to perform an abortion, unless the life
of the mother would be endangered if an abortion were not performed.
(3) Any employee of the department who authorizes payment for an abortion contrary to the provisions of this section is guilty of a class B misdemeanor
and subject to forfeiture of office.
(4) Any person or organization that, under the guise of other medical
treatment, provides an abortion under auspices of the Medicaid program is
guilty of a third degree felony and subject to forfeiture of license to practice
medicine or authority to provide medical services and treatment.
History: C. 1953, 26-18-4, enacted by L.
1981, ch. 126, § 17; 1987, ch. 181, § 2.
Cross-References. — Sentencing for felo-

nies, §§ 76-3-201, 76-3-203. 76-3-301.
Sentencing for misdemeanors, §§ 76-3-201,
76-3-204, 76-3-301.
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Standards for eligibility.

Federal law.
Standards for eligibility.
—Temporary absence from home.
Federal law.
Medicaid is not intended to provide benefits
to the medically needy in circumstances where
financial need is not fully demonstrated and
where benefits would be inconsistent with requirements for the higher priority classification
of the categorically needy. Bleazard v. Utah
Dep't of Health Care Fin., 861 R2d 1048 (Utah
Ct. App. 1993).

—Temporary absence from home.
Federal law requires that eligibility for "medically needy" Medicaid benefits be determined
consistently with the Aid to Families with Dependent Children program and the Supplemental Security Income Program. In the case of an
unemancipated child, resources include those
available from a parent. By these standards, a
child's temporary absence from home will not
qualify him or her for benefits independent of
parental resources. Bleazard v. Utah Dep't of
Health Care Fin., 861 P.2d 1048 (Utah Ct. App.
1993).

26-18-5. Contracts for provision of medical services —
Federal provisions modifying department rules
— Compliance with Social Security Act.
(1) The department may contract with other public or private agencies to
purchase or provide medical services in connection with the programs of the
division. Where these programs are used by other state agencies, contracts
shall provide that other state agencies transfer the state matching funds to the
department in amounts sufficient to satisfy needs of the specified program.
(2) All contracts for the provision or purchase of medical services shall be
established on the basis of the state's fiscal year and shall remain uniform
during the fiscal year insofar as possible. Contract terms shall include
provisions for maintenance, administration, and service costs.
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HEALTH

another state, to the same extent t h a t Medicaid is
furnished to residents in the state.
R414-1-19. R e t r o a c t i v e C o v e r a g e .
Individuals are entitled to Medicaid services under t h e plan during the three months preceding the
month of application, if they were, or would have
been, eligible at t h a t time.
R414-1-20. F r e e d o m of C h o i c e of P r o v i d e r .
Unless an exception under 42 CFR 431.55 applies,
any individual eligible under the plan may obtain
Medicaid services from any institution, pharmacy,
person, or organization t h a t is qualified to perform
the services and has entered into a Medicaid provider contract, including an organization t h a t provides these services or arranges for their availability
on a prepayment basis.
R414-1-21. A v a i l a b i l i t y of P r o g r a m M a n u a l s
and Policy Issuances.
Program m a n u a l s and other policy issuances t h a t
affect recipients, providers and the public, including
the Medicaid agency's rules governing eligibility,
need and amount of assistance, recipient rights and
responsibilities, and services offered by the agency
are maintained in the state office and in each local
and district office for examination and, upon request, are available to individuals for review, study,
or reproduction. All requirements of 42 CFR 431.18
are met.
R414-1-22. G e n e r a l R u l e Format.
(1) The following format is used generally
throughout the rules of the Division. Section headings as indicated and the following general definitions thereunder are for guidance only. The section
headings are not part of the rule content itself. In
certain instances, such format may not be appropriate and will not be implemented due to the n a t u r e of
the subject m a t t e r of a specific rule.
(a) Policy Statement. A concise statement as to
what Medicaid service is covered by the rule.
(b) Authority. A listing of specific federal statutes
and regulations and state statutes t h a t authorize or
require the rule.
(c) Definitions. Definitions that have special
meaning to the particular rule.
(d) Client Eligibility. Categories of Medicaid clients eligible for the service covered by the rule:
Categorically Needy or Medically Needy or both.
Conditions precedent to the client's obtaining coverage such as age limitations or otherwise.
(e) Program Access Requirements. Conditions precedent external to the client's obtaining service such
as type of certification needed from attending physician, whether available only in an inpatient setting or otherwise.
(f) Service Coverage. Detail of specific services
available under t h e rule, including limitations such
as number of procedures in a given period of time or
otherwise.
(g) Prior Authorization. As necessary, a description of the procedures for obtaining prior authorization for services available under the particular rule.
4

(h) Other Sections. As necessary under the particular rule, additional sections may be indicated.
References: 26-1-5, 26-18-1.
History: 11559, NSC, 02/15/91; 14034, AMD, 02/08/93.
NOTES TO DECISIONS
ANALYSIS

Compliance with federal law.
Efficiently and economically operated.
Spend down.
Compliance with federal law.
A reasonable basis existed for the Department to find
that proposed rates were reasonable and adequate to meet
the costs of an efficiently and economically operated facility
as required by federal law: Ninety-three percent of all
long-term health care facilities in Utah were shown to be
meeting their costs under the modified flat rate plan, with
a majority showing a profit. Weber Mem. Care Ctr. v. Utah
Dep't of Health, 751 P.2d 831 (Utah Ct. App.), cert, denied,
765 P.2d 1278 (Utah 1988).
Efficiently a n d economically operated.
Setting rates for payment for services that the state
deems reasonable and adequate and maintaining that an
"efficiently and economically operated facility" is one that
ia able to operate at or below that standard ia a proper
alternative to defining "efficiently and economically operated." Weber Mem. Care Ctr. v. Utah Dep't of Health, 751
P.2d 831 (Utah Ct. App.), cert, denied, 765 P.2d 1278 (Utah
1988).
Since the modified flat rate implicitly defines an efficiently and economically operated facility, evidence of a
nursing home's costs and operation was irrelevant and,
therefore, inadmissible in an action challenging the modified rate plan. Weber Mem. Care Ctr. v. Utah Dep't of
Health, 751 P.2d 831 (Utah Ct. App.), cert, denied, 765 P.2d
1278 (Utah 1988).
Spend down.
Federal Medicaid regulations did not require states to
allow an applicant to spend down excess resources by
applying them to outstanding medical bills, thereby becoming eligible for Medicaid. (Former R810-304-411, R455-1 to
R455-48.) Allen v. Utah Dep't of Health, 829 P.2d 122 (Utah
Ct. App. 1992), afTd, 850 P.2d 1267 (Utah 1993).

R414-1A. M e d i c a i d Policy for E x p e r i m e n tal or U n p r o v e n Medical P r a c t i c e s .
R414-1A-100. Authority and Purpose.
R414-1A-200. Definitions.
R414-1A-300. Policy.
R414-1A-100. Authority a n d P u r p o s e .
(1) This rule establishes Medicaid payment policy
for experimental or unproven medical practices.
(2) This rule is authorized by Sections 26-1-5,
26-1-15, and 26-18-6, and by Subsections 26-18-3(2)
and 26-18-5(4).
R414-1A-200. Definitions.
(1) Terms used in this rule are defined in R4141-1.
(2) In addition:

UTAH ADMINISTRATIVE CODE

April 1, 1996

COVERAGE AND REIMBURSEMENT POLICY
(a) "experimental or unproven medical practice"
means any procedure, medication product, or service
t h a t is:
(i) not proven to be medically efficacious for a
given procedure; or
(ii) performed for or in support of purposes of
research, experimentation, or testing of new processes or products; or
(iii) both;
(b) "medically efficacious" means a, medical practice that:
(i) h a s been determined effective and is widely
utilized as a standard medical practice for specific
conditions; and
(ii) h a s been approved as a covered Medicaid
service by division staff and physician consultants
on the basis of medical necessity, as defined in
R414-13x-l.(5)(a), and in accordance with R414-26l.(2)(f);
(c) "supporting services" means supplies or laboratory, X-ray, physician, pharmacy, therapy, or
transportation services.
R414-1A-300. Policy.
(1) Experimental or unproven medical practices
are not covered Medicaid services.
(2) Division staff and physician consultants shall
estabHsh criteria to determine whether a service or
procedure is a covered Medicaid service.
(3) Procedures or services proven to be medically
efficacious for specific medical conditions may be
provided as covered Medicaid services only for the
conditions specified. Such procedures or services are
not covered for any other conditions or for experimental trials.
(4) Inpatient or outpatient hospitalization for the
purpose of receiving services or procedures t h a t are
experimental or medically unproven, or in support of
such services or procedures, is not a covered Medicaid service. However, when such services or procedures are provided incidentally during a hospitalization for an otherwise medically necessary and
appropriate service, only the experimental or unproven medical procedures and any supporting services specifically identifiable with such services and
procedures are excluded from payment.
References: 26-1-5, 26-18-3(2).
History: 13288, AMD, 10/08/92.

R414-2A-100.
R414-2A-300.
R414-2A-400.
R414-2A-500.
R414-2A-600.

Authority and Purpose.
Program Access Requirements.
Services.
Limitations.
Prior Authorization.

R414-2A-100. A u t h o r i t y a n d P u r p o s e .
(1) This rule defines the scope of inpatient hospital
benefits available for the care and t r e a t m e n t of
Medicaid clients who meet the level of care criteria
April 1, 1996

for admission to an acute-care general hospital for
treatment of disorders other t h a n mental disease.
(2) Inpatient hospital services are required under
Section 1901 et seq. and Section 1905(a)(1) of the
Social Security Act, and by 42 CFR 440.10 (October
1, 1991, edition).
(3) This rule is authorized by Sections 26-1-5,
26-1-15, and 26-18-6, and by Subsections 26-18*3(2)
and 26-18-5(3) and (4).
R414-2A-300. P r o g r a m A c c e s s R e q u i r e m e n t s .
(1) Each hospital providing inpatient services
must have a utilization review plan, as described in
42 CFR 482.30 (October 1, 1991, edition), which is
incorporated by reference.
(2) The attending physician or other practitioner
of the healing a r t s must sign a physician attestation
statement t h a t meets t h e requirements of 42 CFR
412.46 (October 1, 1991, edition), which is incorporated by reference.
(3) The attending physician m u s t certify and recertify the need for inpatient care as described in 42
CFR 441.152 and 456.60 (October 1, 1991, edition),
which are incorporated by reference.
(4) All hospital admissions are subject to review by
the department for appropriateness and medical
necessity as detailed in R414-2A.
(5) For purposes of reimbursement, the day of
admission is counted as a full day; the day of
discharge is not counted.
(6) When a patient receives SNF-level, ICF-level,
or other sub-acute care in an acute-care hospital or
in a hospital with swing-bed approval, payment
shall be made at the SNF or ICF rate.
(7) Inpatient hospital psychiatric services are covered Medicaid services for clients who live in the
counties identified in Table 1 only when such services are coordinated through the contractor identified for the specified county:
TABLE 1
I.

II.

HI.

R414-2A. Inpatient Hospital Services.

R414-2A-400

Counties:

Salt Lake County
Summit County
Contractor: Salt Lake Valley Mental Health,
Salt Lake City, Utah
Counties:
Carbon County
Emery County
Grand County
Contractor: Four Corners Community Mental Health
Center,
Price, Utah
Counties:
Beaver County
Garfield County
Kane County
Iron County
Washington County
Contractor: Southwest Utah Mental Health Center,
St. George, Utah

R414-2A-400. S e r v i c e s .
(1) Inpatient hospital services encompass all
medically necessary and therapeutic Medicaid services and supplies t h a t are ordered by a physician or
other practitioner of the healing a r t s and are appropriate for the adequate diagnosis and t r e a t m e n t of a
patient's illness. These services include nursing,
therapy services, use of hospital facilities, the tech-
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Physician services are available to categorically and medically needy eligible individuals.
R414-10-4. Program Access Requirements.
(1) Physician services are available only from a physician who meets all requirements
necessary to participate in the Utah Medicaid Program and who has signed a provider agreement.
(2) Physician services are available only from a physician who renders medically necessary
physician services in accordance with his specific provider agreement and with Department rules.
(3) An eligible Medicaid client may seek physician services from:
(a) a physician in private practice who is an enrolled Medicaid provider;
(b) a Health Maintenance Organization (HMO) that has a contract with the Department;
(c) a federally qualified community health center; or
(d) any other organized practice setting recognized by the Department for providing
physician services.
R414-10-5. Service Coverage.
(1) Physician services involve direct patient care and securing and supervising appropriate
diagnostic ancillary tests or services in order to diagnose the existence, nature, or extent of
illness, injury, or disability. In addition, physician services involve establishing a course of
medically necessary treatment designed to prevent or minimize the adverse effects of human
disease, pain, illness, injury, infirmity, deformity, or other impairments to a client's physical or
mental health.
(2) Physician services may be provided only within the parameters of accepted medical
practice and are subject to limitations and exclusions established by the Department on the basis
of medical necessity, appropriateness, and utilization control considerations.
(3) Program limitations and noncovered services are established by specific program policy
maintained in the Physician Provider Manual and updated by notification through Medicaid
Provider Bulletins. Following is a general list of medical and health care services excluded from
coverage:
(a) Services rendered during a period the recipient was ineligible for Medicaid;
(b) Services medically unnecessary or unreasonable;
(c) Services which fail to meet existing standards of professional practice, or which are
currently professionally unacceptable;
(d) Services requiring prior authorization, but for which such authorization was not received;
(e) Services, elective in nature, based on patient request or individual preference rather than
medical necessity;
(f) Services fraudulently claimed;
(g) Services which represent abuse or overuse;
(h) Services rejected or disallowed by Medicare when the rejection was based upon any of
the reasons listed above.
(4) Experimental or medically unproven physician services or procedures are excluded from
coverage. Criteria established and approved by the Department staff and physician consultants
are used to identify noncovered services and procedures. Policy statements developed by the
Department of Health and Human Services, Health Care Financing Administration, Coverage
Issues Bureau, are also used to determine Department policy for noncovered services.
(5) Certain services are excluded from coverage because medical necessity, appropriate
utilization, and cost effectiveness of the services cannot be assured. A variety of lifestyle factors
contribute to the "syndromes" associated with such services, and there is no specific therapy or
treatment identified except for those that border on behavior modification, experimental, or
unproven practices. Services include:
(c) 1990-1998 by LEXIS Law Publishing, a division of Reed Elsevier Inc., and Reed Elsevier Properties Inc. All Rights Reserved.
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(a) Sleep apnea or sleep studies, or both;
(b) Pain clinics; and
(c) Eating disorders clinics.
(6) When a service or procedure does not qualify for coverage under the Medicaid program
because it is an elective cosmetic, reconstructive, or plastic surgery, all related services, supplies,
and institutional costs are excluded from coverage.
(7) Medications for appetite suppression, surgical procedures, unproven or experimental
treatments, or educational, nutritional support programs for the treatment of obesity or weight
control, are excluded from coverage.
(8) Cognitive or Office Services:
(a) Cognitive services by a provider are limited to one service per client per day. These
services are defined as office visits, hospital visits except for those following a package surgical
procedure, therapy visits, and other types of nonsurgical services. When a second office visit for
the same problem or a hospital admission occurs on the same date as another service, the
physician shall combine the services as one service and select a procedure code that indicates the
overall care given.
(b) Routine physical examinations, not part of an otherwise medically necessary service, are
excluded from coverage, except in the following circumstances:
(i) Preschool and school age children, including those who are EPSDT (CHEC) eligible,
participating in the ongoing CHEC program of scheduled services and follow-up care.
(ii) New patients seeing a physician for the first time with an initial complaint where a
comprehensive physical examination, including a medical and social history, is necessary.
(iii) Medically necessary examinations associated with birth control medication, devices, and
instructions.
(c) Family planning services may be provided only by or under the supervision of a
physician and only to individuals of childbearing age, including sexually active minors. The
following services are excluded from coverage as family planning services:
(i) Experimental or unproven medical procedures, practices, or medication.
(ii) Surgical procedures for the reversal of previous elective sterilization, both male and
female.
(iii) Infertility studies.
(iv) In-vitro fertilization.
(v) Artificial insemination.
(vi) Surrogate motherhood, including all services, tests, and related charges.
(vii) Abortion, except where the life of the mother would be endangered if the fetus were
carried to term, or where pregnancy is the result of rape or incest.
(d) After-hours service codes may be used only by a private physician, primary care
provider, who responds to treat a patient in the physician's private office for a medical
emergency, accident, or injury after regular office hours. Only one of the after hours CPT codes
may be used per visit.
(e) Only the laboratory tests in the following list are covered as part of a physician's office
service. An independent laboratory shall provide all other laboratory services. The independent
laboratory completing the service must bill the Department directly to receive payment for the
service.
(i) 81000 Urinalysis by reagent strips, any number of components: with microscopy;
(ii) 81002 Urinalysis without microscopy;
(iii) 82270 Blood: occult, feces, screening;
(iv) 82948 Glucose: blood, stick test;
(v) 84702 Gonadotropin, chorionic: quantitative;
(vi) 84703 Gonadotropin, chorionic: qualitative;
(c) 1990-1998 by LEXIS Law Publishing, a division of Reed Elsevier Inc., and Reed Elsevier Properties Inc. All Rights Reserved.
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(vii) 85007 Blood count: manual differential WBC (includes RBC morphology and platelet
estimation);
(viii) 85014 Blood count: hematocrit;
(ix) 85021 Blood count: hemogram, automated (RBC, WBC, HgB, Hct and indices only);
(x) 85022 Blood count: hemogram, automated, and manual differential WBC count (CBC);
(xi) 85023 Blood count: hemogram and platelet count, automated, and manual differential
WBC count (CBC);
(xii) 85024 Blood count: hemogram and platelet count, automated, and automated partial
differential WBC count (CBC);
(xiii) 85025 Blood count: hemogram and platelet count, automated, and automated complete
differential WBC count (CBC);
(xiv) 85027 Blood count: hemogram and platelet count, automated;
(xv) 85031 Blood count: hemogram, manual, complete CBC (RBC, WBC, HgB, Hct,
differential and indices);
(xvi) 85048 Blood Count: white blood cell (WBC);
(xvii) 85650 Sedimentation rate (ESR): Wintrobe type;
(xviii) 85651 Sedimentation rate: Westergren type;
(xix) 86300 Heterophile antibodies: screening (includes monotype test) slide or tube;
(xx) 86317 Immunoassay for infectious agent antigen or antibody, each;
(xxi) 86403 Particle agglutination, rapid test for infectious agent, each antigen;
(xxii) 86580 Skin test: tuberculosis, intradermal;
(xxiii) 86585 Skin test: tuberculosis, tine test;
(xxiv) 87081 Culture, bacterial, screening only, for single organisms;
(xxv) 87082 Culture, presumptive, pathogenic organisms, screening only, by commercial
kit; for single organisms;
(xxvi) 87210 Smear, primary source: wet mount with simple stain, for bacteria, fungi, ova,
and parasites;
(xxvii) 87220 Tissue examination for fungi (e.g., KOH slide).
(f) In addition to the above laboratory services, the following services are covered when a
private physician personally collects the specimen:
(i) 85095 Bone marrow smear or cell block or both: aspiration only;
(ii) 85102 Bone marrow biopsy, needle or trocar.
(g) A specimen collection fee is covered for service in a physician's office only when a
specimen is to be sent to an outside laboratory, and the physician or one of his office staff under
his personal supervision actually extracts the specimen from a patient, and only by one of the
following procedures:
(i) Drawing a blood sample through venipuncture, i.e., inserting into a vein a needle with
syringe or vacutainer to draw the specimen; or
(ii) Collecting a urine sample by catheterization.
(h) Eye examinations are covered, but only once each calendar year.
(i) Contact lenses are covered only for aphakia, nystagmus, keratoconus, severe corneal
distortion, cataract surgery, and in those cases where visual acuity cannot be corrected to at least
20/70 in the better eye.
(9) Psychiatric Services:
(a) Psychiatric services or psychosocial diagnosis and counseling are specialty medical
services. Psychiatric services, whether in a private office, a group practice, or private clinic
setting, may only be provided directly and documented and billed to the Department by the
private physician. Charting and documentation must clearly reflect the private physician's direct
provision of care.
(b) Nonphysician psychosocial counseling services are excluded from coverage as a
(c) 1990-1998 by LEXIS Law Publishing, a division of Reed Elsevier Inc., and Reed Elsevier Properties Inc. All Rights Reserved.
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Medicaid benefit. The personal supervision policy, R414-45-1. may not be applied to psychiatric
services.
(c) Admission to a general hospital for psychiatric care by a physician requires prior
authorization and is limited to those cases determined by established criteria and utilization
review standards to be of a severity that appropriate intensity of service cannot be provided in
any alternate setting.
(10) Laboratory and Radiology Services:
(a) Laboratory services identified by CPT codes 80000 through 89999, and radiology
services identified by CPT codes 70000 through 79999 are ancillary medical services with both a
technical and professional component. The professional component, e.g., analysis, interpretation
and written report, represented by modifier 26, may be provided only by a pathologist or a
radiologist practicing in an independent or hospital laboratory or radiology setting. Pri\ate
physicians who are not pathologists or radiologists may not bill for the service described by
modifier 26 for telling a patient the results of laboratory or radiology procedures as noted on the
laboratory or radiology printout or the written report. Providing such information to the patient is
part of the office call rather than a separate service.
(b) Physicians prepared in a highly specialized field of practice, e.g., neurology or
neurosurgery, who provide consultation and diagnostic radiology services in an independent
setting at the request of a private physician may bill for both the technical and professional
component of the radiology service.
(11) Hospital Services:
(a) A patient hospitalized for nonsurgical services may require more than one visit per day
because of the patient's condition and treatment needs. Since physician visits are limited to one
per day, the physician shall select one procedure code to define the overall care given. If
intensive care services are provided, or critical care service codes are used to define sendee
provided, the Department requires additional documentation from the physician. The medical
record must show documentation of medical necessity and result of the additional service.
(b) If, for the convenience of the physician and not for medical necessity, a patient is
transferred between physicians within the same hospital or from one hospital to another hospital,
both physicians may only use subsequent hospital care service codes to define and bill for
services provided. Under this policy limitation, services associated with the following codes are
excluded from coverage as a Medicaid benefit:
(i) Consultation; and
(ii) Initial hospital care services.
(c) Treatment of alcoholism or drug dependency in an inpatient setting is limited to acute
care for detoxification only.
(12) Abortion, Sterilization and Hysterectomy:
(a) Abortion procedures are limited only to those with medical certification of necessity as
described in 42 CFR 441.203, October 1994 edition, which is adopted and incorporated by
reference.
(b) Sterilization and hysterectomy procedures are limited to those which meet the
requirements of 42 CFR 441, Subpart F, October 1994 edition, which is adopted and
incorporated by reference.
(13) Cosmetic, Plastic, or Reconstructive Services:
(a) Cosmetic, plastic, or reconstructive surgery procedures may only be covered when
medically necessary to:
(i) correct a congenital anomaly;
(ii) restore body form or function following an accidental injury; or
(iii) revise severe disfiguring and extensive scarring resulting from neoplastic surgery.
(14) Surgical Services:
(c) 1990-1998 by LEXIS Law Publishing, a division of Reed Elsevier Inc , and Reed Elsevier Properties Inc. All Rights Reserved.

5
(a) Surgical procedures defined and coded in the CPT Manual are limited by Utah Medicaid
policy to place of service, to prior authorization, or are excluded from coverage. Limitations are
documented on the Medical and Surgical Procedures Prior Authorization List, reviewed and
revised yearly and maintained in the Physician Provider Manual through notification by Provider
Bulletins.
(b) Surgical procedures are "package" services. The package service includes:
(i) the preoperative examination, initiation of the hospital record, and development of a
treatment program either in the physician's office on the day before admission, or in the hospital
or the physician's office on the same day as admission to the hospital;
(ii) the operation;
(iii) any topical, local, or regional anesthesia; and
(iv) the normal, uncomplicated follow-up care covering the period of hospitalization and
office follow-up for progress checks or any service directly related to the surgical procedure for
up to six weeks post surgery.
(c) Interpretation of "package" services:
(i) A physician may not bill for an office visit the day prior to surgery, for preadmission or
admission workup, or for subsequent hospital care while the patient is being prepared,
hospitalized, or under care for a "package" surgical service.
(ii) Consultation services may be billed by the consulting physician only when consultation
and no other service is provided. When a consulting physician admits and follows a patient,
independently or concurrently with the primary physician, only admission codes and subsequent
care codes may be used.
(iii) Office visits for up to six weeks following the hospitalization which relate to the same
diagnosis are part of the "package" service. The only exception to either inpatient or office
service is for service related to complications, exacerbations, or recurrence of other diseases or
problems requiring additional or separate service.
(d) Procedures exempt from the "package" definition are identified in the CPT Manual by an
asterisk. The CPT Manual outlines the surgical guidelines which apply to documentation and
billing of procedures marked by an asterisk.
(e) Complications, exacerbations, recurrence, or the presence of other diseases or injuries
requiring services concurrent with the initial surgical procedure during the listed period of
normal follow-up care, may warrant additional charges only when the record shows extensive
documentation and justification of additional services.
(f) When an additional surgical procedure is carried out within the listed period of follow-up
care for a previous surgery, the follow-up periods continue concurrently to their normal
terminations.
(g) Preoperative examination and planning are covered as separate services only in the
following circumstances:
(i) When the preoperative visit is the initial visit for the physician and prolonged detention or
evaluation is required to establish a diagnosis, determine the need for a specific surgical
procedure, or prepare the patient;
(ii) When the preoperative visit is a consultation and the consulting physician does not
assume care of the patient; or
(iii) When diagnostic procedures, not part of the basic surgical procedure, e.g., bronchoscopy
prior to chest surgery, are provided during the immediate preoperative period.
(h) Exploratory laparotomy procedures confirm a diagnosis and determine the extent of
necessary treatment. A physician may request payment only if the exploratory procedure is the
only procedure done during an operative session. Exploratory laparotomy services identified by
CPT Codes 49000-49060 may not be billed in conjunction with any services identified by the
following CPT Codes: 43500 - 44346 - 44600 - 45180 - 47400 - 47490 - 47600 - 48999 - 49002 (c) 1990-1998 by LEXIS Law Publishing, a division of Reed Elsevier Inc., and Reed Elsevier Properties Inc. All Rights Reserved.

6
49999 - 58140 - 58285 - 58400 - 58960.
(i) The services of an assistant surgeon are covered only on very complex surgical
procedures. Procedures not authorized for assistant surgeon coverage are listed in the Physician
Provider Manual and updated by Medicaid Provider Bulletins as necessary. Medicare guidelines
for limitation of assistant surgeon coverage are used, since those decisions are made at the
national level with physician consultation.
(15) Diagnostic and Therapeutic Procedures:
(a) Diagnostic needle procedures; e.g., lumbar puncture, thoracentesis, and jugular, femoral
vein, or subdural taps, when performed as part of a necessary workup for a serious medical
illness or injury, are covered in addition to other medical care on the same day.
(b) Diagnostic "oscopy" procedures, e.g., endoscopy, bronchoscopy, and laparoscopy, are
covered separately from any major surgical procedure. However, when an "oscopy" procedure is
done the same day or at the same operative session as another procedure, the "oscopy" procedure
may only be covered as a multiple procedure.
(c) Magnetic resonance imaging (MRI) is covered only for service to the brain, spinal cord,
hip, thigh and abdomen.
(d) Therapeutic needle procedures, e.g., scalp vein insertion, injections into cavities, nerve
blocks, are covered in addition to other medical care on the same day.
(e) Puncture of a cavity or joint for aspiration followed by injection of a medication is
covered as one procedure and identified by specific CPT code.
(16) Anesthesia Services:
Anesthesia services are covered only when administered by a licensed anesthesiologist or
nurse anesthetist who remains in attendance for the sole purpose of rendering general anesthesia
services. Standby or monitoring by the anesthesiologist or anesthetist during local anesthesia is
not a covered Medicaid anesthesia service.
(17) Transplant Services
Organ transplant services are limited to those procedures for which selection criteria have
been approved and documented in R414-10A.
(18) Modifiers:
Modifiers may be used only, as defined in the CPT Manual, to show that a service or
procedure has been altered to some degree but not changed in definition or code. The following
limitations apply:
(1) The professional component, modifier 26, may be used only with laboratory and
radiology service codes by a pathologist or radiologist and only when direct analysis,
interpretation, and written report of findings are provided on a laboratory or radiology procedure.
Private physicians may not use this modifier.
(2) Unusual services are identified by use of modifier 22, along with the appropriate CPT
code. A prepayment review of unusual services shall be completed by Medicaid professional
staff or physician consultants. A report of the service and any important supporting
documentation must be submitted with the claim for review.
(3) Anesthesia by surgeon is identified by use of modifier 47. The operating surgeon may
not use modifier 47 in addition to the basic procedure code. Anesthesia provided by the surgeon
is part of the basic procedure being provided.
(4) Mandated services as defined by CPT and identified by modifier 32 are noncovered
services.
(5) Reference laboratory services identified by modifier 90 are noncovered services.
(19) Medications:
(a) Drugs and biologicals are limited to those approved by the Food and Drug
Administration (FDA). Medicaid coverage of drugs and biologicals is based on individual need
and orders written by a physician when the drug is given in accordance with accepted standards
(c) 1990-1998 by LEXIS Law Publishing, a division of Reed Elsevier Inc., and Reed Elsevier Properties Inc All Rights Reserved.
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of medical practice and within the protocol of accepted use for the drug.
(i) Generic drugs shall be used whenever a generic product approved by the FDA is
available. If the physician determines that a brand name drug is medically necessary, the
physician may override the generic requirement by writing on the prescription in his own hand
writing "name brand medically necessary", Preprinted messages, abbreviations, or notations by a
second party, do not meet the override requirement. The pharmacist shall fill the prescription
with the generic equivalent product if the override procedure is not followed.
(ii) Injectable medications approved in HCPCS are identified in the "J" code list published
by the Health Care Financing Administration or the Department, or both. The list is reviewed
and revised yearly and maintained in the Physician Provider Manual by notification and update
through Medicaid Provider Bulletins.
(iii) The "J" code covers only the cost of an approved product.
(iv) Office visits only for administration of medication are excluded from coverage.
However, an injection code which covers the cost of the syringe, needle and administration of the
medication may be used with the "J" code when medication administration is the only reason for
an office call.
(v) When an office service is provided for other purposes, in addition to medication
administration, only the office visit and a "J" code may be used to bill for the service provided.
(vi) The office visit code and injection code may never be used together. Only one of the
codes may be used to define the service provided.
(vii) Vitamin B-12 is limited to use only in treating conditions where physiological
mechanisms produce pernicious anemia. Use of Vitamin B-12 in treating any unrelated
condition is excluded from coverage.
(b) Vitamins may be provided only for:
(i) Pregnant women: Prenatal vitamins with 1 mg folic acid,
(ii) Children through age five: Children's vitamins with fluoride,
(iii) Children through age 15: Fluoride supplement.
(c) Human growth stimulating hormones are not a covered service.
(d) Methylphenidates, amphetamines, and other central nervous system stimulants require
prior authorization and may be provided only for treatment of Attention Deficit Disorder (ADD)
in children between the ages of six and 18 years.
(e) Medications for appetite suppression are not a covered service.
(f) Non-prescription, over-the-counter items are limited, and notification of changes
consistent with this rule is made by Provider Bulletin and Provider Manual updates.
(g) Nutrients may be provided only as established in R414-24A.
References: 26-1-5, 26-18-3.

History: 11442, NEW, see CPR; 11442, CPR, 04/15/91; 17705, AMD, 06/07/96; 18823, 5YR,
03/18/97.
NOTES TO DECISIONS
Breast reduction surgery.
Breast reduction surgery is authorized in particular cases of "medical necessity." Therefore,
because the patient's attending physicians testified regarding the medical necessity of the
procedure and the Department of Health Care Finance failed to give a reasoned basis for
declining to give deference to the testimony of the treating physician, the agency's finding that
the breast reduction surgery was not medically necessary was not supported by substantial
evidence and was reversed. (R414-10-6.) A.M.L. v. Department of Health, Div. of Health Care
Fin., 863 P.2d 44 (Utah Ct. App. 1993).
(c) 1990-1998 by LEXIS Law Publishing, a division of Reed Elsevier Inc., and Reed Elsevier Properties Inc. All Rights Reserved.

COVERAGE AND REIMBURSEMENT POLICY
2) the medical services for which payment is
claimed were actually furnished to the person identified as the recipient at the time and in the manner
stated;
3) the payment claimed does not exceed the provider's usual and customary charges (or the maximum amount negotiated under applicable regulations of the Division of Health Care Financing); and
4) the information submitted in, with, or i n support of the claim is true, accurate, and complete. The
Division of Health Care Financing may terminate
any provider from further participation in the Title
XEX program if the provider shall fail or cease to
satisfy all applicable criteria for eligibility as a
Medicaid Provider as explained in provider manuals.
b. Ineligibility of Provider
The Department may refuse to grant provider
privileges to anyone who has been convicted of a
criminal offense relating to that person's involvement in any program established under Title XVTH,
XJX, or XX of the Social Security Act, or of a crime of
such nature that, in the judgment of the Department, the participation of such Provider would compromise the integrity of the Medical Assistance
Program.
4. QUALITY ASSURANCE
In order for the state to meet Title XIX requirements, certain procedures are required. The State is
responsible to monitor all programs with respect to
medical need, extent and appropriateness of care,
and program effectiveness. These procedures include, but are not limited to:
(a) Audit Procedures
(b) On-Site Reviews
(c) Quality Assurance
(d) Utilization Review
5. MEDICAL STANDARDS
a. A Provider must furnish or prescribe medical
services to the recipient only when, and to the extent
that, it is medically necessary. A service is "medically necessary" if it is (1) reasonably calculated to
prevent, diagnose, or cure conditions in the recipient
that endanger life, cause suffering or pain, cause
physical deformity or malfunction, or threaten to
cause a handicap; and (2) there is no other equally
effective course of treatment available or suitable for
the recipient requesting the service which is more
conservative or substantially less costly. Medical
services shall be of a quality that meets professionally recognized standards of health care, and shall
be substantiated by records including evidence of
such medical necessity and quality. Those records
shall be made available to the Department upon
request.
b. Determination of Compliance with Medical
Standards
A provider's failure to comply with medical standards may be determined by peer review. Initial
determinations as to whether or not a provider has
failed to comply with medical standards, will be
made by Division of Health Care Financing employApril 1, 1995

R414-13X-1

ees or consultants. If the determination has been
made by the Division of Health Care Financing that
noncompliance exists, the Division of Health Care
Financing will notify the provider of the failure to
comply in writing pursuant to the notice provisions
of the Division of Health Care Financing ADMINISTRATIVE HEARING PROCEDURES Section 2.
Either the Division of Health Care Financing or
the provider may request to have formal peer review
of the Department's detennination.
A written request by either the Division of Health
Care Financing or provider for formal review must
be made within 30 days following the date of the
original notice to the provider of the Division of
Health Care Financing determination that noncompliance had occurred. The written request from the
provider must be submitted by him/her to:
Division of Health Care Financing
Bureau of Program Review
ATTN: PEER REVIEW
P. O. Box 16580
Salt Lake City, Utah 84116-0580
This written request will be submitted to the
appropriate Professional Society requesting that
their Peer Review Committee conduct a formal peer
review of the Division of Health Care Financing
determination.
The informal hearing requirements of Section
26-23-2-d) UCA, (1953) are satisfied by the professional peer review process.
If either the Division of Health Care Financing or
the provider is dissatisfied with the results of the
formal peer review they may request a formal hearing before the Department of Health pursuant to
Section 23-32-2, UCA (1953) by complying with the
formal hearing procedures set forth in the Division
of Health Care Financing ADMINISTRATIVE
HEARING PROCEDURES.
In situations of violations of compliance of professionally recognized medical standards, identified by
peer review, the Division of Health Care Financing
may pursue any legal sanction for recovery of overpayments.
Should Federal Financial Participation (the
amount the federal government contributes to provider reimbursement) be disallowed on reimbursements made to the provider, the provider will reimburse to the State the total amount that the State
paid for the services disallowed (including Federal
audit, quality assurance review, or prior authorization requirements) only if the provider was at fault.
References: 26-1-5.
History: 13550, 5YR, 11/15/92.

R414-14. Home Health Service.
R414-14-0.
R414-14-1.
R414-14-2.
R414-14-3.
R414-14-4.
R414-14-5.

Policy Statement.
Authority and Purpose.
Definitions.
Eligibility Requirements/Coverage.
Program Access Requirements.
Service Coverage.

UTAH ADMINISTRATIVE CODE

57

Addendum C

w u n riu& I*\J. ^-»-'<* ' T w w

W & r i i t t IhmW W W 1

One Utah Center, Suite 900
201 South MaiaStreet
4Satt Lake Cftv. Utah 84111

1
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3
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4
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5
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6

8:30 a.m. on December 8, 1997, before

7
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THE COURT:

I have Mrs. Peterson here and

7

Juliana Rich.

And then for Health Care Financing, Utah

8

Medicaid, Dr. John Hylen and Penny Nahley who's an R.N.

9

And then Steve Gatzemeier will be coming shortly.

I

10

think I'm going to have you testify first, Dr. Jackson,

11

and I'll get into that a little bit more in a moment.

12

Basically I need to tell you that the tape

13

recorder is on now and it's a formal hearing in the

14

matter of Markelle Frei-Peterson versus Utah Department

15

of Health, Division of Health Care Financing and the

16

Case Number is 97-209-11.

17

I'm the administrative law judge assigned to preside

18

over today's hearing.

19

and it's approximately 8:30 in the morning.

20

My name is Margaret Clark.

Today is Monday, December 8th,

Procedures for today's hearing are governed

21

by the Utah Administrative Procedures Act, Title 63,

22

Chapter 46(b) of the Utah Code and Utah Administrative

23

Rule R410-14.

24

also Duane Park, who's a pharmacist for Health Care

25

Financing.

Mr. Gatzemeier just entered the room and

IZC-A
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1

As I was saying the procedures are governed

2

by Title 63, Chapter 46(b) and Utah Administrative Rule

3

R410-14 which contain the Division of Health Care

4

Financing's hearing policies.

5

will prepare what is called a Recommended Decision.

6

That decision will contain my Findings of Fact and my

7

Conclusions of Law.

8

Health Care Financing will then issue a final decision

9

called a Final Agency Order and that order may affirm,

10

reverse, remand or modify my Recommended Decision based

11

only upon the evidence from the record as a whole, and

12

that would be the sworn testimony taken today or any

13

exhibits that are entered into evidence.

14

After today's hearing I

The director of the Division of

Should the outcome be unfavorable my

15

assistant has provided copies of appeals rights to Mrs.

16

Peterson.

17

them feel free to call our office.

18

If you have any questions should you need

First I'm going to have Health Care Financing

19

enter their appearances.

20

representing, Mr.Gatzemeier?

21

MR. GATZEMEIER:

22

THE COURT:

23
24
25

Are you going to be

Yes.

Would you like to introduce

yourself?
MR. GATZEMEIER:
Gatzemeier.

Okay.

My name is Steven

I'm a Health Program Manager for Coverage

M>
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1

and Reimbursement Policy, Division of Health Care

2

Financing.

3

is a registered nurse and who is the prior

4

authorization reviewer and was the evaluator, the

5

initial evaluator in this case.

6

Hylen who is an M.D. who will be available for

7

testimony.

8

pharmacist.

9
10

to hear?

11

us okay.

12
13

We also have Dr. John

And we have Duane Park who is a registered

THE COURT:

Okay.

I'm sorry.

Dr. Jackson, are you able to hear

DR. JACKSON:

Dr. Peterson, are you able

Yes.

For the state was that

Mr. Gatzemeier?

14
15

Testifying today will be Penny Nahley, who

THE COURT:

Yes.

Okay.

I'm having to move

his speaker a little bit closer.

16

I'd like to have you testify first, Dr.

17

Jackson, since you have the burden of proof, or Miss

18

Peterson has the burden of proof of as the moving

19

party.

20

pleadings and the prehearing conference, is whether or

21

not Utah Medicaid should cover payment for a growth

22

hormone.

23

Care Financing as I understand it because it's

24

considered to be experimental and experimental

25

procedures are excluded from coverage by the

And the issues, as I understand it from the

And this is not normally covered by Health

/ ^
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1

Administrative Code.

2
3

Is that the issue as everyone understands it?
Mr. Gatzemeier?

4

MR. GATZEMEIER:

Yes.

Experimental and I

5

believe it's our understanding that this drug is also

6

being used for an off-legal use.

7

be but that's the understanding I have.

8

THE COURT:

Okay.

9

the issue as you understand it?

10

DR. JACKSON:

That may or may not

And, Dr. Jackson, is that

Right.

It's the use of growth

11

hormone for an indication other than stimulating

12

somatic growth.

13

adaptation.

It's for accelerating intestinal

14

THE COURT:

Okay.

15

DR. JACKSON:

Although it's not within the

16

specific experimental protocol like some other

17

therapies that we sometimes used it's not exactly...

18

THE COURT:

I'm sorry, doctor, before you go

19

any further I need to swear you in so everything you

20

say is accountable.

21

please.

22

23

If you'll raise your right hand,

DR. J A C K S O N :

Okay.

WILLIAM DANIEL JACKSON, M.D.,

24

appearing as a witness on behalf of the

25

Petitioner, having been first duly sworn,

( & -

1
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1

testified as follows:

2

DIRECT TESTIMONY

3
4

THE COURT:

State your name for the record

again.

5

DR. JACKSON:

6

THE COURT:

William Daniel Jackson.
Thank you.

I'm sorry.

Now if

7

you'd like to start testifying in narrative fashion if

8

you'd like.

9

to address being not —

I think a couple of things that you'd like
not being represented by an

10

attorney is the medical necessity role which I believe

11

Health Care Financing was supposed to have sent you a

12

copy.

Did you receive that?

13

DR. JACKSON:

14

THE COURT:

Yes, I did.
Okay.

If you could possibly in

15

your testimony address those two elements of medical

16

necessity, and then anything else you'd like to tell

17

us, and also why you think this procedure, this use of

18

the drug is not experimental in this case, if that's

19

what you're contending.

20

but I'm just trying to kind of give you some guidance

21

here.

I'll just leave it up to you,

22

DR. JACKSON:.

23

went over in the previous hearing.

24
25

THE COURT:

Okay.

Right.

Some of these issues we

And that was just a

prehearing and that wasn't on the record, so we need to

IlL-
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1

reiterate anything that's important because this is the

2

official hearing record.

3

DR. JACKSON:

Okay.

Markelle Frei-Peterson

4

is a 24-month-old toddler now with short bowel

5

syndrome.

6

support for much of her nutritional needs.

7

Is dependent upon parenteral nutrition

THE COURT:

Okay.

I need to back up just one

8

more second.

I'm sorry to do this to you again.

9

need to get your credentials for the hearing record.

10

DR. JACKSON:

11

THE COURT:

12

DR. JACKSON:

13

I

M.D.
Uh-huh.
Do you need to know where I

trained or what do you need to know?

14

MR. GATZEMEIER:

15

THE COURT:

16

anything that tells us

17

DR. JACKSON:

Specialties.

Specialties, board certification,
—
I'm board certified in

18

pediatrics and board certified in pediatric

19

gastroenterology and nutrition.

20

Have fellowship training in pediatric gastroenterology

21

and n u t r i t i o n .

22

23
24
25

Recently recertified.

H a v e an M . D . and a b a c h e l o r ' s d e g r e e .

THE C O U R T :

Okay.

And w h e r e are you working

now?
DR. JACKSON:

I'm an assistant professor of

pediatrics at University of Utah School of Medicine and
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1

I'm based at Primary Children's Medical Center where

2

I'm the Medical Director of Nutrition Support Services.

3

THE COURT:

4

DR. JACKSON:

5

Okay, thank you.
And I practice in pediatric

gastroenterology.

6

THE COURT:

Thank you.

I hope I won't be

7

interrupting any more.

8

were starting to tell us that Markelle Frei-Peterson is

9 a

I'll let you go ahead.

You

toddler about 2 4 months old?

10

DR. JACKSON:

Yes, she's a two-year-old

11

little girl with short bowel syndrome dependent upon

12

parenteral nutrition support which is I.V. nutrition

13

for I would say 9 0 percent of your nutritional needs.

14

She is receiving continuous gastrostomy feeds which are

15

feedings into her gastrointestinal tract.

16

variable amounts but generally around 2 0 cc's per hour.

17

She has begun to eat and she does consume a certain

18

amount, it's difficult to quantify, of oral feedings

19

now.

And around --

These are ~- some of these are new changes that --

20

THE COURT:

21

DR. JACKSON:

How recent approximately?

This is over the last two to

22

three —

23

three to four months that she's having increasing

24

intake of oral feedings.

25

you know, I'd say last two to three, maybe

THE COURT:

Okay.

/ ^ -
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1

DR. JACKSON:

And her stool consistency has

2

changed at times.

So there's been a number of changes

3

that have occurred in the past few months since we

4

started this appeal process.

5

THE COURT:

Uh-huh.

6

DR. JACKSON:

In any case she still remains

7

dependent upon parenteral nutrition and our main

8

project and the number one I guess impetus and concern

9

in a patient with short bowel syndrome is dependent

10

upon such an expensive technology and possibly lifetime

11

technology of parenteral nutrition is to get them off

12

of that and get there G.I. tract, the gastrointestinal

13

tract to adapt and to accommodate enteral nutrition and

14

basically take over all of their needs.

15

The other I guess omen along the path for her

16

besides the risk of central line catheter infections

17

and eventual loss of I.V. access sites is consequences

18

on the liver.

19

syndrome who can't be fed adequately enterally they

20

develop liver dysfunction that is progressive.

21

biopsy these patients7 livers and you see fibrosis,

22

like a scarring process --

In children that have short bowel

23

THE COURT:

24

DR. J A C K S O N :

25

You can

Uh-huh.
—

that occurs in t h e l i v e r .

A n d it g o e s a t v a r i o u s d i f f e r e n t rates in d i f f e r e n t

K I N G S B U R Y A N D A S S O C I A T E S , C E R T I F I E D SHORTHAND R E P O R T E R S
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1

patients•

So I think that's probably the biggest

2

concern is that a lot of our patients that have short

3

bowel syndrome that are parenterally nutrition

4

dependent who can't adequately adapt their G.I. tract

5

have a risk of progressing to -- well, have a high risk

6

of progressing to liver failure and require liver

7

transplantation.

8

So not only do they have the cost of chronic

9

TPN and the cost of maintaining the central line which

10

requires repeated hospital admissions as well as they

11

have the risk long term of possibly requiring a liver

12

transplantation.

13

certain situations as is the TPN.

14

Which is covered by Medicaid in

So I guess my impetus in this case, the

15

bottom line in my case is a clinical judgment as to

16

I consider it a medical judgment

17

THE COURT:

18

DR. JACKSON:

—

—

Uh-huh.
—

rather than a legal

19

judgment.

Although I understand that, you know, her

20

survival and her situation in this case and the

21

reimbursement situation is from public funds.

22

THE COURT:

Right.

23

DR. JACKSON:

And there's a responsibility.

24

I completely understand this.

I've been over this with

25

Dr. Hylen before with some other transplantation
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1

issues.

And those are larger ethical, economic

2

THE COURT:

3

DR. JACKSON:

—

Right.
—

issues.

And I completely

4

understand all those.

In this case on the other hand I

5

think from both the citizen point of view and the

6

public trust point of view and a money point of view,

7

although perhaps it might be premature in terms of the

8

letter of law and the indications for example, the off

9

label, et cetera, the evidence that it's experimental,

10

et cetera like that, even though that may be, from a

11

medical point of view I —

12

other physicians around the country, many much smarter

13

than I am, including Dr. Book who's a division chief,

14

who feel that in certain situations using growth

15

hormone which is commonly used in many, many children

16

for the indications of just somatic growth, it's not

17

going to threaten their life, it doesn't threaten much

18

of anything except for their —

19

esteem, et cetera.

20

short-stature patients, that is covered by Medicaid as

21

an on-label use.

22

and there are a number of

it threatens self

But growth hormone for

In this case we're using it off of that label

23

but for what I think is a higher indication which is

24

and obviously has to do with judgment and making a

25

guess of probabilities, but for saving someone's life.

i2lo-

—

13
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1

THE COURT:

2

DR. JACKSON:

3
4 a

Okay.

What

—

But also I think from an

economic point of view the way I add up I thought that
reasonably short-term course of this would be —

if

5

it worked would be a cost effective approach in terms

6

of the huge magnitude of the cost of lifetime TPN

7

and/or liver transplantation.

8
9

THE COURT:

What is the growth hormone called

specifically?

10

DR. JACKSON:

11

recombinant human growth hormone.

12

THE COURT:

13

DR. JACKSON:

14

It's called —

well, it's

Okay.
And it's called humatropef

h-u-m-a-t-r-o-p-e.

15

THE COURT:

Thank you.

Okay.

So if I

16

understand your testimony are you saying that this

17

growth hormone in this procedure would be reasonably

18

calculated to prevent liver dysfunction?

19

DR. JACKSON:

20

THE COURT:

21

DR. JACKSON:

Indirectly.
Okay.
What it promotes —

its direct

22

role —

and there's a lot —

in fact there's more

23

than —

I said some to you, but there's been more since

24

then.

25

adaptation in terms of absorption of electrolytes,

There's a lot of data about effects on
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1

amino acids.

2

carbohydrate absorption and changes of stool output.

3

There's —

4

studies of human studies recently that are just been

5

published.

6

There's also a lot of data on protein,

from animal studies.

And there's also some

The question is are these studies —

in my

7

mind these studies are not large, they're not the kind

8

of studies in which someone would say on a blanket case

9

that this would be a —

that you will do this for

10

everybody.

But for certain indications there's enough

11

promise there to motivate a number of different people

12

to continue to work along these lines.

13

fringe people, they're mainstream.

14

biggest protagonists of this is the person that

15

actually developed total parenteral nutrition, Doug

16

Wilmore, in 1968.

17

have been with this for a long time.

18

there is controversy.

It's been —

19

THE COURT:

20

DR. JACKSON:

And they're not

In fact one of

these are people that
And there's

—

Uh-huh.
It's like any other kind of

21

burgeoning, you know, new therapy.

But there's enough

22

promise there.

23

anyway, there's a lot of data on growth hormone itself

24

stimulating transcription of certain regulatory genes

25

that turn on growth of the lining of the intestine.

I don't think it's cold fusion.

So
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1

And there's lots of demonstrations in certainly animal

2

models and there's some reports in human studies of

3

mucosal growth.

4

There's also some where they looked, for

5

short term at least, like three-week studies, where

6

they weren't able to see a change, but they were able

7

to see some changes in absorption and amino acid

8

uptake.

9

So it's —

it definitely is an area where

10

there's active work and controversy.

11

the basic science elements of it at least are the

12

growth factors including those stimulated by growth

13

hormone stimulating intestinal growth.

14

The big question is —

But there is

—

one of the big

15

questions is what is the timing for doing this, what is

16

the outcome?

17

published some, has shown even in patients who have had

18

their —

19

show response.

20

people.

21

most of that information over.

22

THE COURT:

23
24
25

Wilmore's group, the group that's

lost their intestine years and years ago still
And that doesn't make sense to some

But anyway.

copies of that.

So there's —

Okay.

I've kind of sent

Actually I don't have

Will the Respondent's be entering

DR. JACKSON:

—

I sent some articles over with

my appeal to Ms. Nahley back on June 23rd of '97.

And
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1

then there was —

2

more things.

3

I just did a search and I found some

So there's

THE COURT:

—

What I'd like to do is keep the

4

record open so you could submit whatever you found

5

recently,

6

DR. JACKSON:

One other piece of information

7

in the letters I read -- I read two letters.

8

June 2 3rdf the other one was —

9

was a little bit later.

One was

I didn't date it but it

I guess it was about seven

10

months ago.

Anyway, since then she has been able to

11

get growth hormone and so she's been on that for a

12

number of months now.

13

was to do growth hormones for a short period of timef a

14

limited time such as three months back in June.

15

THE COURT:

16

DR. JACKSON:

And one of my recommendations

Uh-huh.
And the argument then was this

17

is worth itf try it.

18

signs of some benefit then we would like to pursue this

19

and keep going.

20

process has basically dragged on over this six months

21

so in the meantime we've already used it.

22

attribute what's happening to her now on that?

if there is

The trial process or the hearing

23

THE COURT:

24

DR. JACKSON:

25

If there is no —

So can I

Yes, I think it's relevant.
It's circumstantial, but

there's been some -- I mean I think Ms. Peterson can
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1

probably attest to what's happening with respect to

2

Markelle7s ability to eat, take some solid foods, do

3

some things that are often great —

4

challenges you have with some of these patients that

5

have been chronically fed with TPN and tube feeding is

6

inability to take things orally.

7

she's been able to get her to eat things is a big step

8

forward.

9

THE COURT:

10

one of the biggest

So the fact that

Would you like

DR. JACKSON:

—

Billy Rich perhaps might be

11

someone else from a medical or nursing background who

12

could comment on things like that.

13

there been some changes?

14

some changes.

15

done anyway without this?

16

trials.

And Dr. Hylen would certainly say, yes, of

17

course.

So this could all just be anecdotal, et

18

cetera.

19

So, you know, have

Yeah, I think there have been

Is that something that she would have

THE COURT:

That's why we do randomized

Could you —

20

long —

21

hormone?

22

idea how long she would need it?

23

DR. JACKSON:

do you know how

how long will she be needing this growth
I mean is it indefinite or do you have any

I think it's self limited-

I

24

think that my original feeling would be to use it for a

25

year.

But I think that her ability to adapt or start
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1

being able to accommodate to more enteral feeding, that

2

by itself is somewhat protective on the liver.

3

feedings itself are stimulatory to the G.I. tract.

The

4

Though we are really stuck —

when we first

5

proposed this in June the impetus behind this was

6

and I was actually slower than some of my colleagues to

7

want to go for this therapy.

8

liver tests —

9

of her liver test at that time.

But I think that her

she had kind of a marked abnormalities
I was basically

10

worried that she was starting to show signs of

11

accelerated liver disease.

12

And her —
And I —

since then her liver tests have

13

normalized.

14

a concern.

15

stuck in terms of her ability to take in things.

16

it was —

17

having lots of troubles.

18

—

but anyway, at that time that was

We weren't making any progress.

She was

she was in and out of the hospital.

And

We were

So there are a few things that we changed at

19

the time.

But the biggest one since then has been

20

basically adding the growth hormone.

21

know —

22

child now than she was before, and that could just be a

23

maturity process, it could just be that she's gradually

24

been able to, you know, adapt from the feedings or

25

could be, you know, or it could be due to this.

So I don't

I think she's a different baby now, different
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1

That's why we do these kind of trials is to

2

know for sure what it is.

I would say that at the end

3

of that year period I don't think there is any —

4

mind at that point, particularly given what —

5

progress she's made so far, I would think at that point

6

there would be diminishing returns because we're

7

getting at the point now where she taking in —

8

won't be that much more.

9

enteral feedings where that whole —
hopefully sustain itself.

11

stimulates the G.I. tract to adapt.
THE COURT:

13

DR. JACKSON:

it

that process may

The feeding itself

Okay.
And whoever —

the people, you

14

know —

15

growth hormone to date —

16

that, you know, they've been quite generous.

17

the

But she could take in more

10

12

in my

I think that, you know, whoever provided the

THE COURT:

I think I.H.C. has been doing

Okay, thank you.

So...

I'm going to

18

swear Mrs. Peterson in and then you will be able to ask

19

some questions but since this is on the same track I

20

just want to ask her about the changes.

21
22

MR. GATZEMEIER:
his testimony.

23

THE COURT:

24

MR. GATZEMEIER:

25

I have some questions about

Right.
Going to swear both of them

at the same time?

lu

20
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1
2
3

THE COURT:

I'd just like to get comments on

that one area and then you can ask them both questions.
Will you raise your right hand, please?

4

HEIDI PETERSON,

5

appearing as a witness on behalf of the

6

Petitioner, having been first duly sworn,

7

testified as follows:

8
9
10
11
12

DIRECT TESTIMONY
THE COURT:

Your name for the record.

MS. PETERSON:

My name's Heidi Peterson and

I'm Markelle Frei-Peterson's aunt.
THE COURT:

Okay.

I was just going to ask

13

and I'll probably want you to testify later, but just

14

if you wanted to comment on Dr. Jackson's remarks about

15

how she had improved since the hormone therapy.

16

MS. PETERSON:

Markelle used to stool up to a

17

thousand cc's of stool a day and now we're down to

18

between three and four hundred cc's of stool a day.

19

h a v e upped her feedings from —

20

g e t t h r e e months ago —

21

growth hormone this month —

22

her tube feedings was 15 cc's an hour.

23

with turning her on and off through the night.

24

up to 21 cc's an hour.

25

the maximum we used

w e ' r e on our third month

I
to

of

the maximum we got to in
And that was
Now I'm

We are doing feeding therapy through a speech

lie-21
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1

therapist.

2

eat.

3

kind of thing.

4
5

She eats with her mouth every meal that we

We 7 re teaching her how to drink juices and that
So I mean it's a lot.

THE COURT:

Okay.

Do you have any questions

you want to ask Miss Peterson now?

6

Okay.

Then I'll go back to Dr. Jackson.

And before

7

1 finish questioning you then Health Care Financing has

8

the right to cross-examine so they7re going to ask some

9

questions.

Then I'm going to have them put on their

10

case.

11

questions you'd like to ask of them.

12

end if you'd like to provide any rebuttal evidence and

13

both sides can summarize.

14

You will be able to cross-examine them, ask any
And then at the

Okay?

WILLIAM DANIEL JACKSON, M.D.f

15

appearing as a witness on behalf of the

16

Petitioner, having been previously duly sworn,

17

testified further as follows:

18
19

DIRECT TESTIMONY (CONTINUING)
THE COURT:

Dr. Jacksonf since I need to

20

consider this in my decision and I'm bound by the Utah

21

Administrative Code, could you just go over the medical

22

necessity role and state why or why not, why you think

23

that Markelle Frei-Peterson needs this?

24

going to read it and let you address it.

25

can add anything else you want.

And I'm just
And then you

Then we'll have both

(ZL
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1
2

your findings and questions•
It says a service is medically necessary if

3

it's reasonably calculated to prevent, diagnose or cure

4

conditions in the recipient that endanger life, cause

5

suffering or pain, cause physical deformity or

6

malfunction, or threaten to cause a handicap.

7

want to take that one on first?

8
9

DR. JACKSON:

Do you

That's the first part.

Well, from my biased

perspective I feel like it's reasonably calculated to

10

use this agent and the goal would be to basically

11

prevent premature death, reduce —

12

of life by reducing dependence on total parenteral

13

nutrition, and increasing her chances of becoming

14

independent of that by being able to eat and consume

15

foods normally.

or improve quality

16

Avoid the future suffering of —

17

and things that she's already encountered of central

18

line infections, complications of central venous

19

catheters to provide the total parenteral nutrition.

20

Including infection and dislodgement and vascular

21

thrombosis.

22

disease that plagues so many patients that are on

23

chronic TPN, with the possibility of requirement for a

24

liver transplantation.

25

well, future

And finally to prevent chronic liver

THE COURT:

Okay.

And then the second part:

/ZC-

23
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1

There is no other equally effective course of treatment

2

available or suitable for the recipient requesting this

3

service which is more conservative or substantially

4

less costly.

5

Could you address that too?

DR. JACKSON:

There's no —

the alternative

6

basically is to do what we've done before which is to

7

try to encourage feedings and give time.

8

THE COURT:

9

DR. JACKSON:

Has that worked?
To my —

in my estimation it

10

hadn't worked.

11

working.

12

severe short bowel that she hasf that have been on TPN

13

as long as she had, with the struggles that she had had

14

did not have a good prognosis.

15

were destined to be TPN dependent for a long —

16

many babies in situations like this who have progressed

17

on to get liver disease.

18

We were stalemated and it wasn't

And my experience has been that patients with

In other words had a

—

we see

I have one patient who has a similar

19

situation where she lost —

she basically had somewhat

20

less bowel than Markelle has, but ended up progressing

21

on and she ended up getting a liver and small bowel

22

transplant.

23

liver transplants.

24

because they haven't been able to adapt their G.I.

25

tracts have not been counted for liver transplants and

We have others that have gone on to get
We have others that have basically
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1

so they just died,

2

So that's -- I guess in the life of a

3

pediatric enterologist an infant with short bowel

4

syndrome that's dependent on total parenteral nutrition

5

who can't adapt their G.I. tract is —

6

likelihood of progressing on to end stage liver

7

disease, cirrhosis and the complications related to

8

that.

9

has a very high

So in some ways I guess that's probably what

10

powers our urgency and interest in wanting to do things

11

like this.

12

gone through the randomized —

13

controlled type of trials, the large ones.

And maybe put a product on line before it's

14

THE COURT:

15

DR. JACKSON:

called the randomized

Okay.
So anyway, I would say that the

16

customary standard therapy that we've used for this has

17

not worked.

18

working.

19

credibility and has quite a few —

20

accumulating number of people working on it and

21

publishing in it, is this combination of growth hormone

22

therapy, glutamine, which in this case is provided in

23

the Vivonex, which is the formula which she's getting,

24

and a relatively high carbohydrate diet.

25

things that we have data on.

Or at least has a very low probability of

And the only alternative that has any
you know, has an

Those are the
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THE COURT:

Okay.

Is there anything else

you'd like to add at this time or should I let Health
Care Financing ask their questions?
DR. JACKSON:

I think that our —

I can admit

up front that the indications are not in your code for
using it this way.

The area is -- does have

controversy as with any new therapy, and there is a
possibility that this could be disproved.

And there

have been other times when medicine has gone down the
wrong path and thought they were —

had a therapy that

was helpful but it turned out not to be true.
Or there's some other element that they
weren't quite right on, they didn't know the dose, or
the timing, or the combinations weren't exactly right.
So all those kinds of things are things that can be
granted.

However, the relationship between the patient

and this physician at least in terms of background,
training, and the colleagues that I've consulted and
worked with has been —

have basically led me to

advocate the use of this therapy.

And at least in my

judgement and tying together the benefits outweigh the
risks and the costs.
THE COURT:
DR. JACKSON:

Okay.
The costs if it's successful

will be much, much less than the alternative.

in —-26
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1
2

THE COURT:

Okay, thank you.

Dr. Hylen, do

you have questions for Dr. Jackson?

3

DR. HYLEN:

Yeah, I have a question.

4

Have you given any patient growth hormone

5

that clearly prevented liver disease or liver

6

transplant over the long term?

7

DR. JACKSON:

It's a new —

no, it's a new

—

8

for us, our particular group here, it's a new approach.

9

We have probably —

Dr. Book has two patients that are

10

receiving it.

I have one other patient that's

11

receiving it.

And they're our most difficult patients.

12

So they're desperate situations actually for those

13

patients.

14

is that those patients have shown some improvement

15

since being started on it.

16

And Dr. Book's impression, albeit anecdotal,

These are, you know, these are rightfully

17

labeled and disparaged as anecdotes and that's where we

18

are.

19

justify doing this are those from the people who have

20

published in the field from Mayo Clinic and from

21

particularly from Brigham and Women's Hospital in

22

Boston.

23
24
25

The only stronger data I can have that would

THE COURT:

Okay.

—

Have those articles

already been submitted?
DR. JACKSON:

Several of those articles have

lU

,21
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1

been submitted.

2

October '97 and there's some others.

3

these come down on the side of —

4

editorial in that same article.

5

over to Dr. Hylen.

6

There's been some recent ones in

They don't —

You know, some of

and there's an
So I could fax those

they don't in my mind —

they

7

demonstrate increased —

you know, some measures of

8

increased absorption and function but over the short

9

term.

And this one small human study, eight humans in

10

a crossover study for 21 days, which is a very short

11

period of time, and these are adults, those ones don't

12

show morphologic changes.

13

what you could see when you looked microscopically at

14

the bowel.

15
16
17

THE COURT:

And there was changes in

Well, I'll leave that up to you

if you think that would be helpful then.
DR. JACKSON:

It will just be —

I don't

18

think it strengthens the case over what previous things

19

I've submitted.

But

—

20

THE COURT:

21

DR. JACKSON:

Okay.

It would certainly maybe give

22

Dr. Hylen more —

23

it's just a controversial area.

24
25

I mean since it just says it's more —

THE COURT:
10 days if you want to

Okay.

Thank you.

I'll give you

—

/ « -

28
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1

DR. JACKSON:

2

THE COURT:

3

Okay.
—

submit that or even fax that

over to us.

4

DR. JACKSON:

Okay.

5

THE COURT:

Dr. Hylen?

6

DR. HYLEN:

What's the longest that any of

7

your patients have been on growth hormone for this sort

8

of problem?

9

DR. JACKSON:

I think Dr. Book's —

I think

10

we're on about six months on one of my other patients,

11

five months on my other patient.

12

patient is probably greater than that.

13

seven months.

14

DR. HYLEN:

And Dr. Book's
Probably six or

One comment you made was that

15

since she's been on growth hormone that her liver

16

function tests have normalized.

17

they're totally normalf and what were they before, and

18

can you give us more documentation of

19

DR. JACKSON:

Does that mean that

Yes, I can.

—
I don't know why

20

her -- I actually don't know why her liver tests jumped

21

as they did.

22

that if I look back I think they jumped up and

23

normalized independent of growth hormones.

24

words I think by September they had come back down.

25

And I think

But -- and they have —

my feeling is

In other

—

,n

29
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1

DR. HYLEN:

2

DR. JACKSON:

What

—

Growth hormone was initiated in

3

December.

4

right here.

5

they had come back down some.

6
7

So I don't know that —

They weren't completely normal then but

THE COURT:

Doctor, do you want to come up

—

can you hear Dr. Hylen okay?

8

DR. HYLEN:

9

DR. JACKSON:

10

I have the data

Yeah, he can hear me.
He's in the distance but I can

hear him.

11

THE COURT:

Okay.

All right.

12

DR. HYLEN:

Anyway, we would like

13

quantification of the date she was started on growth

14

hormone and what her liver function tests were before

15

and subsequent to the —

16

what her liver functions did.

17

DR. JACKSON:

18

DR. HYLEN:

through the whole time period

Okay.

I think --

Because it's hard for us to

19

comment on some of the things that you're saying growth

20

hormone's going to do when we don't have

21

DR. JACKSON:

22

think that growth hormone did not

23

don't think growth hormone caused the normalization of

24

these liver tests.

25

DR. HYLEN:

I don't —

—

I don't really —
—

I

in my mind I

Okay.

lib-
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1

DR. JACKSON:

I don't think that it did that.

2

1 think that was an acute -- I don't know what caused

3

that exactly.

4

transaminases went up into the several hundreds without

5

much cholestasis.

6

And that's basically what one of our concerns was, that

7

she was going to start showing us some liver disease,

8

which is something we always had worried about.

9

We didn't do a liver biopsy.

Her

And her GGT went up a little bit.

But by the time that the growth hormone was

10

begun I think those numbers had come back, had started

11

to come back down.

12

know, as early as September, we have pretty much near

13

normal levels.

14

on during that period of time.

15

In fact we have some normal, you

The GGT remained slightly high off and

But I'm not claiming that the growth hormone

16

normalized liver functions.

17

stimulating adaptation of the G.I. tract and improving

18

her tolerance of enteral feedings that could set up a -

19

set the stage for continued adaptation.

20

enteral feedings she can get the more protection her

21

liver has.

22

have a much lower incidence of progressing on to liver

23

disease, even if it's partial feedings.

24

not 100 percent.

25

Its role in my mind is in

And the more

Our kids that can be fed somewhat enterally

In other words

But those that can't like she was before, as
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Ms. Peterson commented on, when she was really having
difficulty even tolerating 15 cc's an hour, that's a
tablespoon an hour of an elemental formula, that's
that was problematic.

—

That meant her G.I. tract was

not able to be fed and the risk there was of her liver
not getting the appropriate stimulation that it likes
to get to keep it from developing liver disease.
THE COURT:

Okay.

With that additional

information from Dr. Jackson, Dr. Hylen, would that
still be helpful, that information?
DR. HYLEN:

I think we still need some

quantification.
DR. JACKSON:

I'll put that together, okay.

I'll put it together in a flow sheet.
DR. HYLEN:

The other thing that I think

makes it sort of difficult here at the hearing is not
having the articles and the editorial.
DR. JACKSON:

I sent all of those articles

over back in June and I just have some of these other
recent ones.

One's as recent as October.

MR. GATZEMEIER:

Those recent ones would be

valuable.
DR. HYLEN:
DR. JACKSON:
DR. HYLEN:

We don't have the recent things.
Right.
So I think it's hard for us to
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1

comment without seeing those.

2

are you going to send us I think is what we'd like to

3

know?

4
5
6 a

DR. JACKSON:

What additional articles

I could send you an article

from Gastroenterology, 1997 October.

I could send you

recent search on short bowel and growth hormone use

7

that has the literature summarized from '93.

8

have, you know, the previous articles that I'd sent

9

over that I could put together and send again.

10

THE COURT:

11

DR. JACKSON:

And I

Okay, that would be very helpful.
There's an editorial on this

12

one article that's published by the Mayo Clinic.

13

give you a perspective.

14

not come down saying that everybody should do this.

15

THE COURT:

It'll

You know, it obviously does

Okay.

Well, what I would

16

probably like to do after Health Care Financing has had

17

an opportunity to review all that is maybe continue the

18

hearing briefly by telephone just so you can —

19

can ask you questions and vice versa.

20

other questions right now?

21

DR. HYLEN:

I don't, no.

22

THE COURT:

Mr. Gatzemeier?

23

MR. GATZEMEIER:

Yes.

they

Do you have any

First of all, Dr.

24

Jackson —

well, first of all I want to know if you've

25

read your contract with the University of Utah, the
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1

fine print.

I understand the University of Utah has in

2

fine print that nobody up there can use the word "cold

3

fusion."

4

DR. JACKSON:

That's right.

5

MR. GATZEMEIER:

Anyway, the concern I have

6

is that the reason we refused this was not on medical

7

necessity.

8
9

THE COURT:

I need to swear you in, too, now

that you 7 re presenting your case.

10

MR. GATZEMEIER:

11

THE COURT:

12

You were cross-examining but

MR. GATZEMEIER:

THE COURT:

16

MR. GATZEMEIER:

Okay.

No, whenever you7re ready.

THE COURT:

19

MR. GATZEMEIER:

21

You can swear me whenever

you want.

18-

20

I'm just asking him some

questions.

15

17

Or we can not swear, we can

attest.
THE COURT:

Whenever you're ready to present

22

your case we'll swear you in.

23

cross-examining go ahead.

24

MR. GATZEMEIER:

25

—

okay.

13
14

We're just cross-examining.

If you're

Okay.

Dr. Jackson, the

reason that was given for the state denying this was
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1

not medical necessity, it was on experimental.

2

1 understand your testimony you indicated that this

3

practice was still considered experimental?

4

DR. JACKSON:

Now, as

I think there's a lot of

5

therapies that we use that are rightfully considered

6

experimental which in terms of —

7

terms of data being accumulated and evaluating the

8

efficacy, the appropriate dosage, the appropriate

9

indications, things like that.

if you think of it in

And this one

10

particularly as early a therapy as this is, as young a

11

therapy I guess as this is would definitely I think

12

have to be considered that.

13

In my —

the strict interpretation of

14

experimental in my mind would be is she on an

15

experimental protocol of like one patient in a study.

16

And I guess I don't consider it that.

17

more of a situation of taking a therapy that's been

18

that is in use, that is new, that is not 100 percent

19

validated and may very well have certain subjects,

20

certain patients in which it works in and certain

21

p a t i e n t s that it d o e s n ' t .

22

worked o u t .

23

I consider it
—

That stuff is all being

And so I see this more as just a decision in

24

the —

I guess -- I don't know whether you call it the

25

art of medicine but it's the idea of taking data, what

/ # -
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1

data is available, and a desperate clinical situation

2

and adding up pluses and minuses and trying to come to

3 a

judgment.

And that judgment could be deemed

4

erroneous by peers or other people, but on the other

5

hand there are a number of different peers and

6

superiors to me who agree with trying this kind of

7

therapy, so they have been my guide.

8
9

So I see it in that sense as more of a
medical judgment.

I think that's what —

I think

10

that's what's interesting about this whole process here

11

is how do you decide, based on the rules and

12

regulations and your charge to take care of lots of

13

people with that pool of money, what's the best way to

14

spend that money?

15

know, is this foolishness that should not be supported?

16

And I think that just comes down to where you make it.

17

Is this a gamble?

Is this, you

If I'm her physician my judgment is that I

18

would like to try this.

I have a certain idea of how

19

to use it.

20

details and we often don't in making practice decisions

21

and making clinical decisions, we often don't.

22

don't know that this indeed is what cured the patient

23

or this indeed is what did anything.

24

j u s t claim c r e d i t for things that would h a v e

25

better

We don't have all the information or

We

A lot of times we
gotten

anyway.
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1

You look at antibiotic use for ear infections

2

or for all around -- I mean huge expenditures of money

3

on therapies that are given to people who would get

4

better anyway.

5

that are out there.

6

therapy that you do pay for, that is approved for

7

non-life threatening short stature related to

8

idiopathic growth hormone deficiency, and I'm comparing

9

that to paying for that for a child who has a

There's a lot of therapies like that
And I'm weighing this against a

10

life-threatening problem in which some people, and

11

people that have worked hard and have produced some

12

evidence in favor of it, suggest that that can be

13

beneficial.

14

The data in pediatrics is later, much later

15

than the data in adults in this case, which is often

16

the case.

17

pediatrics where we apply things —

18

drugs that are used that have never been verified or

19

proved in pediatrics.

20

of the drug reference groups for most of the

21

medications that we use it says pediatric indications

22

and use have not been established.

23

of life for practicing pediatrics.

24
25

And so we had that other issue from
there are many

You look through the PDR or any

That's just a fact

And part of it is that the society has not
deemed it necessary to study children in that regard.
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It's expensive to do that and there's concerns about
the well being of children in those situations.

So

what's happened to pediatricians is they have to take
those drugs that aren't approved for pediatrics and use
them.

And there's a very, very long tradition of doing

that, both for good and for bad for children.
So I guess I fit myself within that tradition
of making a physician's decision weighing the evidence.
And obviously I'm at the mercy of the court for looking
at the letter of the law and making a decision that
way, as is Markelle.

So I would —

what I was

proposing was a self-limited, short-term use of this
within the reason —

you know, the reasonable use of

this drug as it has been used with patients that have
growth hormone deficiency to see if it's going to make
a difference.
And are we validated by what's happened in
the last three months by her being treated?
certainly hasn't gone the other —

Well, it

hasn't gone the

wrong direction, and she seems to have made some
progress.

So that does not prove anything.

I don't

think there's anything you could write an article about
or it'd be a very dubious case report.

I don't know

what kind of a case report that would be at this point.
But it was not done within an experimental protocol.

izc
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1

It would be something —

2

that I would deem purely an experiment that way.

3

more of a medical just judgment decision based on a

4

certain amount, perhaps not optimal amount, of data

5

that's out there.

6

THE COURT:

7

MR. GATZEMEIER:

it's not the kind of thing

Okay.

It's

Any more questions?
Yeah.

Dr. Jackson, I'm sure

8

you're aware of the fact that the reasons —

and I

9

agree 100 percent with what you're saying on —

you

10

know, you have to use things as you deem appropriate

11

from a medical perspective to try and treat things.

12

Unfortunately we are in a situation in Medicaid where

13

we are governed totally by rules.

14

government because of some of the inappropriate use of

15

federal programs in the MO's and '50's have totally

16

eliminated the ability to utilize things that are

17

considered experimental predominantly, primarily

18

because they were used in a poor context previously.

19

And, you know, in the M O ' s and '50's they

The federal

20

took groups and used experimental procedures which were

21

not beneficial to the groups but were negative to the

22

groups.

23

basically said you do not use things which are

24

experimental on any of these groups.

25

laws, cuts both ways.

And so when the Medicaid law was written it

That, as most

Cuts to cut out the

lit,
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1

inappropriate experimentation, but it also eliminates

2

the ability to experiment with things that could in

3

fact be beneficial.

4

And that is one of our concerns, is that even

5

though procedures and things may be considered

6

beneficial —

7

this situation with Phen-Phen where everybody thought

8

we had a wonderful miracle thing.

9

are limited to doing things which are proven or

and we don't know.

You know, we just had

But the fact is we

10

considered proven, recognizing Phen-Phen was a

11

non-label use.

12

DR. HYLEN:

13

MR. GATZEMEIER:

14

No, it was an off-label.

DR. HYLEN:

16

MR. GATZEMEIER:

17

THE COURT:

19

But it was

approved by the FDA for that purpose.

15

18

All right.

No.
Wasn't it?

Well, that's not relevant, let's

not get into that.
MR. GATZEMEIER:

Either way.

The fact is

20

this is an off-label use as we understand it of this

21

drug and the fact is because it's an off-label use it's

22

considered experimental to us and we have a real

23

difficulty dealing with both the federal regulations

24

and the state regulations.

25

information, doctor, that shows that this drug has been

Do you have any

/ic-
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approved by either the FDA or the drug manufacturer for
on-label use for this purpose?
DR. JACKSON:
in the —

Nof nof I don't think so.

as far as I know it's not.

There might be an

INDf you know, for the people that are doing —
using it in a research setting.

Not

are

There has to be.

But

as far as I know it's not approved as an extended

—

you know, as an indication for this.
MR. GATZEMEIER:
THE COURT:
Okay.

Okay.

That's

—

Any other questions?

Duane Park has a question.

MR. PARK:

Just one question, doctor.

Before

you started the supplemental use of the growth hormone
did you do a blood level to determine what the normal
circulation was?
DR. JACKSON:

Yes, I did, actually.

I

checked IGF-1 which is a marker for that.

And she has

normal levels of IGF-1.

as I

And that's not —

understand the information I have, literature, that's
not -- that would be expected.

They don't have low

they don't have those kind of indications.

—

In other

words she doesn't have growth hormone deficiency.

The

use of growth hormone came out of observations that in
resection growth hormone levels go up.

And the

products that that stimulates that stimulate growth

lib

—
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1
2

THE COURT:
the tape.

3
4

Excuse me, doctor, I have to flip

I'm sorry.
(Whereupon, the hearing was briefly

interrupted to begin Side 2 of Tape 1.)

5

THE COURT:

Okay.

6

DR. JACKSON:

Basically the fact that your

7

growth hormone levels are normal does not necessarily —

8

does not mean -- that's not the reason that the growth -

9

why the growth hormone is being used.

It's higher than

10

normal levels of growth hormone are observed in

11

patients that have lost small bowel, and the idea that

12

they stimulate growth factor production in the body,

13

including epidermal growth factors, things like that

14

that work on the lining of the intestine to stimulate

15

growth.

16

And those are -- the other —

another

17

experimental line has been in animals that have

18

excessive growth, have tumors that express growth

19

hormone, excessive growth hormone, have hyperplasia of

20

their small bowel.

21

if you give excessive growth hormone it induces

22

transcription of the genes for all these growth factors

23

and stimulates growth of the small bowel.

24
25

And so the idea basically is that

So basically the goal here is to use it as a
pharmacologic agent rather than a replacement agent.

KINGSBURY AND ASSOCIATES, CERTIFIED SHORTHAND REPORTERS
JANE G. SAVILLE, C.S.R.

Markelle Frei-Peterson Hearing, 12/8/97

1

Though the indications for using growth hormones for

2

people of short stature is one based on replacement of

3

something that is missing.

4

used in the lines of a pharmacolgic agent to actually

5

stimulate the kind of growth factors that would be

6

required to try to make the small bowel develop and

7

grow more.

8

THE COURT:

9

DR. JACKSON:

In this case it's being

Sort of like a catalyst?
Nof it would be more actually

10

as a growth hormone, as something that you would —

11

mean, I guess Schwartzenegger could use it.

12

along those lines of a drug.

13

using it at a higher superphysiologic level.

14

I

But it's

In other words you 7 re

We're not monitoring levels, for example, of

15

IGF-1 and things like that.

16

don't know.

17

might be some of the things that people have not

18

they've looked at those things in the studies but

19

they've not used that as a marker for adjusting the

20

dose.

21

There's a lower dose that someone has used, much lower

22

than what we're using, and so there's some

23

experimentation.

24

doses.

25

Should that be done?

That might be an —

I

some of those things
—

They've just taken pretty much a standard dose.

There's some people trying different

THE C O U R T :

Okay.

Any other

questions?
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1
2

MR. GATZEMEIER:
that

Doctor, you mentioned

—

3
4

Yeah.

THE COURT:

This is Steve Gatzemeier for the

record.

5

MR. GATZEMEIER:

Yes, I'm sorry.

6

You mentioned that Markelle is receiving

7

growth hormone at this point.

8

how is that happening?

9
10

THE COURT:
know.

I believe he testified he didn't

But do you know, doctor?

11

DR. JACKSON:

12

Julie Rich would know.

13

I think I.H.C. is doing it.
I think I.H.C.

MS. PETERSON:

14

supplying that for us.

15

DR. JACKSON:

16

MS. PETERSON:

17

Who's supplying that,

Primary Children's funds is

Oh, Primary Children's

—

Primary Children's pennies,

their charity is providing the funds right now.

18

THE COURT:

That was Heidi Peterson.

19

Anything else?

20

Did you have anyone else you wanted to

21

testify for you on Markelle Frei's condition that would

22

be relevant or has the doctor pretty much covered

23

everything?

24
25

MS. RICH:

Well, I was case manager for a

brief time with Markelle.

I'm Julie Rich.

And I'd

at-
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1

just like to say that what Heidi has seen at homef if

2

you look at Markelle as a holistic person that we want

3

to make developmental milestones and progress then we

4

need to support her in this.

5

having so much stool output it made it difficult for

6

her to meet any of her milestones or progress at all.

7

It's made it a lot easier to care for her.

8

makes it easier for us to even look at decreasing

9

nursing hours in the home.

10

THE COURT:

Okay.

The fact that she was

And it

Do you solemnly swear or

11

affirm that the testimony that you have just given and

12

may be about to give is the truth, the whole truth, and

13

nothing but the truth?

14

MS. RICH:

15

THE COURT:

16

MS. RICH:

17

THE COURT:

18

Yes.
And your name?
My name's Juliana Rich.
Okay.

And was there anything

that you wanted, either of you...

19

M S . SMITH:

I'm A b b y

20

THE COURT:

Okay.

21

Smith.

R a i s e y o u r right h a n d ,

please.

22

ABBY SMITH,

23

appearing as a witness, having been first duly

24

sworn, testified as follows:

25

THE COURT:

Your name for the record?
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1

MS. SMITH:

Abby Smith.

2

THE COURT:

Okay.

3

MS. SMITH:

I'm from I.H.C. Access.

We don't

4

provide anything in the way of drugs for any Medicaid

5

patients so we would really not be able to do anything

6

for Markelle.

7

THE COURT:

8

MR. GATZEMEIER:

9

Were you able to hear that,

doctor?

10
11

Okay.

DR. JACKSON:

I lost her after she said "We

are not able to provide anything but..."

12

MS. SMITH:

Medicaid provides all of the

13

drugs for I.H.C. Access patients.

14

allowed to provide monies for drugs.

15

MR. GATZEMEIER:

So we are not

The pharmacy portion of the

16

Medicaid program is not funded through I.H.C. Access.

17

They're being paid for other services but the actual

18

expenditures of the pharmacy comes directly from the

19

state.

20

21
22

THE COURT:

Medicaid

—
MR. GATZEMEIER:

23

have some questions.

24

THE COURT:

25

Okay, any more questions from

Not at this time.

He may

Would you like to go ahead and

present --

IU-
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1
2

MR. GATZEMEIER:

Certainly.

Should we swear

all of us at the same time?

3

THE COURT:

Yes.

I'm going to swear Health

4

Care Financing in now.

5

after I administer the oath and if you'll state your

6

name then for the record.

7
8

And I'm going to point to you

(All witnesses for Health Care Financing
were sworn.)

9

MR. PARK:

10

DR. HYLEN:

11

MR. GATZEMEIER:

12

MS. NAHLEY:

13

THE COURT:

14

Yes.

Duane Park.

I do.

John Hylen.

Yes.

Yes.

Steve Gatzemeier.

Penny Nahley.

Thank you.

PENELOPE NAHLEY,

15

appearing as a witness on behalf of Health

16

Care Financing, having been first duly sworn,

17

testified as follows:

18
19
20

EXAMINATION
BY MR. GATZEMEIER:
Q

Okay.

Miss Nahley, you were the one who

21

initially took the action to deny this request.

22

you tell us what process you went by to deny that and

23

what the rationale was for denying the request?

24
25

A

Well, I went —

Can

I got out the both criterias

to see if she met any of that and she did not meet that
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1

the criteria.

2

from the physicians knowing that this was not a common

3

use for the drug according to our criteria.

4

asked for additional information to be sent and that

5

was to include any literature they had that would

6

support the use of this drug.

7

function tests, her clinical records, what type of TPN

8

she was on, her entero products, that sort of thing.

9

I asked for additional documentation

So I had

I asked for liver

That all came in and it was reviewed.

I

10

reviewed it.

11

presented it to the Check Utilization Review Committee

12

and they reviewed it and agreed that this was not a

13

typical use for this drug, that it was an experimental

14

and we denied it.

15

Q

I took a lot of notes on it and then

Okay.

When you say you took it to the Check

16

Utilization Review Committee can you tell us what the

17

constitution of that committee is.

18

A

It's made up of physicians and nurses.

19

Q

Okay.

20
21

I believe there's also a social worker

or a check portion of it?
A

I believe she is —

22

then there's the consultants.

23

consultants.

24

Q

25

Okay.

she's a social worker and
We have OTPT

And that committee reviewed this

request and determined that it was denied.

What was

/ # -
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1
2
3
4

the rationale again?
A

It was to be denied that the documentation

indicated it was an experimental procedure.
Q

Okay.

You also indicated, Miss Nahley, that

5

you looked at the criteria for growth hormones and it

6

did not meet the criteria.

7

did it not meet?

8
9

A

Specifically what criteria

She did not have a documented failure of

growth due to an endogenous growth hormone secretions.

10

Or she did not have insufficiency due to kidney

11

failure.

12

Q

Okay.

Now, the doctor has already testified

13

that this isn't really the rationale for providing this

14

drug, however this is the rationale and the

15

documentation that the state uses to determine whether

16

the drug should be prior authorized.

17

where this is found, what this comes from?

Can you tell us

18

A

Where this criteria comes

—

19

Q

Yes.

20

A

This comes from our pharmacy provider manual.

21

Q

Okay.

And the pharmacy provider manual

22

outlines the state's policy related to particular drugs

23

or utilization of

—

24

A

Yes.

25

Q

Drug types?

/2L-
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1

A

2
3

Yes.
THE COURT:

Are you going to be submitting

that into evidence?

4

MR. GATZEMEIER:

5

THE COURT:

6

Do you have any objection to

that, Dr. Jackson?

7

DR. JACKSON:

8

THE COURT:

9

Yes, we will.

Q

Oh, no.
Okay.

(By Mr. Gatzemeier)

Okay.

So you looked at

10

the information, you issued a denial letter, you got a

11

request for reconsideration.

12

information that you looked at following that denial?

13

A

Was there any additional

I'm not really sure how that came.

I believe

14

in with the hearing request there were some other

15

documentation on studies that have been done.

16

that was looked at

And so

—

17

Q

You did review that information?

18

A

—

19

Q

Did that change at all your position?

20

A

No, it's definitely stated in there that

at that time.

Uh-huh.

21

these were small groups and that it was study groups

22

that were being done.

23

It still was experimental.

24
25

Q

Okay.

Still didn't meet our criteria.

What is the documentation or the

justification for the denial on experimental?

In the

I7G _ 50
KINGSBURY AND ASSOCIATES, CERTIFIED SHORTHAND REPORTERS
JANE G. SAVILLE, C.S.R.

Markelle Frei-Peterson Hearing, 12/8/97

1

denial letter you have a citation.

2

where that came from?

3

A

Can you tell us

Let me just find it real quick.

Okay, that's

4

Utah Administrative Code R414-10-6, Physician's Covered

5

Services.

6

unproven physician services or procedures are excluded

7

from coverage."

8
9
10

MR. GATZEMEIER:
questions I have.

THE COURT:

14

THE COURT:
submitting those

16

No, that's okay.
Okay.

the denial letter

—
Yes.

Well, that is part of

—

THE COURT:

Oh, that's part of the —

okay,

that will be Respondent's --

20

MR. GATZEMEIER:

21

THE COURT:

22

Thank you.

Are you going to be

MR. GATZEMEIER:

18
19

Do you have any questions for

Miss Nahley, Dr. Jackson?
DR. JACKSON:

17

That's all the

Are there any questions of Miss

13

15

Okay.

Nahley?

11
12

And it states, "Experimental or medically

—

that you already have.

Oh, it's part of the record

already?

23

MR. G A T Z E M E I E R :

24

THE C O U R T :

25

MR. G A T Z E M E I E R :

Yes.

Okay.
Okay.

Then we'd like to

K I N G S B U R Y A N D A S S O C I A T E S , CERTIFIED SHORTHAND
JANE G. SAVILLE, C.S.R.

REPORTERS

Markelle Frei-Peterson Hearing, 12/8/97

1

call Dr. Hylen.

2
3

THE COURT:

Okay.

Dr. Hylen, want to be

sworn?

4

MR. GATZEMEIER:

Well, we'd like to call

5

Duane Park.

Duane, you've been sworn in.

6

want to get up close to a microphone.

7

You might

DUANE PARK,

8

appearing as a witness for Health Care

9

Financing, having been first duly sworn,

10

testified as follows:

11
12

EXAMINATION
BY MR. GATZEMEIER:

13

Q

Can you tell us what your credentials are?

14

A

I'm a registered pharmacist and have a

15

master's in health administration.

16

coordinate and develop the drug utilization review

17

process for the state of Utah, which is mandated by the

18

over laws of 1990, '93, and more recently in the

19

Reconciliation Act of 1997.

20
21

MR. GATZEMEIER:

DR. JACKSON:

23

MR. GATZEMEIER:

25

Can you hear him okay,

doctor?

22

24

My job is to

Q

Yes, thank you.
Okay.

(By Mr. Gatzemeier)

Mr. Park, in your

capacity with the state are you familiar with the Drug

fiL
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1

Utilization Review Board?

2

A

Very familiar with it.

3

Q

Can you tell us what that board is and who

4
5

constitutes it?
A

This is a review board composed of

6

physicians, pharmacists, one advocate for clients or

7

patients, and one advocate for the drug manufacturers'

8

organization called Pharma, and also one dentist.

9 a

It's

12-member board as defined by law what the membership

10

will be derived from.

So the numbers are set for the

11

number of physicians, pharmacists, one dentist, one

12

advocate, and one manufacturer representative.

13

Q

Okay.

What is the purpose of that board?

14

A

This board is to do drug review and

15

utilization.

16

by Medicaid are in fact used according to the law and

17

in a cost effective and patient effective manner.

18

Q

Their job is to see that the drugs used

Okay.

Has that board at all looked at the

19

possibility of —

20

that this particular drug that we're looking at is

21

basically an off-label use.

22

other than what the drug was originally identified for.

23

Has the drug utilization review board ever looked at

24

the possibility of utilizing drugs for off-label use?

25

A

you've heard testimony by Dr. Jackson

They have.

It's a new use of the drug

Growth hormone was placed on

/Zf-
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1

prior approval through the action of the DUR board.

2

They have recently passed a policy on off-label use,

3

That was independent of the recent Reconciliation Act.

4

That use recognized label use, listed unlabel user and

5

unlisted uses that would fall into the experimental

6

area.

7

MR. GATZEMEIER:

Okay.

We do have a copy of

8

the notes and the action of that board which we would

9

like to submit

10
11

—

THE COURT:
that, Dr. Jackson?

12

DR. JACKSON:

13

THE COURT:

14

Okay.

MR. GATZEMEIER:

What number?

Is that

Are we at 1 now?

Respondent's Exhibit 1.

17
18

Oh, no.

Respondent's Exhibit 1?

15
16

Do you have any objection to

THE COURT:

Okay, it was part of the record

already.

19

MR. G A T Z E M E I E R :

20

Exhibit

21

record.

1 just came in.

This w a s n o t , R e s p o n d e n t ' s
T h e other w a s part of t h e

22

THE COURT:

Okay, it's admitted.

23

(Whereupon, Respondent's Exhibit 1 was

24

received into evidence.)

25

Q

(By Mr. Gatzemeier)

All right.

Mr. Park,

/ *
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1

based on the actions of that board and as I understand

2

it you are the Department of Health staff to that

3

board; is that correct?

4

A

That is correct.

5

Q

Okay.

Based on the actions of that board and

6

the drug that we've been talking about this morning how

7

would use of that drug fall within the adopted policy

8

of that board?

9

A

This policy was developed to address a

10

mechanism for dealing with drugs just such as growth

11

hormone that have enormously broad application.

12

recognizes that the current technology and information

13

that's coming out so rapidly has yet to be codified and

14

put into approved or FDA reviewed status.

15

merely a policy that gives physicians like youf Dr.

16

Jackson, a mechanism to go to the board and request

17

that this particular drug be considered for —

18

board for coverage for a select cne-on-one patient.

19

Q

Okay.

It

So it's

by the

Based on that action of the board

is

20

the c u r r e n t requested use of the recombinant

21

growth hormone that we're talking about in this hearing

22

covered —

23

currently?

24

A

25

human

would it be covered under Medicaid

No, it would have to be —

the determination

would have to come from the DUR board, your peers, for

/ # -
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1

this specific client.

2

MR. GATZEMEIER:

And I do think that that is

3

an important notef Dr. Jackson.

That board does meet

4

monthly.

5

this is kind of —

6

Currently is that the drug is not covered but that

7

board does have the ability to say a drug will be

8

covered for a specific purpose, which in this case it

9

would seem that that might be something that you would

What our position would be currently, and
I guess it's kind of testimony.

10

want to take to that board and say, "Can this drug be

11

approved for this purpose?"

12

Recognizing we also have the capability

13

through this hearing process to review that, but, you

14

know, to preclude situations like this from happening

15

in the future if the board says that is a covered

16

Medicaid process we would not have to be in the hearing

17

process to review it.

18

THE COURT:

Would the board be reviewing the

19

use in that way for just this particular patient or for

20

all similar

21
22

—

THE WITNESS:
policy one time.

So far they have only used this

It was for a particular patient.

23

THE COURT:

24

THE WITNESS:

25

THE COURT:

For a particular patient.
For a singular use of a drug.
So that is a possibility should —

;u-
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1
2

THE WITNESS:

Uninvestigated possibility at

this point, yes.

3

THE COURT:

Okay.

Should the

4

DR. HYLEN:

I think they also could take a

5

class of patients for unlabeled.

6

either way.

7
8

THE COURT:

Okay.

—

So I think it's

Thank you for that

clarification.

9

DR. JACKSON:

Could I ask a question?

10

THE COURT:

11

DR. JACKSON:

What is DUR?

13

THE WITNESS:

Drug Utilization Review Board.

14

DR. JACKSON:

Thank you.

15

MR. GATZEMEIER:

12

Yes.
Utilization

Review?

You do have a representative

16

from the University of Utah —

17

the School of Pharmacy —

18

THE WITNESS:

actually I think it's

that is on that board.

That's correct.

Dr. Lynda

19

Oderda from the College of Pharmacy serves on the

20

board.

21

Medicine who serves on the board.

22

We also have Dr. Hare from the College of

THE COURT:

Okay.

Should he not prevail at

23

this hearing can you give him any more information on

24

how to approach that?

25

THE WITNESS:

If the policy was sent to him

UL
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1

he could see that there is an avenue that he can

2

explore which would be very similar to this one.

3

would provide all the current articles he has to the

4

board for their review and then they would determine

5

whether it's covered or not.

6

MR. GATZEMEIER:

He

Could you see that a copy of

7

that is sent to him so that he will have that avenue

8

available to him?

9
10

THE WITNESS:
doctor?

11
12

MR. GATZEMEIER:

THE COURT:

Okay.

DR. JACKSON:

16

MR. GATZEMEIER:

17

apparently don 7 t.

18

can send it to him.

19

THE COURT:

Nof thank you.
I was mistaken.

We

Okay.

Apparently they do need

your fax number.

DR. JACKSON:

22

THE COURT:

It's 588-2375.
Okay.

Was there anything else

that...

24
25

Do you have any other

So if we have that information we

21

23

We

questions for Mr. Park, Dr. Jackson?

15

20

We have the information.

can give it to you afterward.

13
14

May I have your fax number,

MR. GATZEMEIER:

Yes we'd like to call Dr.

Hylen.
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1
2

THE COURT:
now.

Thank you, Mr. Park.

3
4

Dr. Hylen is going to testify

THE COURT:

You've already been sworn,

DR. HYLEN:

Yes, I have.

doctor.

5
6

JOHN HYLEN, M.D.,

7

appearing as a witness on behalf of Health

8

Care Financing, having been first duly sworn,

9

testified as follows:

10
11

EXAMINATION
BY MR. GATZEMEIER:

12
13

Q

Okay, Dr. Hylen, you've reviewed the

situation related to this case?

14

A

Yes, I have.

15

Q

Okay.

17

A

Maybe we should start with my credentials.

18

Q

Okay.

A

Yes, I have a doctorate in medicine, and a

16

19
20

Can you tell us what your findings

are?

Can you tell us what your credentials

are?

21

master's of public health, and I'm board certified in

22

internal medicine, cardiovascular medicine, and

23

geriatric medicine.

24
25

Q

Okay.

Can you tell us what your finding and

conclusions were related to this case?
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1

A

Well, I think one of the things that concerns

2

me is that this is an area where the Drug Utilization

3

Review Committee by federal law has been set up to have

4

controls over off-label use.

5

important that they be involved in any decision that

6

would open this up.

7

they're going to approve the use of this drug in this

8

case since their judgment has to be not only based on

9

the findings of this case but also a review of the

And so I think that it's

I think I have concern that

10

literature.

11

growth hormone for this use could be disapproved, which

12

to me sounds like that it hasn't been proven yet that

13

it's effective in preventing liver disease and

14

preventing the need for liver transplants.

15

And I think Dr. Jackson has testified that

And the other thing I think we have to be

16

concerned about, what are the toxicities.

17

you're going to use this for more than a year what are

18

the toxicities for children.

19

You know, if

So I think there's several things that are of

20

concern in this case.

One certainly is expenses.

It's

21

an expensive medication.

22

the side effects and also if it is not documented to

23

prevent liver disease, progression of liver disease and

24

liver transplantation, if this is only a medication

25

that promotes feeding then are there other more

I have concerns about whether
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1

cost-effective ways to get the child or infant to eat.

2

So I think there are a lot of unanswered questions.

3

THE COURT:

The biggest one I have is is it

4

Health Care Financing's contention that I don't have

5

the jurisdiction to —

6

should be paid for in this case because of the DUR?

7

I'm

8
9
10
11
12

if I were to pay —

to say this

—
MR. GATZEMEIER:

Care Financing's

No, no, no.

It's Health

—

THE COURT:

Otherwise it shouldn't have come

this far to me.
MR. GATZEMEIER:

No, it's Health Care

13

Financing's contention that there is a —

14

administrative process set up to establish these.

15

hearing process is also an administrative process which

16

has been set up.

17

against each other.

18

that one could utilize the other.

19

there is an
The

I don't know that they have to work

THE COURT:

I think that the mechanism is such

I'm just concerned about judicial

20

efficiency and wasting everybody's, potentially wasting

21

everyone's time.

22

DR. HYLEN:

I don't have the answer to that.

23

Certainly administrative hearings have been around a

24

lot longer than the DUR C o m m i t t e e .

25

g o v e r n m e n t did set up and m a n d a t e , I m e a n , w h o ' s t h e r e ,

But the

federal

n<>-
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1

and you will function, and you will control the

2

utilization of what medications are used and how

3

they're used amongst Medicaid clients.

4

And so...

And the other thing is that I think is very

5

pertinent to the court is that the DUR has addressed

6

unlabeled uses and has set up mechanisms for approval

7

both of for individual patients and for classes of

8

patients that they can set up guidelines so that —

9

that it's not an impossibility to receive medications

10

so

on it for unlabeled uses.

11

THE COURT:

12

Uh-huh.

Okay, thank you.

Do you

have questions for Dr. Hylen, Dr. Jackson?

13

DR. JACKSON:

No.

I just reiterate that it's

14

not —

the growth hormone's indication for this

15

petition is not to try to make Markelle eat simply as

16

an appetite stimulant or anything like that.

17

really specifically to get her to reduce her dependence

18

or eliminate her dependence on parenteral nutrition.

19

And t h a t ' s t h e p r i n c i p a l reason

20

DR. H Y L E N :

21

MR. GATZEMEIER:

It's

and...

And I w o u l d agree with t h a t .

And we would all agree with

22

that.

And that's basically the reason I think the

23

state has taken for saying this is not covered.

24

hormone according to the state provider manual, the

25

drug criteria manual, is utilized —

Growth

there's two

/fr -62
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1

groups.

Both of them are growth failure.

2

recognize that is what the primary or the initial

3

rationale for utilizing this drug was.

4

different approach to utilizing the drug.

5

covered in policy as far as this is one of the things

6

we can approve.

7

which is what the DUR would address

8
9
10

We all

This is a
It's not

So until we get some change of policy,

DR. JACKSON:

—

I understand that was the

motivation for the hearing, otherwise it would have
been pretty simple.

11

THE COURT:

12

about a couple of minutes ago.

13

have the jurisdiction to do this it should have just

14

gone to the DUR Board.

15

have jurisdiction to make the ruling independent of the

16

DUR Board.

17

processes.

18
19

That's exactly what I was talking

But apparently I believe I do

I think they're two separate administrative

UNIDENTIFIED FEMALE SPEAKER:

THE C O U R T :

21

MR. GATZEMEIER:

22

THE COURT:

24
25

Were we

n o t i f i e d about the DUR before w e came this

20

23

You knowf if I don't

far?

No.

No.

And I wasn't aware how that

process worked either.
MR. GATZEMEIER:

And that's one of the things

we wanted to flush out in here is what processes there

Hit-
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1 I were, what other mechanisms and options there were.
2

UNIDENTIFIED FEMALE SPEAKER:

3

avenue we could have taken months ago?

4

MR. GATZEMEIER:

Yeah.

And this is an

Now, they just

5

addressed the issue of off-label drug use policy

6

November 13th.

7

So they have been

DR. HYLEN:

—

Well, they've been addressing it

8

over a long period of time, but this particular policy

9

came out.

10

a long

But they've been looking at that issues for

—

11

UNIDENTIFIED FEMALE SPEAKER:

So our first

12

denial we could have started this avenue?

13

have been notified about this process we could have

14

started?

15

MR. GATZEMEIER:

16

UNIDENTIFIED FEMALE SPEAKER:

17

THE COURT:

If we would

Right.
Okay.

I'd just like to encourage you,

18

Dr. Jackson, to get any other information you can in to

19

us and would five business days

20
21
22
23
24
25

DR. JACKSON:

Sure.

—
I'll just have them just

fax it to you and Dr. Hylen.
THE COURT:

Andf Dr. Hylen, how long would it

take you to review that?
DR. HYLEN:

Well, since they're going to have

more current data I think we probably should do the

I7S-'

64

KINGSBURY AND ASSOCIATES, CERTIFIED SHORTHAND REPORTERS
JANE G. SAVILLE, C.S.R.

Markelle Frei-Peterson Hearing, 12/8/97

1

same.

But that shouldn't take long.

2
3

THE COURT:
to exchange

4
5

What I'd like then is both sides

—

DR. JACKSON:

I'll send the search that I

have and I have copies of those articles.

6

THE COURT:

Then I'd like to ask Dr. Hylen to

7

send his —

8

Hopefully we don't have to have

9

the results of his research to you.

DR. JACKSON:

10

THE COURT:

—

Sure.

—
We may have the same

another hearing.

—

If you'd

11

like to, you know, comment in writing —

12

don't know if it's going to do any good to have another

13

continuation of the hearing where we discuss the

14

literature.

15

that —

16

approved then that's fine.

We know we wouldn't have to

17

go further in the hearing.

Otherwise I think I will

18

just make a decision on all the documents that are

19

s u b m i t t e d , and the evidence in the record, and t h e

20

testimony.

I think, you know, if Dr. Hylen decides

based on this literature that it should be

21
22

DR. JACKSON:

I think that's fine.

We have a

point of closure.

23

THE COURT:

24

UNIDENTIFIED FEMALE SPEAKER:

25

you know, I

Yes.
I have a

question.

/ZL-

65

KINGSBURY AND ASSOCIATES, CERTIFIED SHORTHAND REPORTERS
JANE G. SAVILLE. C.S.R.

Markelle Frei-Peterson Hearing, 12/8/97

1

THE COURT:

Yes.

2

UNIDENTIFIED FEMALE SPEAKER:

In this

3

information can it be provided from pharmacy and also

4

from Dr. Jackson or my insurance how much Markelle,

5

where we're talking about cost efficiency, how much it

6

would cost today for the growth hormone, how much she

7

costs to live for her TPN, her nutrition, my nursing,

8

and all of that so that the cost efficiency can be

9

determined in that way also?

10

THE COURT:

Yes.

11

UNIDENTIFIED FEMALE SPEAKER:

Because in the

12

long run if this does help her that would eliminate a

13

big cost every month.

14

THE COURT:

15

UNIDENTIFIED FEMALE SPEAKER:

16

So could that

be included someplace?

17
18

Okay.

THE COURT:
that would take

19

Uh-huh.

Do you know how long

—

UNIDENTIFIED FEMALE SPEAKER:

We have figures

20

and I know myself I called pharmacies to self pay for

21

the growth hormone.

22

THE COURT:

23

sufficient?

24

p e r i o d l e t m e know.

25

the court

Would five business days be

If you have any trouble with that time
If y o u 7 1 1 s u b m i t a copy of t h a t to

—
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1

UNIDENTIFIED FEMALE SPEAKER:

2

THE COURT:

3

so Dr.

Okay.

And also to Health Care Financing

—

4

UNIDENTIFIED SPEAKER:

5

MR. GATZEMEIER:

Yes.

One question.

We need to

6

clarify that it's our position that one does not

7

preclude the other.

8

experimental process.

9

elimination of the other costs but there is no cause

This growth hormone is an
Theoretically it could lead to

10

and effect proved right now.

11

this and see if it can reduce these costs.

12

this does not necessarily -- it's not given that we

13

would reduce the other costs by doing the growth

14

hormone.

15

THE COURT:

We're saying we will try

Understood.

But I —

But trying

yeahf I can

16

give the evidence the weight that I determine that it

17

should have based on what it is.

18

MR. GATZEMEIER:

We would also —

it would

19

probably be advantageous if when we're giving this

20

information to Dr. Jackson if we send him a copy of

21

this Respondent's Exhibit 1.

22

THE COURT:

Respondent's Exhibit 1, okay.

23

You can fax that right after the hearing.

24

anything

25

Is there

else?
DR. J A C K S O N :

Not from my s i d e .

K I N G S B U R Y A N D A S S O C I A T E S , CERTIFIED SHORTHAND

JANE G. SAVILLE, C.S.R.
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1

II

2

THE COURT:

Is there anything else from

Health Care Financing?

3

MR. GATZEMEIER:

4

THE COURT:

5

DR. JACKSON:

7

THE COURT:

8

DR. JACKSON:

9

THE COURT:

11 ||

—

okay, thank you very much for

your time, Dr. Jackson.

6

10

No, I think that's

Thank you.
Thank you all.
Goodbye.
Goodbye.

(Whereupon, the proceedings were
concluded for the day.)

12
13
14
15
16
17
18
19
20
21
22
23
24
25
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1

STATE OF UTAH

2

COUNTY OF SALT LAKE )

ss.

3
4

I, Jane G. Saville, Certified Shorthand

5

Reporter and Notary Public for the State of Utah,

6

residing in Salt Lake County, certify:

7

That the foregoing reporter's transcript of

8

audiotaped proceedings were stenographically prepared

9

by me upon listening to audio tape labeled "Markelle

10

Frei-Peterson" provided to me by the Utah Department of

11

Health;
That the foregoing reporter's transcript of

12
13

audio taped proceedings represents a complete

14

transcription of my stenographic notes so taken;

15

I further certify that I am neither counsel

16

for nor related to any party to said action, nor in

17

anywise interested in the outcome thereof;
In witness whereof, I have subscribed my name

18
19

and affixed my seal this

20

1998.

/

day o f

/PL/ist-nzd„

21
22

JANE G^ SAVILLE , \ C S ( R ^ a n d ^ p T A R Y

PUBLIC

23
24
25

Notary Public
J
JANE G. SAVILLE
I
1078 Lake Street
I
Sari Lake City. UthC-'/Cj I
My Commission E;:-:~:
March 11,1C: J

•
|

Stale of Utah
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Off-Label Use Drug Policy
November 13, 1997
OFF-LABEL USES
Utah restricts the covered drug products on the open formulary to uses approved and documented
by the officially recognized compendia [OBRA 1993, section 1927 (d) (6)]. The designated
compendia are:
1.
package insert, FDA approved uses
2.
American Hospital Formulary Service Drug Information (AHFS)
3.
American Medical Association Drug Evaluation (AMADE)
4.
United States Pharmacopeia Drug Information Drug Information (USP- DI)
5.
DRUGDEX
The DUR Board may approve an unlisted off-labeled use for a given drug if the off labeled use
meets the following criteria.
1.
Use must be diagnosis specific as defined by an ICD9 code (s).
2.
Off-labeled use must be supported by one major multi-site study or three smaller
studies published in JAMA, NEJM, Lancet or specialty peer review medical
journals such as Journal of Cardiology. Articles must be current - within five
years.
3.
Off-labeled use must have a defined dosage regimen.
4.
Off-labeled use must have a defined duration of treatment.
5.
The off-labeled use shows clear and significant clinical or economic advantage
over existing approved drug regimens.
The UMA, Utah based Group Practices or Utah based prescribers may have the option of
petitioning the DUR Board for coverage for an unlisted off-labeled use of a given drug. The
petitioner(s) must schedule an appearance before the Board to present the case for the petitioned
drug. Petitioners must provide documentation including one published major multi-cite study or
a minimum of three recent (five years) articles from JAMA, NEJM, Lancet or peer review
specialty medical journals such as the Journal of Cardiology, supporting the petition's
position. The documentation must be submitted six weeks in advance of the scheduled DUR
Meeting.

dp/pol icy/offlabel_use_4
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Addendum D

Short Bowel Rehabilitation Program: A Unique Approach
Including Glutamine, Growth Hormone and Special Diet
D. Wilmore, Boston
The short bowel syndrome is a lethal disease which lacks an effective low-cost method
of treatment. Because the bowel can hypertrophy following resection, we have evaluated therapy
which will enhance future compensation of the residual bowel following enterectomy. A variety
of animal studies have demonstrated the trophic effects of growth hormone (GH), glutamine
(GLN) and dietary fiber in enhancing intestinal growth and absorption of nutrients from the
gastrointestinal tract. To evaluate this effect in humans, we initially studied 15 TPN-dependent
short-bowel patients over 3-4 weeks in the Clinical Research Center; the first week served as
a control period and during the next 1-3 weeks the specific treatment was administered and
evaluated. Throughout the study, food of known composition was provided and all stool was
collected and analyzed to determine absorption across the remaining bowel. The effect of a highcarbohydrate, low-fat diet (DIET), GLN and GH administered alone or in combination with the
other therapies (GH+GLN+DIET) was evaluated. While both GH and GLN demonstrated
some independent effects, these studies indicated improvement in absorption of protein by 39%
accompanied by a 33% decrease in stool output with the combination therapy. Because of the
clinical improvement which occurred with the GH+GLN+DDET, the study was expanded to 47
adults (25 men, 22 women) with the short bowel syndrome, dependent on TPN for 6 ± 1 years.
The average age was 46+2 years and the average jejunal-ileal length was 5 0 + 7 cm (median 35
cm) in those with all or a portion of colon and 102+24 cm (median 102 cm) in those with no
colon. After 28 days of therapy, the patients were discharged on only GLN + DIET. Forty
percent of the group remain off TPN and an additional 40% have reduced their TPN
requirements, with the longest follow-up being over 5 years.

In addition to the adults, 12

children have been treated to date and these patients have shown enhanced growth velocity and
improved absorption.
This approach offers a potential method for providing cost effective rehabilitation of
surgical patients who have the short bowel syndrome or other complex problems of the
gastrointestinal tract.

This therapeutic combination may also be useful to enhance bowel

function in patients with other gastrointestinal diseases or to consider in those patients where
gastrointestinal disease or its treatment prevents a full growth potential.
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A New Treatment Option for Patients with
Short Bowel Syndrome: Bowel Rehabilitation with
Growth Hormone, Glutamine, and a Modified Diet
Theresa A. Byrne, DSc, RD, CNSD; Barbara Browning, BSN, CRNI; Natalie Tu, RD, CNSD; Douglas W. Wilmore, A
Introduction
Short bowel syndrome (SBS) is a
disorder characterized by the signs,
symptoms, and metabolic alterations
that occur due to the loss of functional
absorptive surface area of the gastrointestinal tract. The patient presents with
diarrhea, dehydration, electrolyte disturbances, malabsorption and progressive malnutrition. SBS is usually the
result of extensive small-bowel resection following intestinal infarction due
to mesenteric vascular disease, intestinal volvulus, trauma, malignancy, congenital abnormalities, or complications
of Crohn's disease. Less often the
defect is functional, rather than anatomical, as in patients with radiation
enteritis or active Crohn's disease.
The severity of this disorder depends
upon the length, location, and health of
the remaining bowel and the degree to
which the remnant bowel adapts following intestinal resection. The minimal length of small bowel required to
maintain enteral autonomy is 50-70
cm of jejunum-ileum (if the colon is
left intact) or 110-150 cm if the resec-

tion is associated with a colectomy. If
less bowel remains or if the remnant
bowel is severely diseased or damaged, dependence upon total parenteral
nutrition (TPN) is usually permanent.
In some individuals, bowel adaptation
may occur with time, and TPN is
needed for only 6-24 months.
Maximal bowel adaptation is achieved
within 1-2 years following resection.
However, if the patient is still dependent on TPN at this time in spite of
optimal medical and nutrition management, it is unlikely that the bowel will
undergo sufficient adaptation to support the individual. In these cases,
dependence on parenteral nutrition is
usually permanent (1-3) (Table 1).
Contributions and Limitations of
Long-term TPN
The first comprehensive report of
small-bowel resection in humans was
published by Haymond in 1935 (4).
From his analysis of 257 patients, he
concluded that resections of greater
than 50 percent of the small bowel
were associated with metabolic complications and a poor outcome. The

overall operative mortality u
percent and only 20 percent«
patients survived more than <
With time, developments of
diagnostic techniques and ad
intraoperative management a
for prompt surgical intervent
improved operative survival.
it was the demonstration in 1
that weight gain, growth, anc
ment could be achieved if all
nutrients were administered f
that has had the most dramat:
ence on the survival of patier
ing massive intestinal resecti*
Shortly thereafter, the concep
care evolved, and it became [
provide TPN in the home. As
of these developments, it has
mated that approximately 70
of patients with SBS are disci
from the hospital and a simik:
are alive one year later (6). B<
(Continued on t
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Table 1: Primary Factors Determining Long-term Dependence on TPN

"One of the greatest pair

Inadequate bowel length
< 50-70 cm of jejunum-ileum with colon
< 110-150 cm of jejunum-ileum with no colon

human nature is the pain

Incomplete bowel adaptation
maximized 1-2 years following resection

new idea."
Walter Bagehot( 1826English economist
-&*r
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TPN's dramatic impact on patient survival, this form of therapy quickly
became the standard approach to the
care and management of patients with
severe SBS.
Although long-term parenteral nutrition is a life-sustaining therapy for
these individuals, the complications
and extraordinary costs are now
recognized. The complications include
hepatic dysfunction (7), progressive
renal insufficiency (8), bone demineralization (9), numerous nutrient deficiencies (10, 11) and catheter sepsis
(12). Patients receiving home TPN are
hospitalized on average twice a year,
usually for septicemia. In addition, the
cost of home-administered TPN is now
estimated to be approximately $100,000
per patient year (12). Because of the
expense, many patients remain on
medical disability even though the
majority want to return to daily activities, including work. Socialization and
rehabilitation are often suboptimal. As
the patient remains dependent upon
TPN, the quality of life often deteriorates, and two-thirds of the population
report problems such as the loss of
friends, failure to find employment,
and depression (13).
Treatment Options
Because of the risk, complications,
limitations, and costs associated with
long-term TPN, researchers have
explored alternative therapeutic options
aimed at reducing or eliminating longterm parenteral nutrient requirements.
Surgical procedures to lengthen short
intestines and/or slow intestinal transit
have resulted in relatively poor clinical
outcomes (14). Successful cases of
intestinal transplantation have been
reported; however, this form of therapy
remains experimental and is associated
with significant morbidity and mortality
and tremendous costs ($500,000 per
transplant and $20,000 per patient year
for medical follow-up and immunosuppressive medications) (15). There is also
concern about the potential development
of lymphoproiiferativc disease (eg, lymphomas) in transplanted bowel seg-

ments; this problem is only no
addressed by a variety of resea
cols. Others have explored the
of bowel rehabilitation, which
the administration of specific g
factors, nutrients, and/or enten
enhance the normal physiologi
of bowel adaptation/compensa
BOWEL REHABILITATIC
Intestinal Adaptation in She
Syndrome
One of the most intriguing •<
SBS is the gradual improver™
symptoms following intestina
tion. Bowel adaptation, first d
by Flint in 1912 (16), is assoc
with a decrease in diarrhea an
sorption and an increase in tol
enteral feedings with time. Th
process is characterized by el<
and dilation of the remnant be
an increase in villus height, cr
depth, cell proliferation, and e
activity. Although the precise
nisms that account for these al
in bowel morphology and fun<
not known, similar changes ca
when one administers various
factors (eg, growth hormone, i
like growth factor 1 [IGF-1]),
exposure of the mucosa to spe
nutrients (eg, glutamine, short
fatty acids) and from the vario
tors brought into play by the p
of enteral feedings (eg, enteric
mones, pancreatic biliary seen
Together these trophic stimuli
the remnant bowel to adapt (h]
phy) (17). In addition, the com
of the diet can greatly influenc
ability of both the small and la
bowel to compensate followinj
sive intestinal resection.
Growth Hormone and the In
Tract
The exogenous administratio
growth hormone (GH) or its an
has been shown to influence bo
adaptation by enhancing mucos
hyperplasia following extensive
nal resection in animals (18, 19
Christensen and colleagues hav

Wnmwwiimimm
that GH administration increases
colonic mass (20); an effect that may
enhance the reservoir function of the
colon. The exogenous administration of
IGF-1, which is regulated by GH, has
been shown to enhance bowel hyperplasia and hypertrophy in rats following extensive jejuno-ileal resection
(21). Others have demonstrated that
IGF-1 induces ornithine decarboxylase
(22, 23), the rate-limiting enzyme in
the synthesis of polyamines (substances that are necessary for normal
cellular growth and differentiation).
While the inhibition of ornithine decarboxylase activity suppresses DNA synthesis and results in the complete
absence of intestinal adaptation following resection (24), the intraileal infusion of IGF-1 has been shown to
increase polyamine synthesis and produce a significant trophic effect on the
gastrointestinal mucosa (25).
In addition to the morphologic
effects of GH and IGF-1 on the bowel,
exogenous GH exerts specific functional effects. Growth hormone
increases water and sodium transport
in the small intestine and in the colon
(26, 27) and appears to regulate intestinal amino acid absorption in several
animal models (28). More recently,
others (29) have demonstrated that the
exogenous administration of GH
increases amino acid transport in the
human jejunum and ileum.
Glutamine and the Intestinal Tract
Like GH, glutamine (GLN) exerts
important morphologic and functional
effects on bowel. Glutamine is a major
fuel source for both the enterocytes
and the colonocytes (30) and is necessary for the maintenance of intestinal
structure, in both normal and stress
states. In animals, infusion of giutaminase markedly reduces the concentration of blood GLN: simultaneously
diarrhea, villous atrophy, mucosal
ulcerations, and intestinal necrosis
results (31). In vitro studies demonstrate that the addition of GLN to an
incubation medium stimulates cryptcell proliferation in healthy human

ileum, proximal, colon, and rectosigmoid colon (32). Animai studies have
documented that the addition of GLN
to standard amino acid solutions prevents the villous atrophy associated
with the provision of TPN in the
absence of enteral feedings (33-36). In
hospitalized patients unable to take
adequate enteral nutrition, the addition
of GLN to standard TPN solutions has
been shown to prevent TPN-induced
gut permeability (37). Enteral (rather
than parenteral) GLN has also been
shown to induce trophic or regenerative
effects on the bowel (38,39).
Glutamine is also now recognized
as a required substrate following
extensive small-bowel resection in
both animals (40) and humans (41).
Intravenous GLN supplementation has
been shown to accelerate post-resection hyperplasia following massive
intestinal resection in several animal
models (42,43).
Enteral GLN also appears to play an
important role in maximizing bowel
function by influencing nutrient
absorption. The luminal (or enteral)
administration of GLN enhances glucose absorption (44), an effect that was
not observed when GLN was administered intravenously. Others have
described the ability of enteral GLN to
enhance sodium absorption in various
models of experimentally induced
diarrhea (45-48). The administration
of oral GLN has also recently been
shown to increase circulating levels of
GH in humans (49), an effect that
could indirectly contribute to important trophic and functional effects
within the resected bowel.
The Role of Diet
Enteral nutrition is essential to the
process of bowel adaptation. Intestinal
adaptive hyperplasia does not occur in
the absence of enteral feeding — even
when the necessary calories are given
via the intravenous route (50). The
intestinal mucosa of parenterally fed
animals becomes hypoplastic and
hypofunctional (51). Levy et al (52)
provide evidence that the provision of

luminal nutrients during the t
adaptive phase of SBS incre:
likelihood of enteral autonon
patients who would otherwis
dependent. Although some a
elemental or peptide-based f
facilitate absorption, Levy et
suggest that polymeric diets
equally or more effective in
SBS patients during the earl'
erative period. The hyperosr
some of these solutions is th
contribute to diarrhea and lin
delivery of adequate calories
However, these concerns m£
unfounded, for there are no ?
which prospectively, randon
patients with very short segr
bowel to the various (eleme:
elemental, polymeric, etc.) 1
mulas and systematically ev
effect on nutrient absorptior
long-term TPN dependence
In addition to the role of e
nutrition in stimulating the p
intestinal adaptation during
postoperative period, specifi
ommendations are often inte
further assist the bowel in cc
ing for the limited surface ai
minimizing nutrient malabs<
Although some clinicians fa
continued use of liquid fonr
the long-term nutrition man;
most patients are successful
tioned to solid foods. The oi
position of these diets deper
length and location of the re
functional small bowel and
ence of colon.
Although estimates of adi
intestinal length vary from
(or about 365-600 cm) (53,
nal intubation studies have
absorption of carbohydrate,
and simple fatty acids begir
duodenum and is complete
100 cm of jejunum (55). Th
ineff ciency in absorption ii
is the uptake of triglyceride
proximal intestine is also th
area for the absorption of ir
(Continued oi
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cium, and water-soluble vitamins. If
the jejunum is removed, the ileum
adapts and assumes its absorptive
function. However, there are functions
that are unique to the ileum; they
include the absorption of vitamin B 12
and bile salts. In addition, the ileum
has a marked effect on slowing transit.
When less than 100 cm of ileum is
resected, watery cholerheic diarrhea
with little or no steatorrhea often
results. When more than 100 cm of
ileum is resected, bile salt loss in the
stool can be considerable (56).
The presence of unabsorbed bile
salts can alter the tonicity of the luminal contents and produce a secretory
state within the colon. Consequently,
there are fewer bile salts available in
the jejunum, which limits the absorption of fats and fat-soluble vitamins,
resulting in steatorrhea. The unabsorbed free fatty acids bind with calcium, magnesium, and zinc to form
insoluble intraluminal soaps. The formation of unabsorbable calcium soaps
prevents intraluminal calcium from
binding to dietary oxalates. The
unbound oxalates pass to the colon,
where they are reabsorbed and subsequently excreted in the urine. This
state of hyperoxaluria, particularly
when associated with a state of marginal hydration and decreased renal
perfusion, renders the patient more
prone to the development of calciumoxalate nephrolithiasis. An additional
factor influencing calcium absorption
is the reduction in serum 25-hydroxy
vitamin D levels, which is related in
part to the loss of ileal surface area and
the associated malabsorption of fatsoluble vitamins. The suboptimal levels of calcium and vitamin D are
thought to contribute to the osteopenia
and osteomalacia of the SBS (9,57).
Thus, for patients who have undergone extensive ileal resections (with or
without jejunal resection), the restriction of fat is thought to minimize steatorrhea, reduce the excessive loss of
divalent cations and associated complications, and if the colon is present.

diminish the bile salts that can induce
secretory diarrhea. Others have suggested that the absorptive capabilities
for high-fat and high-carbohydrate
diets (58) are similar in patients with
SBS, and argue that restriction of
dietary fat deprives these patients of
important calories (58,59). However,
because the majority of patients in
these studies did not have colons, such
recommendations cannot be applied
when the colon remains in continuity
with the remnant small bowel.
For patients with colons, low-fat,
high-carbohyrate diets aid in the compensatory response following resection.
The anaerobic bacterial metabolism of
carbohydrates (fibers and proteins) that
either resist digestion or escape absorption in the upper intestinal tract
result in the production of short-chain
fatty acids (acetate, propionate, and
butyrate), hydrogen gas, carbon dioxide, methane, and water. The shortchain fatty acids (SCFA), the major
byproducts of bacterial fermentation,
are readily absorbed by the colonic
mucosa and utilized for energy (60).
Thus, some of the carbohydrate calories that would have otherwise been
lost because of upper-intestinal tract
malabsorption can be salvaged by this
process (61). Under normal circumstances, it has been estimated that the
absorption of short-chain fatty acids
from the colon provides 5 to 10 percent of daily energy requirements (62).
For patients with short bowel syndrome, Nordgaard et al demonstrated
that a change to a 60 percent high-carbohydrate, 20 percent low-fat diet
diminished the fecal loss of calories,
compared with a diet with the reversed
ratios (63). The percentages of calories
absorbed were significantly increased
on the high-carbohydrate diet (69%)
compared to the high-fat diet (49%).
For patients without colons, the percentage of absorbed energy was similar
with both the high-carbohydrate and a
high-fat diet. In addition, the authors
noted thai intake of either diet (highfat or high-carbohydrate) did not sig-

nificantly affect the daily total <
of stool or jejunostomy output <
total fecal nitrogen content. Th<
suggest that dietary manipulate
alone could not adequately proi
independence from parenteral n
infusions that provide not only
quate calories but other imports
nutrients and necessary fluid.
CLINICAL TRIALS
Because of the stimulatory efl
GH and GLN on bowel structur
function, it was hypothesized th
substances could enhance nutrie
absorption and thereby eliminat
reduce TPN requirements when
alone or in combination with an
diet designed to enhance bowel
pensation in patients with seven
Preliminary human studies ev
ing the effect on nutrient absorp
GH, GLN, or a high-carbohydn
modified oral diet alone produo
minor biochemical changes (65
Subsequently, their combined a<
tration (GH + GLN + Diet) was
ated in a small group of SBS pa
(n = 8) that were far beyond the
of maximal adaptation (6 ± 1 ye
from the time of resection) and I
jejunal-ileal lengths (mean = 37
with colonic remnant) that class
them as individuals who would
dependent on TPN for life. All [
were admitted to a metabolic wj
28 days; the first week served as
trol period when nutrition (enter
parenteral) and medical manage
simulated their usual home then
Thereafter, exogenous GH. supp
mental IV, oral GLN, and a mod
high-carbohydrate, fiber-contain
diet were administered. The effii
of net nutrient absorption (perce
absorbed) for total calories, prot<
fat, carbohydrate, water, and sod
was calculated from the measure
nutrient intake and stool losses.
Following three weeks of treat
with GH, GLN, and the modifiec
total caloric absorption increasec
60.1 ± 6.0 to 74.3 ± 5.0 percent (
0.003), protein absoiption from <

um
1 Table 2. Effects of GH+GLN+Diet on TPN requirements.
Patient characteristics
Sex
Age
Years on TPN
Jejunal-ileal length

25 men, 22 women
46 ± 2 years
6± 1
50 ± 7 cm (median = 35 cm) with colon, n=43
102 ± 24 cm (median = 102 cm) with no colon, n =4

Results
Off TPN
Reduced TPN

n=19(40%)
n= 19(40%)

No Change in
TPN Requirements

n = 9 (20%)

Table 3. TPN requirements and selected indices of
nutritional status before and after treatment with GH+GLN+Diet.
Before GH+GLN+Diet After* GH+GLN+Diet
TPN volume (L/week)
11 ± 1
TPN calories (kcal/week)
8,816 ± 941
TPN protein (gms/week)
434 ± 27
Body weight (pounds)
132 ± 4
1 Serum albumin (gm/dL)
3.7 ± 0.1
Values represent the Mean ± SEM.
* After = 10 ± 1 months following treatment.
+ = p< 0.0001, #= p< 0.001 vs before treatment.
4.8 to 63.0 ± 5.4 percent (p < 0.006),
and carbohydrate absorption from 60.0
± 9.8 to 81.5 ± 5.3 percent (p < 0.02).
Fat absorption did not change (61.0 ±
5.3 to 60.3 ± 7.9 percent, p = NS), and
appeared to be adversely affected by
the intake of soluble fiber. Water and
sodium absorption increased from 45.7
± 6.7 to 65.0 ± 7,3 percent (p < 0.002)
and from 49.0 ± 9.8 to 69.6 ± 6.5 percent (p < 0.04), respectively. These
absorptive changes resulted in a 33
percent decrease in stool output (1,783
±414 g/day control period vs 1,308
±404 g/day by the third week of
treatment, p < 0.05).
Thus, the combined administration
of GH, GLN and a modified diet significantly enhanced the ability to
absorb calories, protein, carbohydrates,
water and sodium from the remnant
bowel following massive intestinal
resection. These changes occurred in a
group of patients that had previously
failed to adapt to the provision of

7±1 +
5,201 ± 880 #
230 ± 33 +
130 ± 4
3.8 ±0.1

enteral nutrients.
Because of the positive effects of
GH+GLN+Diet on nutrient absorption,
a subsequent study was conducted to
determine whether GH+GLN+Diet
could eliminate or reduce TPN requirements in patients with severe SBS
(65). Forty-seven adult patients who
were also far beyond the period of
maximal adaptation and had jejunalileal lengths that would classify them
as individuals who would be dependent upon TPN for life were studied
(Table 2). All patients received exogenous GH, supplemental IV and/or oral
GLN and a high-carbohydrate, modified oral diet for a minimum of 26
days. Thereafter, GH was discontinued
and patients were discharged home on
supplemental oral GLN and the modified diet.
The administration of GH+GLN+Diet
markedly altered TPN requirements.
With an average follow-up of 1 year
(range 5 months to 5 years), 40 percent

of the group remain off TPN
another 40 percent have redu
TPN requirement (Table 2).'
percent of the patients expen
significant change in TPN re
ments (65).
Thirty-one of the patients p
pated in a prospective study :
to evaluate the effects of this
on specific TPN requirement
selected indices of nutritiona
± 1 months following dischai
3). The significant decrease i
calories, protein and fluid rec
ments allowed patients to elii
reduce TPN days per week (\
turn decreased TPN-related c
Despite these significant redi
TPN requirements, body wei:
serum albumin concentration
adequately maintained. Addit
low-up studies have also indi
serum electrolytes and param
renal and liver function have
mained stable following treatn
Summary
These data suggest that tres
with GH+GLN+Diet offers ai
tive alternative to long-term 1
some patients with severe SB
Prospective, randomized trial:
underway to determine wheth
use of only one of the treatme
modalities (GH, GLN or the f
bohydrate diet) will produce e
lent results to the combined tfc
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Growth Hormone, Glutamine, and a
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Objective
The purpose of this study was to initially determine if growth hormone or nutrients, given alone or
together, could enhance absorption from the remnant small bowei after massive intestinal
resection. If clinical improvement were observed, this therapy would then be used to treat patients
with the short-bowel syndrome over the long term.

Summary Background Data
Patients who undergo extensive resection of the gastrointestinal tract frequently develop
malabsorption and require long-term parenteral nutrition. The authors hypothesized that the
administration of growth factors and/or nutrients could enhance further compensation of the
remnant intestine and thereby improve absorption. Specifically, animal studies have shown that
there is enhanced cellularity with the administration of growth hormone (GH) or glutamine (GLN),
or a fiber-containing diet.
Methods
Initially, 17 studies were performed tn 15 total parenteral nutrition (TPN)-dependent short-bowel
patients over 3 to 4 weeks in the clinical research center; the first week served as a control period,
and during the next 1 to 3 weeks, the specific treatment was administered and evaluated.
Throughout the study, food of known composition was provided and all stool was collected and
analyzed to determine absorption across the remaining bowei. The effect of a high-carbohydrate,
low-fat diet (DIET), the amino acid glutamine (GLN) and growth hormone (GH) administered alone
or in combination with the other therapies (GH 4- GLN + DIET) was evaluated. The treatment was
expanded to 47 adults (25 men, 22 women) with the short-bowel syndrome, dependent on TPN
for 6 ± 1 years. The average age was 46 ± 2 years, and the average jejunal-ileal length was 50 ±
7 cm (median 35 cm) in those with ail or a portion of colon and 102 ± 24 cm (median 102 cm) in
those with no colon. After 28 days of therapy, the patients were discharged on only GLN + DIET.

Results
The initial balance studies indicated improvement in absorption of protein by 39% accompanied
by a 33% decrease in stool output with the GH + GLN + DIET. In the long-term study, 40% of the
group remain off TPN and an additional 40% have reduced their TPN requirements, with follow-up
averaging a year and the longest being over 5 years.
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Conclusion
GH + GLN + DIET offers a potential method for providing cost-effective rehabilitation of surgical
patients who have the short-bowel syndrome or other complex problems of the gastrointestinal
tract. This therapeutic combination also may be useful to enhance bowel function in patients with
other gastrointestinal diseases and those requiring extensive intestinal operations, including
transplantation.

Intestinal resection is a commonly performed operation that is usually without complications. Occasionally,
however, removal of large segments of the small bowel
with or without a portion of the colon is necessary because of thrombosis of a mesenteric vessel, progressive
inflammatory disease, major abdominal injury, or the
presence of congenital abnormalities. These operative
procedures result in short-bowel syndrome, a disorder
characterized by an intestinal absorptive surface area
that is insufficient to support the host. This intestinal loss
results in malabsorption of fluid, electrolytes, and other
essential nutrients; severe diarrhea; dehydration; and
progressive malnutrition.1
Surgeons have long been aware of the ability of the
small bowel to compensative after massive intestinal resection. This response, first described by Hint2 in 1912
and later characterized in greater detail by many others,3"5 is accompanied by elongation and dilation of the
remnant bowel and hypertrophy of the intestinal villi,
resulting in a greater absorptive surface area and prolonged transit time. With bowel compensation, absorption of enteral nutrients is gradually enhanced and diarrhea and malabsorption are reduced6; occasionally the
clinical problems resolve. Although this adaptive response may support normal hydration and nutrition in
individuals with resection of up to 80% of the small
bowel, patients with less than 50 to 70 cm of jejunumileum (approximately I */2—21/2 ft) with an intact duodenum and a portion of colon in continuity usually require
total parenteral nutrition (TPN) for life.17 Other factors,
such as normal structure and function of other gastrointestinal organs, health of the intestinal mucosa, the presence and length of the remaining colon, and the age of
the individual, also determine the ability of a patient to
adapt and become independent of parenteral support.
Although TPN is regarded as lifesaving to patients af-
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ter massive bowel resection,8 data emerging over the pai
20 years have detailed both short- and long-term compl
cation rates of this therapy,9'" described the effect c
nightly infusions on the disruption of a normal lift
style,12 and quantitated the costs associated with the thei
apy.13 All of these factors have limited more compreher
sive rehabilitation and shortened longevity, and invest:
gators are now seeking alternative methods of care fc
this group of patients. Reconstructive procedures on th
remnant bowel and intestinal transplantation are area
of special interest to surgeons working in this field.
This report provides details of the evolution of a treai
ment program that enhances absorption of nutrient
from the remnant bowel through the use of growth fac
tors and specialized nutrients. Absorption has been er
hanced by using a combination of therapeutic agent
and this approach has now been applied to a larger grou
of patients with short-bowel syndrome to reduce orelim
inate the need for TPN for prolonged periods.

MATERIALS AND METHODS
Absorption Studies
Patients
Seventeen studies were performed in 1 5 patients (
women, 6 men; mean age, 44 years; range. 24-68 yean
with severe short-bowel syndrome. All patients had pre
viously undergone extensive bowel resection for traum*
mesenteric infarction, or inflammatory bowel diseas
with or without colonic resection. The average length c
jejunum-ileum in the group, as determined from opera
tive reports and confirmed by perioperative radiograph!
was 54 cm (range, 8-120 cm) in the 12 patients with
portion of colon in continuity and 60 cm (range, 40-10
cm) in those without a colon. All patients were chroni
cally dependent on specialized nutritional support. Th
patients were ambulatory, clinically stable, and did nc
demonstrate evidence of infection or active inflamma
tory bowel disease. In addition, they had no extradiges
tive organ failure, were free of cancer and diabetes, am
did not have a history of cancer for the past 5 years. A!
patients were able to tolerate an ad libitum oral diei
however, without parenteral support they were unable t<
adequately maintain hydration and/or nutritional sta
tus. The protocol was approved by the Brigham an<
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Women's Hospital's Committee for the Protection of
Human Subjects from Research Risks, and informed
consent was obtained from all subjects.
Study Design

The patients were admitted to the Clinical Research
Center of the Brigham and Women's Hospital for a 21 to
35 day stay. For the patients receiving a high-carbohydrate low-fat (HCLF) diet alone or diet plus growth hormone plus glutamine, the first week served as a control
period during which time the patients' nutritional (parenteral feedings, tube feedings, and ad libitum oral intake) and medical management (antidiarrheal agents,
etc.) simulated their usual home therapy. The patients
were instructed to consume the quantity and type of
foods and beverages that best represented their usual eating habits and food preferences. Only foods and beverages of known nutrient composition were provided.
Meals and snacks were made available six times per day
and beverages were readily available on an ad lib basis.
During the control period, the infusions of parenteral
nutrients and fluid volumes were matched to those prescribed by the patient's physician.
During the remaining 3 weeks, these patients received
a diet high in complex carbohydrates and low in fat but
nearly isocaloric and isonitrogenous to that which the
patient received during the control period. The diet was
targeted to provide approximately 60% of total calories
from carbohydrate, 20% from fat, and 20% from protein.
Calories and protein were divided into six feedings and
provided as meals or snacks throughout the day. Nearisotonic fluids containing glucose and sodium (Gatorade,
The Gatorade Company, Chicago, IL, and Pedialyte, Ross Laboratories, Columbus, OH) replaced both
hypo-osmolar and hyperosmolarfluidsand served as the
primary source of enteral hydration.
Two of these 10 patients received the modified diet
(HCLF diet) only. The remaining eight patients received
recombinant methionyl growth hormone (Protropin,
Genentech, Inc., San Francisco, CA) at a dose of 0.14
mg/kg/day by parenteral administration. They also received supplemental parenteral and/or enteral L-glutamine (given as an average dose of 0.6 g/kg/day (Ajinomoto USA, Raleigh, NC).
The seven additional studies examined the effects of
administering glutamine alone or growth hormone
alone. The patients received a fixed diet throughout the
entire 21 to 28 day period, which involved foods of their
choice on a 2-day rotational schedule. After the first
week, either glutamine or growth hormone was provided
as described above and the diet continued. Intravenous
feedings, fluid volume, calories, and protein were maintained at a constant level of intake throughout the entire
study period.
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During all investigations, all enteral intake and stool
output was weighed and the nitrogen, water, and sodium
contents determined. Enteral nutrient balance and absorption were then calculated from the measured enteral
intake and stool losses. Body weight was recorded daily.
Blood samples were analyzed biweekly to monitor the
response to therapy and to adjust electrolytes added to
the parenteral solution.
Determination of Nutrient Intake

All food and fluid was weighed and prepared by the
Clinical Research Center's metabolic kitchen. The total
daily intake of protein, calories, carbohydrate, fat, sodium, and water (including the water content of all foods
and beverages) was determined by a computer program
(GCRC Diet Planner, Version 2.03, Clinical Study Center, University of California, San Francisco, CA), which
translated the gram weight of intake into nutrient composition. For foods not analyzed or available on the computer program, nutrient values were determined by referring to Handbook 814 or other standards.15 On random days of the study, duplicate patient trays were
prepared and analyzed to confirm the nitrogen, fat, and
sodium content of the diet.
Measurement of Nutrient Losses

All stool was collected for consecutive 24-hour periods
between 7:30 A.M. and 7:30 A.M. beginning on the morning after admission and continuing until completion of
the study. Samples were prepared frozen at -20 C and
analyzed for water, nitrogen, sodium, and, in selected patients, fat and calories as previously described.16 Body
weight was recorded each morning to the nearest 0.1 kg
using a leveled platform scale (model SR2MI01, Acme
Scale, Oakland, CA). All blood chemical and urine analyses were determined using standard hospital analytical
techniques.
Calculations of Nutrient Absorption

The absorption of nitrogen and sodium was calculated
by subtracting the quantity of the substance present in
the stool from the enteral intake for each 24-hour period.
Stool output was the mean of the 24-hour measurements
for each week. Because nutrient intake was constant, nutrient absorption of sodium and nitrogen was calculated
by subtracting the balance of the final study week from
thefirstor control week. This was expressed as a percentage change in absorption by dividing this difference by
the control value and multiplying it by 100. The percentage change in stool weight (output) was calculated in a
similar manner.
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Table 1.
Patient
No.

PATIENT CHARACTERISTICS

Age
Gender

(yr)

Cause of R e s e c t i o n

M
F
M
F
M
F
F
F
M
M
M
F
M
M
F

44
40
29
44
47
42
42
31
48
19
68
34
27
54
57

F
F
F
F
M
M
F
M
M
F

34

28
42

28

M
M
F

61
65
44

29
30
31
32
33
34
35
36
37
38
39
40

F
M
M
M
M
M
M
F
F
F
F
M

65
70
40
54

41

F
M
F
M
M
F
M

SMA thrombosis
Small bowel volvulus
Small bowel volvulus
Small bowel volvulus
SMA thrombosis
Small bowel volvulus
Small bowel volvulus
Trauma to SMA
SMA thrombosis
Malrotation
Crohn's disease
Venous ectatic disease
Trauma
SMA thrombosis
Small bowel obstruction
secondary to adhesions
Mesenteric infarction
Portal vein thrombosis
SMA thrombosis
SMA thrombosis
SMA thrombosis
SMA thrombosis
Trauma
Volvulus
Small bowel volvulus
Small bowel obstruction
secondary to adhesions
Mesenteric infarction
SMA thrombosis
Multiple resections secondary
to adhesions
Crohn's disease
SMA thrombosis
Crohn's disease
Volvulus
Crohn's disease
Crohn's disease
SMA thrombosis
Crohn's disease
Mesenteric infarction
Crohn's disease
Congenital malrotation
Small bowel obstruction
secondary to adhesions
Crohn's disease
Volvulus
Crohn's disease
Crohn's disease
Crohn's disease
Crohn's disease
Small bowel obstruction
secondary to adhesions

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

42
43
44
45
46
47

58
50
30
71
47
45
44

26
51
57
46
55
46
38
76
34
48
54
24
70
30
53

AND RESPONSES TO

JejunumIleum (cm)

ICV

(+/-)

Colon
Rectum

THERAPY
TPN
(yr)

Discharge
TPN

Current
TPN

Off
Reduced
Reduced
No change
Reduced
Off
Reduced
Off
Off
Off
Off
No change
Off
Off
Off

Reduced
Reduced
No change
Reduced
Reduced
No change
No change
Off
Reduced
Off
Off
No change
Reduced
Off
Reduced

Reduced
Off
Off
Off
Off
Off
Reduced
Off
Off
Off

Reduced
Off
Off
Off
Off
Off
No change
Off
Off
Off

_
+
+
+

TDR
TDR
TDR
TDR
TDR
TDR
All
TDR
TDR
All
All
DR
TDR
TDR
AT

5
4
13
13
3
10
3
1.5
5
15
1
7
3
13
4

All
TDR
All
TDR
TDR
TDR
TDR
All
TDR
TDR

8
0.6
1
6

43
43

+
+
+
~~

45
46
46

+

None
TDR
AT

4.4
2
9

No change
Reduced
Off

No change
No change
Off

53
58
60
67
75
75
76
80
83
90
91
91

+
+
+
+

TDR
TDR
All
All
TDR
TDR
TDR
TDR
TDR
TDR
All
None

5
9
8
2
3
10
0.3
1
14
9
10
6

Reduced
No change
No change
Reduced
Off
Reduced
Off
Off
Reduced
Reduced
Off
Reduced

Reduced
Reduced
Reduced
Reduced
Reduced
Reduced
Off
Off
No change
Reduced
Off
Reduced

100
100
112
122
137
159
240

+
+

TDR
All

6
3
7

Off
Off
No change

Off
Off
No change
Reduced
Reduced

0
0
0
8
8
10
15
15
20
20
20
24
30
30
30
30
30
30
30
30
30
35
40

None
DCR
TDR
None
TDR

ir
7
11
7
2
1

9
10
8
5

Off
Reduced
Off
Off

Off
Reduced

TDR = transverse and descending colon and rectum; TPN = total parenteral nutrition; DCR •= descending colon and rectum; AT = ascending and transverse coion; + - with
Heal cecal valve; - = without ileal cecal valve; SMA = superior mesenteric artery.
* Received TPN and intermittent tube feedings during this time.
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Bowel Rehabilitation
Patients
This portion of the clinical investigation was performed at the Bngham and Women's Hospital Boston
Massachusetts, and at the Nutritional Restart Center
Hopkinton, Massachusetts, the latter a low-cost unit for
adults and children with severe malabsorptive disorders
Study protocols were approved by the Bngham and
Women's Hospital's Committee for the Protection of
Human Subjects from Research Risks, and informed
consent was obtained
Forty-seven adult patients with short-bowel syndrome
(25 men, 22 women, age 46 years [range, 19-76 years])
were admitted for study The clinical characteristics and
primary diagnoses of the patients are given in Table 1
All patients had undergone extensive small-bowel resection with or without colonic resection Combined jejunoileal length of the 43 patients with a colonic remnant
was 50 cm ± 7 cm For the four patients with no colon,
the combined jejunoileal length averaged 102 cm ± 24
cm Most patients (n = 39) were referred for rehabilitative therapy while they received TPN This group, on average, had received intravenous feedings for 6 years ± 1
vear Some patients (n = 8) were referred because of lack
of central venous access and progressive malnutrition
Seven patients in this category were treated without the
use of TPN On admission, all patients were clinically
stable and without evidence of infection Patients with
diabetes mellitus, cancer within 5 years of treatment
clinically active inflammatory bowel disease, s>mptomatic strictures or bowel adhesions, or severe gastrointestinal dysmotility that precluded oral intake were excluded
from study This series represents a group of patients
studied in a consecutive manner with no other exclusions
Method of Treatment
On the morning after the day of admission, a baseline
assessment of the patient's nutritional and hydration status was performed Weight was recorded to the nearest
0 1 kg, whole-body bioelectncal resistance (ohms) was
measured by a plethysmograph (model 101 A, RJL Systems, Mt Clemens, MI), and the readings were used to
calculate body water as described previously l7 In a subgroup of 31 patients followed prospectively, blood was
obtained to determine concentrations of selected nutrients (vitamins, trace elements, and essential fatty acids)
and indicators of organ function using standard analytical techniques Unne was collected to determine 24-hour
volume and creatinine excretion
Thereafter, recombinant growth hormone was administered by subcutaneous injection at a dose ranging from
0 03 to 0 14 mg/kg/day (average dose of 0 II mg ± 0 01
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mg/kg/day) Supplemental glutamine was provided by
both the parenteral and enteral routes As stool output
decreased, TPN (including the quantity of intravenous
glutamine) was reduced Parenteral glutamine dose averaged 0 16 ± 0 02 g/kg/day Because it was not possible
to determine the proportion of enteral glutamine that
was absorbed, a standard daily dose of 30 g was administered (5 g of enteral glutamine powder were mixed with
a hypotonic, cold beverage and taken six times per day)
In addition to growth hormone and glutamine, ail patients underwent extensive diet modification and nutntional education l6 The quantity and frequency of TPN
administered was gradually reduced as enteral intake
and 24-hour unne volumes increased and stool output
decreased Blood was drawn biweekly to monitor serum
electrolyte concentrations
In all but three of the persons studied, body weight,
total body resistance, intravenous fluid volume and calones, enteral fluid volume and calones, and stool and
unne volumes were measured daily. The mean of the
first 3 days (baseline) was compared with the mean of the
last 3 days of treatment (discharge) to evaluate the effect
of 4 weeks of therapy
On completion of the 26-day protocol, growth hormone was discontinued and the patients were discharged
home on oral glutamine (30 g/day) and the modified oral
diet The parenteral nutnent prescnption on discharge
was individualized for each patient, based on the individual's overall response to treatment with growth hormone plus glutamine plus HCLF diet For those patients
whose baseline nutntional assessment indicated an essential fatty acid deficiency, parenteral lipid emulsions
were prescribed Parenteral and/or enteral vitamin, trace
element, and electrolyte supplements were prescnbed at
dosages to conect nutnent deficiencies identified dunng
the baseline assessment and to maintain normal serum
concentrations
Follow-up data were collected at regular intervals and
compared with the baseline data in the group of 31 patients entered into the prospective protocol This evaluation included TPN requirements (days of infusion per
week, volume of fluid per week, intravenous protein and
calones administered per week), serum albumin concentration, and body weight Cost of pretreatment intravenous feedings and current TPN requirements were calculated using Medicare reimbursement rates ,8
At discharge, patients were classified into one of three
categones based on their response to treatment off*, reduced, and no change Off was defined as a patient who
was removed from TPN at the end of therapy In addition, patients who were referred for central line placement and received this treatment and were discharged
without the need for TPN were placed in this group
However, several of these patients occasionally received
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Table 2.

SODIUM AND PROTEIN INTAKE AND BALANCE, AND STOOL WEIGHT DURING
SPECIFIC TREATMENT PROTOCOLS
Control Period

Diet(n = 2)
Sodium
Protein
GLN(n = 3)
Sodium
Protein
GH (n = 4)
Sodium
Protein
GH + GLN + DIET(n = 8)
Sodium
Protein

Oral Intake
(g/day)

Intestinal
Balance
(9/day)

4.26 ±0.49
135.2 ±24.8

+2.24 ± 0.60
+99.0 ± 12.8

3.27 ±1.40
64.2 ±11.7

+ 1.25± 1.06
+30.9 ± 11.8

4.52 ± 0.89
118.2 ±8.3

+2.77 ± 0.05
+70.6 ±7.3

3.48 ± 0.56
88.6 ±18.8

+ 1.51 ±0.68
+45.3 ±12.3

Final Week of Treatment Period
Stool
Weight
(9/day)

Oral Intake
(g/day)

Intestinal
Balance
(g/day)

4.66 ±0.82
117.5 ±19.6

+2.46 ± 0.60
+79.4 ± 3.8

4.88 ±0.84
68.3 ±10.2

+ 1.11 ±0.86
+30.5 ±11.9

5.77± 1.16
110.5± 14.8

+4.45 ± 0.02
+73.2 ±11.0

3.73 ± 0.50
86.7 ±15.3

+2.55 ± 0.36
+54.2 ±10.7

Stool
Weight
(g/day)
1334±508

1117 ± 332

1953 ±231

2197 ±669

2268 ± 437

1872 ±351

1783 ±418

1308 ±408

% Change
with
Treatment
+ 16.3 ±10.$
+10.6 ±3.2
-19.0 ±6.7
+8.5 ± 20.:
+35.3 ± 34.S
+ 1.2±14.i
-12.9±11.'
+60.8 ± 3.5
+6.4±16i
-33.1 ± 10.C
+37.1 ± 4 0 i
+38.8 ±13.$

Values are mean ± SEM.
+ « improved protein or sodium absorption: - = decreased stool loss.
• Different from other treatment groups, p < 0.05.

specific nutrients intravenously to treat a deficiency. In
addition, these patients may have required occasional
hydration fluid. Patients who continued to receive similar amounts of TPN when compared with baseline were
considered unaffected by therapy. This was confirmed by
analyzing costs, which also demonstrated no change. Patients who were classified as reduced were, those who had
a decrease in their TPN requirements and also experienced a cost reduction.
STATISTICAL ANALYSIS
Data were analyzed using standard statistical software
(Statview No. 512, Abacus Concepts, Inc., Berkeley, CA,
on a Macintosh SE personal computer, Apple Computer, Cupertino, CA). For normally distributed data,
the paired Student's t test was used to determine differences between the control period and the last week of the
treatment period. For nonnormally distributed data, the
Wilcoxon signed rank test was used. Analysis of variance
was used to identify between-group differences. Simple
and multiple linear regression analyses were used to
identify which variables significantly influenced response to therapy. A probability value of less than or
equal to 0.05 was considered statistically significant. Results are expressed as mean ± SEM.
RESULTS
Absorption Studies
All patients were clinically stable throughout the study
period. Weight gain over the 3 to 4 weeks of study was

gradual and averaged approximately 1 kg/week. The on
dietary intake remained relatively constant throughoi
the study. The patients consumed about 2800 kcal/da
and 100 g protein/day by the enteral route, althoug
there were large variations among individuals due t
food intolerances and preferences (calories ranged fror
a group average of 1800-3700 kcal/day, and protein ir
take ranged from 64-135 g/day).
With diet modification only, sodium and protein at
sorption did not change significantly, and stool outpi
increased slightly compared with the control period (T<
ble 2). When glutamine was added to a fixed standar
diet, sodium absorption was slightly enhanced (approx
mately 35%, not significant), and protein absorption an
stool volume were likewise unaffected. Administratio
of growth hormone alone also tended to improve sodiui
absorption and somewhat enhanced protein uptake bi
reduced stool output slightly. With the administration c
all three treatment components (growth hormone pli
glutamine plus diet) there was a 37% increase in sodiui
absorption (not significant) and a 38% improvement i
protein absorption (p < 0.02). Stool loss decreased b
about one third (p < 0.05) (Fig. 1). This decrease in sto(
output was accompanied by a reduction in the frequenc
of bowel movements and often a change in stool chara<
ter from liquid to semiformed.
Response to Four Weeks of Therapy
All subjects entered into the protocol were able t
complete the treatment program, and there were n
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proximately the same quantity of parenteral support as
was necessary at the start of therapy. For each subgroup,
the changes in absorption of nutrients and fluid during
the 4-week treatment period are shown in Table 3. An
examination of the characteristics of the subjects in each
group revealed that the patients who could not be weaned
from TPN were slightly older (p = 0.02) and had Crohn's
disease as the cause of resection (p = 0.04) compared with
the other patients who were weaned from or received reduced intravenous nutrition (Table 4). In addition, the patients who failed the therapy (no change) initially had
larger stool output (p < 0.002) than the other two groups
(Table 3). There was no significant difference in bowel
length among the three groups.
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Figure 1. The effect of HCLF diet, glutamine. growth hormone, and
growth hormone plus glutamine plus HCLF diet on absorption of (top
panel) sodium, (middle panel) protein, and (bottom panel) stool output. An
increase in absorption above the 0 balance line indicates enhanced uptake; a negative change indicates decreased absorption A negative
change in stool output indicates a reduction in stool volume

dropouts. The major side effect of the treatment was fluid
retention, manifested by peripheral edema and arthralgia, which varied depending on growth hormone dose.
This problem was attenuated by limiting fluid intake, reducing the growth hormone dose, or administering diuretics. In this group of 47 patients, 15 febrile episodes
occurred; many were attributable to upper respiratory
tract infections, and these individuals were treated symptomatically. Patients diagnosed by culture with bacterial
infections (urinary tract, sinusitis, catheter sepsis) were
treated with specific antibiotics.
For the group, the 4 weeks of therapy resulted in weight
gain, an increase in intake of enteral calories and fluid,
maintenance of urine output, and diminished need for intravenous fluid and nutrients (Table 3). These responses
were variable, however; at the end of the treatment period,
27 of the 47 patients (57%) did not require TPN, 14 (30%)
had reduced TPN requirements, and 6 (13%) required ap-

The length of follow-up for all patients has been between 5 months and 5 years. During this time, most of
the patients have been cared for by their primary care
physicians and the nutritional support team located in
their immediate geographic area. Nutritional compliance was constantly reinforced and hydration state evaluated by frequent telephone interviews between ourselves and the patients. This information was conveyed
to the primary care and home care providers, who likewise emphasized the nutritional plan. We cared for and
followed directly a smaller group of patients who lived
in the New England area. Over the past 18 months, 31
patients have been entered into a prospective study to

Discharge

Current

Figure 2. The TPN status of patients after discharge after 28 days of
treatment and approximately 1 year after treatment. "Off" indicates no
TPN, "Reduced" indicates less than what was initially given, and "No
Change" indicates similar volume and calories to those initially administered.
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evaluate periodically the effect of the therapy on lonj
term nutritional intake, route of feeding, costs, and ni
tritional status.
Eight of the 27 patients who had had TPN discor
tinued eventually experienced increased requireraenl
for TPN. This occurred because of recurrence of diseas
in three patients (e.g., recurrence of active inflammator
bowel disease), dietary noncompliance in three patient*
and inappropriate removal from TPN by the care tear
in two patients. With follow-up at 1 year, 40% of th
group were off TPN, 40% received a reduced TPN pre
scription, and the remaining 20% of the patients receive
TPN similar to their initial pretreatment requiremen
(Fig. 2). At this time of follow-up (approximately 1 year
body weight and serum albumin concentration were we
maintained, despite the reduction of intravenous calc
ries and protein (Fig. 3, Table 5).
For the 31 patients followed prospectively, we could «
timate the cost savings that occurred with decreased us
of TPN. In those patients weaned from TPN, the anniu
savings was $102,270/year, and those withreducedTPI
volume, calories, and protein saved approximatel
$25,338/year (Table 4). If one assumes that all patient
would have received TPN for the coming year, applyin
these savings to the entire group in the proportion showi
at 1 year (see Fig. 2), the money saved for TPN alone wouli
equal $2,310,396/year, or about $49,157/patient/year.
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The treatment of patients with loss of large segment
of the intestinal tract has evolved rapidly over the past 31
years. In the early 1960s, it was common to simply clos
the abdomen of a patient after laparotomy if extensiv
bowei loss was identified, because no treatment wa
available after massive intestinal resection. The develop
ment of TPN provided a method for stabilization an<
support of these patients with the hope that adaptatioi
of the remnant bowel would occur over time. Althougi
this has occurred in many patients who have had ade
quate lengths of remaining small bowel, it has not beei
the case in many other persons with inadequate smal
intestine. It has been estimated that about 10,000 t<
20,000 patients with short-bowel syndrome in th
United States are now at home being maintained on in
tra venous feedings.13 That these persons can be main
tained out of the hospital over the long term is a remark
able accomplishment, and it should be realized that pa
tients with short-bowel syndrome served as the stimulu
for the growth of a new health service industry—homi
care—which has facilitated this process. However, th
long-term experience with home TPN now reveals tha
a variety of short- and long-term complications occur
including repeated episodes of catheter sepsis, nutri
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CHARACTERISTICS OF PATIENTS IN GROUPS

n
Age (yr)
Gender (male:femaie)
Jejunum-iieum length (cm)
With colon (mean)
(median)
Without colon
Years of TPN

Off

Reduced

No Change

27
43±3
15:12

14
51 ± 4
7:7

6
50±6
3:3

53±10(n = 26)
30
159(n = 1)
5±1

49± 11 (n = 11)
46
91 (n= 1)
7±1

38±13(n = 4)
41
78(n = 2)
8±1

Values are mean ± SEM.
TPN = total parenteral nutrition.

tional deficiencies, progressive failure of the liver and
kidneys, and severe osteoporosis. These problems, associated with the compromised lifestyle and major costs
(about $ 100,000/year for the TPN alone), have resulted
in other initiatives to solve the problems of patients with
short-bowel syndrome. Surgeons are evaluating the
effects of bowel reconstruction19 and intestinal transplantation20 in this group of patients.
In the past 10 years, however, several important experimental developments have contributed to the evolution
of the approach presented in this report. First, it was discovered that glutamine was the major nutrient for the
bowei. Providing parenteral feedings that contained this
amino acid supported mucosal growth under a variety of
conditions,21 including mucosal hypertrophy that occurred after extensive small-bowel resection.22 Other
studies have documented improved bowel function, including absorption, when L-glutamine was provided by
parenteral23 and/or enteral feedings.24
Second, both animal and human studies have demonstrated that growth hormone, now available in recombinant form, stimulates intestinal growth25 and enhances
transport of nutrients across the small bowel.26 Although
we observed few significant clinical effects when these

Weight
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Figure 3. Body weight and albumin at baseline and currently at approximately 1 year.

agents were administered alone, under the conditions of
our study, enhanced absorption was observed when the
agents were given together. Animal studies have revealed
a molecular basis for this proliferative response using
combined agents.27
The issue of optimizing dietary intake is more controversial, and investigators have differed in their preference
for a low-fat28 or a high-fat (unmodified) diet.29 Absorption was maximized by providing a diet that contained
20% to 25% fat, similar to recent recommendations by
others.28 However, for these patients with very short segments of jejunum-ileum, we were unable to document
major effects of diet alone. The exception to this finding
occurred when a patient consumed a high-fat intake
(>40% of total calories) during the control period and
was then placed on a 20% fat diet during the treatment
period. In addition, we have found that many patients
were sensitive to lactose and also increased their stool
output and complained of bloating with the ingestion of
simple sugars (fructose and glucose). We therefore have
provided a diet tailored to the individual but that provides about 60% of calories as complex carbohydrates,
20% as protein, and the remainder as fat. This is provided as six feedings given throughout the day, with nutrients distributed into three meals and three snacks. Vitamins and minerals are supplemented by the oral route.
Hydrogen-blocking drugs were often helpful to diminish
gastric secretion; in contrast, we have observed little benefit with the administration of somatostatin analogues,
even in the patients with high stool losses.
In this clinical trial, each subject served as his or her
own control. This approach was chosen because of the
large variation among subjects in terms of bowel disease,
length of remnant bowel, and volume of stool lost. We
found that it was possible to wean a large proportion of
these patients from TPN using this combined therapeutic approach; another sizable segment of this group was
able to reduce their weekly TPN requirements, thus giv-
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CHANGES IN TPN REQUIREMENTS, ANNUAL COSTS, AND NUTRITIONAL INDICES
BEFORE TREATMENT AND AT THE PRESENT TIME
Reduced(n=16)

Off(n = 7)
Baseline

Current

0
TPN days/wk
6±1
0
TPN voJume/wk (L)
12±2
TPN protein/wk (g)
387 ±80
0
0
TPN caJofles/wk (kcai) 9451 ±2909
Annual costs ($/yr)
102,270
0
54.0 ±2.7
Weight (kg)
57.7 ± 3.6
Albumin (g/dL)
3.9 ±0.1
3.8 ±0.1

P

Baseline

0 0001
0.002
0 003
0.018
0.0002
NS
NS

6±0
12± 1
476 ± 32
9188±1088
107,143±7117
59.5 ± 2.7
3.6 ±0.1

Current

No Change (n = 6)
P

Baseline

4±0
0.0001
6±1
7± 1
0.0006
11 ± 2
259 ± 28
0.0001
392 ±15
5744 ± 950
7518 ±1719
0.0001
81,805 ±7081 0.0003 95,227 ±12,271
60.4 ± 2.7
NS
62.7 ± 4.5
0.1
3.6 ±0.1
3.8 ±0.1

Current
6±1
I
10±2
I
375 ± 72
I
8665 ±1953
I
107.911 ±13,182 I
60.4 ± 4.5
0
3.6 ± 0.2
I

Values are mean ± SEM.
TPN • total parentefal nutrition; NS = not significant.

ing them nights off from infusion. Body weight and seindependence during the year after the initial treatme
rum albumin, major indicators of nutritional status,
Our longest-term patient has been independent of Tl
were stabilized over the follow-up period, which averfor 5 years (patient 8,15 cm jejunum anastomosed to I
aged 1 year. This series represents the largest group of transverse colon), and during the last year she becai
adult patients with short-bowel syndrome studied to date pregnant, carried a normal child to term, had a nom
by a single group of investigators, and additional
delivery, and breast-fed the infant, events that reflect I
multicenter trials are in progress involving both adults
capacity to withstand additional nutritional stress. O
and children to evaluate the effect of this approach in
ers have been free of TPN, but short-term illness has;
randomized trials.
cessitated brief intervals of intravenous support. In th<
It could be argued that the patient's response to growth eight persons who were initially weaned from TPN I
hormone plus glutamine plus HCLF diet occurred be- who eventually required intravenous feedings, about c
third were placed back on TPN because of recurrei
cause special attention was given to provide the approof
their underlying disease; dietary noncompliance v
priate diet or that specific nutrients were provided to satanother
cause of failure in several other persons. C
isfy deficiencies or because the investigators have a soplans
need
to be developed allowing for all of these p
phisticated understanding of the underlying fluid,
electrolyte, and nutritional derangements that occur in sons to receive appropriate long-term care to cc
effectively support the patient with short-bowel s
this group of patients. Although this is possible, we bedrome through intercurrent illness. For example, sevc
lieve our initial study in the Clinical Research Center indays of intravenous fluid may be necessary during p
dicates that this combination of therapeutic agents, couods of viral gastroenteritis, but with resolution of the
pled with sound nutritional and physiologic manageness and adequate hydration, enteral feeding can be
ment, resulted in the responses observed—the ability to
started. In addition, some patients may need to be
take patients off or keep them off TPN or reduce their
treated with growth hormone plus glutamine plus HC
requirements in more than 80% of this population. Numerous patients were referred to us after failure to re- diet at appropriate time intervals and/or have diet
compliance frequently reinforced by their care pro>
spond to growth hormone or glutamine administered by
ers. Further adaptation may occur with time—we h
their own physicians, and all of these patients demonworked with several patients with large daily stool IOJ
strated decreased stool output when growth hormone
(>3 L/day) who have reduced their stool output in
plus glutamine plus HCLF diet were administered in
subsequent 12 months after therapy to about one hal
combination. In addition, 14 of 21 patients who were
this volume while the diet and fluid intake have sta;
discharged without TPN and who have maintained their
the same or increased.
nutritional state in follow-up had less than 50 cm of jejunum-ileum. This is an important observation, because
Physiologic and morphologic changes occur in
this length of intestine is consistently regarded as less
bowel after therapy. With treatment, small-bowel i
than the necessary length for adequate absorption and further hypertrophy, the bowel dilates and elongates, i
nutritional maintenance by enteral feedings.1,7
intestinal transit time becomes prolonged. Colonic
Not only did the patients respond to 4 weeks of thersorption is thought to be enhanced via the process oft
apy, but also, many were able to maintain this state of
terial fermentation. This process stimulatesfluid«'
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electrolyte absorption and salvages both carbohydrate
and protein calories, which are malabsorbed by the small
bowel remnant.30 In addition, volatile fatty acids generated in the colon enhance mucosal growth and prolong
transit time.31
Because the bowel is constantly renewing its surface
area, this organ is ideal for modification by administration of selected nutrients and growth factors. Other hormones are also known to exert effects on the bowel, but
growth hormone and glutamine are currently approved
agents, readily available, safe, and reasonably inexpensive compared with the other therapeutic options. This
method of treatment should be evaluated and considered
for patients with inflammatory bowel disease, those undergoing intestinal transplantation, and those with dysfunctional loops of distended bowel who require rehabilitation. Various laboratory and clinical observations suggest that these therapeutic agents administered singly or
in combination affect intestinal structure and function
in a wide variety of conditions. These observations of patients with short-bowel syndrome may demonstrate for
the first time that we can use growth factors and nutrients
together to enhance the proliferative response of specific
tissue and therefore improve function. This concept may
have broad applications to support or enhance the
growth and function of other organs and thus improve
care of patients.
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Discussion
DR. JOHN L ROMBEAU (Philadelphia, Pennsylvania). Dr.

Wilmore and colleagues and a number of members of this Association have created a very exciting new area of surgical nutrition and metabolism; namely, the area of nutritional pharmacotherapy This is broadly defined as providing some nutrients that indeed seem to have more pharmacologic effects than
nutritional effects per se, in addition to giving some drugs that
in turn either enhance nutrient utilization or modify the metabolic environment of the host.
We have been very interested in the effects of the ammo acid
glutamine on the transplanted small intestine In a model of
transplanted small intestine in the rat, we compared the effects
of supplemental glutamine given either intravenously or directly into the graft on small bowel glucose absorption as measured with C-14 labeled glucose As shown, the addition of glutamine, when compared with an isonitrogenous controlled diet
balanced with a mixture of nonessential amino acids, significantly enhanced the ability of the small intestine to absorb glucose nearly equivalent to baseline pretransplant levels
I have one question for Dr Wilmore, and this relates to the
human short bowel setting There is very limited information
obtained from intestinal biopsies in patients that have suffered
from short bowel syndrome This information shows that the
small intestine seems to reach a maximal rate of adaptive hyperplasia somewhere between 2 and 3 years postoperatively
In Dr Wilmore's study, 10 of the 19 patients that remained
off total parenteral nutrition had been on total parenteral nutrition for periods greater than 3 years In fact, one of these
patients had actually been on total parenteral nutrition for 15
years prior to the usage of this combined therapy
My question is, what are the mechanisms by which this combined therapy enhances the absorptive function of the remaining gut in an intestine that has already had at least 3 years to
adapt endogenously?
DR. PAUL R. SCHLOERB (Kansas City, Kansas) I am as impressed by this paper as I was a quarter of a century ago when
Doug Wilmore, working with Dr Rhoads, Dr Dudnck, Dr
Vars, and others in Philadelphia, maintained an infant for
many, many weeks by total parenteral nutrition for the first
time
When you have reviewed this manuscript, as I have had the
privilege of doing, I think you will agree that this kind of study,
with careful clinical observations and measurements, could
only be canned out in a clinical research center, although it was
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not called that at the Bngham when Dr Francis Moore set
up 47 years ago
One may philosophize, I suppose, to the extent that natu
has a way of correcting defects like this The more weight th
is lost, the less nutrients are required
But it is worth emphasizing as Doug pointed out, that p
tients with less than 50 cm of jejunum-ileum are almost de
tined to require total parenteral nutrition. Two thirds of the
patients in this category were taken off total parenteral nuti
tion.
Weight gam to the tune of approximately I kg per week w,
observed in their study And I have to ask whether this weigl
was in fact water, because growth hormone does indeed pn
duce fluid retention
These favorable results are probably due in large measure 1
the effect of growth hormone, and yet the patients were di
charged while not receiving growth hormone. So my questic
is, what did growth hormone do9 What effect did it have th<
continued beyond the administration of growth hormone?
Whether it is pediatric cardiac surgery, orthotopic liver tran
plantation, or carcinoma of the pancreas, the best results ai
obtained by centralized patient care I think centralization <
care applies to this rather unusual circumstance of short-gi
syndrome. Dr. Wilmore makes reference to the possibility <
multicenter trials, and I wonder if he would share with us som
of his plans and ambitions in this regard
And finally, in terms of centralized care, I wonder, Doug,
you would acquaint us a little more with the so-called Nutr
tional Restart Center, which, from mv limited understandinj
represents a real boon to patients with short-gut syndrome.
DR STANLEY J DuDRiCK(Waterbury, Connecticut): I thoi
oughly enjoyed this impressive paper, which is in an area <
great personal clinical and scientific interest to me. I, too, ha
the opportunity to read the manuscript, which is replete wit
data that were not able to be presented here in its entirety. D
Wilmore did not have time to explain all aspects of the entr
criteria and the therapy, and, therefore, I would like to ask hir
a few questions To reduce some of the variables, patients wit
active infection and inflammatory bowel disease, cancer withi
5 years of treatment, diabetes melhtus, other extra digestive oi
gan failure, and severe gastrointestinal dysmotihty, were e*
eluded I wonder if the team had any experience treating som
of these patients that were excluded from the study? Furthei
more, do you have any recommendations for how one migh
manage patients with those exclusionary comorbid factors?
Regarding your choice of the recombinant hormone, hoi
did you determine the dosage used7 Was the final recom
mended dose arrived at by trial and error? Or did you giv
growth hormone to the point at which you began to have com
plications and then back off? Or were you able to discern som
optimal dose above which you had no additional beneficia
effects9 Additionally, what does a course of growth hormon
cost?
In measuring body water, did you fractionate the total bod
water into intracellular and extracellular water7 If so, wouI<
you share those data with us7
In the paper, you described a pregnant woman with short
bowel syndrome who came off the total parenteral nutntioi
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and eventually completed her pregnancy with delivery of the
child, apparently resulting in both a healthy mother and infant.
Did you have to reinstitute total parenteral nutrition at any
point to support her through this additional stress? Or was she
able to sustain her child and herself nutritionally entirely without the total parenteral nutrition?
Lastly, do you have any thoughts about the future use of
growth factors, including growth hormone, administered together with nutrient substrates, in the management of the failure of other single organs such as the liver, kidney, pancreas,
and brain?
I thank the authors for the opportunity to read and discuss
this fine paper, and I thank the Association for the privilege of
the floor.
DR. DONALD D. TRUNKEY (Portland, Oregon): Doug, I en-

joyed your paper very much. A couple of questions about your
no-change group.
You imply that these were patients who had chronic inflammatory bowel disease. I postulate that when you started
them in the study, they were probably in remission. My question is, what percent of the protein loss in these patients represents stool white cells? If they did get an exacerbation, did that
protein loss increase because of the white cells?
DR. W. GARDNER SMITH (Baltimore, Maryland): A clinical

question for Dr. Wilmore. Nowadays, when we explore a patient who has had an acute ischemic event to their intestine, is
there ever any indication to do what we used to do in 1965 and
simply quit? If there are indications for this course of action,
are there parameters that can help us to make that judgment,
such as length of viable intestine remaining or the age of the
patient?
DR. DOUGLAS W. WILMORE (Closing Discussion): Thank

you for the thoughtful questions and clear discussion.
The mechanisms of adaptation clearly appear related to villus hypertrophy and elongation of the remnant bowel. In animals, there is thickening of the muscularis mucosa and transit
time becomes prolonged; initially in these patients, it takes approximately 15 minutes to see barium reach the colon from the
mouth, but after 4 weeks of treatment, this time is about an
hour or so. So simply the prolongation of transit times allows
increased nutrient exposure to the absorptive surface area.
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Dr. Schloerb, as you know, the weight gain in these patients
was in part water and in part protein. The patients lose some of
the water as they come off the growth hormone. The enhanced
absorption probably continues for a prolonged period of time
for several reasons. One, we are giving oral glutamine to maintain the nutrition of the mucosa and maintain cell turnover.
But we are also using the colon as an organ for fermentation
and nutrient absorption. The unabsorbed carbohydrate and
protein that reach the colon are processed by bacteria and the
by-products absorbed so that we are converting these individuals to hind-gut ruminants.
Two multicenter trials of this therapy are being performed
in adults in the United States and in Europe. There is also a
multicenter trial being formed to use the therapy in a group of
children.
We care for the patients in a low-cost, assisted-Iiving center
where we have designated beds for patients with malabsorption
disorders. Patients have their own apartments, but interact with
the nurses, dietitians, and physicians on a regular and scheduled basis.
The doses of growth hormone we used were determined from
dose-response studies. Growth hormone costs about $300 per
day at this dose. However, growth hormone is going off orphan
drug status and will be less expensive in the next year or so as
other pharmaceutical companies bring their growth hormone
to market.
If we maintain the proportion of patients that we were able
to take off total parenteral nutrition at I year—that is, 40% off,
40% reduced, and 20% no change—the number of dollars that
we save from total parenteral nutrition cost alone is about $2.3
million a year, or approximately $50,000 per patient.
Patients who could not be taken off total parenteral nutrition
did not have active acute inflammatory disease. Which patients
should not be considered for this therapy? This is an issue of
debate because some pediatric surgeons feel that babies with
congenital lesions and little hope of survival should not be
treated. We have not treated patients with cancer or those with
known motility disorders. In general, younger patients from 20
to 55 years of age or so who have losses of large segments of
bowel are good candidates for rehabilitation. Older patients
should still receive the therapy, but may not respond as well,
particularly if they have associated heart disease and other comorbid disorders.
Thank you for the opportunity to present this work.
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Growth Hormone, Glutamine, and a Modified Diet Enhance Nutrient
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ABSTRACT. Background: Massive loss of intestinal surface nutrient absorption (percent absorbed) for total calories,
area results in the short bowel syndrome characterized by protein, fat, carbohydrate, water, and sodium was calculated
malabsorption of fluid, electrolytes, and other nutrients. from the measured nutrient intake and stool losses. Results:
Although the remaining bowel undergoes morphological and Three weeks of treatment with growth hormone, glutamine.
functional adaptation, often these changes are inadequate to and a modified diet increased total caloric absorption from
support the individual by enteral feedings, and parenteral 60.1 ± 6.0% to 74.3 ± 5.0% (/> < .003), protein absorption
nutrition is required to prevent dehydration, electrolyte from 48.8 ± 4.8% to 63.0 ± 5.4% (fi < .006), and carbohydrate
disturbances, and malnutrition. Substances such as growth absorption from 60.0 ± 9.8% to 81.5 ± 5.3% (p < .02). Eat
hormone, glutamine, and fiber exert bowel-specific trophic absorption did not change (61.0 ± 5.3% to 60.3 ± 7.9%, p =
effects and either directly or indirectly influence nutrient NS). Water and sodium absorption increased from 45.7 ± 6.7%
absorption. This study was undertaken to determine whether to 65.0 ± 7.3% (p < .002) and from 49.0 ± 9.8% to
the co-administration of exogenous growth hormone, supple- 69.6 ± 6.5% (p ^ .04), respectively. These absorptive changes
mental glutamine, and a modifiedfiber-containingdiet could resulted in a decrease in stool output (1,783 ± 414 g/d control
enhance nutrient absorption in patients who had undergone period vs 1,308 ± 404 g/d third week of treatment, p < .05).
massive intestinal resection. Methods: Ten patients (5 men, 5 Treatment with diet alone did not influence nutrient absorption
women, aged 43 ± 4 years) with short bowel syndrome were or stool output Conclusions: The combined administration of
studied 6 ± 1 years after surgical resection. All patients were growth hormone, glutamine, and a modified diet enhanced
admitted to the Clinical Research Center for a 28-day period; nutrient absorption from the remnant bowel after massive
the first week served as a control period when nutritional intestinal resection. These changes occurred in a group of
(enteral and parenteral) and medical management simulated patients that had previously failed to adapt to the provision
usual home therapy. Thereafter, eight patients received of enteral nutrients. This therapy may offer an alternative to
exogenous growth hormone, supplemental glutamine, and a long-term dependence on total parenteral nutrition for patients
modified high-carbohydrate, high-fiber diet Two patients were with severe short bowel syndrome. (Journal of Parenteral ana
treated with the modified diet alone. The efficiency of net Enteral Nutrition 19:296-302, 1995)
nent 2 Although parenteral nutrition is life^ustaining, it
can be associated with debilitating complications,
repeated hospitalizations, and significant costs (at least
$75,000 to $150,000 per patient year).3
For the patient with short bowel syndrome, various
operative approaches have been employed in attempts
to prolong intestinal transit or expand absorptive surface
area. Intestinal transplantation has also been proposed
as a solution to the problem of intestinal failure.
However, these procedures have major limitations,4*6 and
there remains a need for a relatively safe and
cost-effective treatment for these patients. We postulated
that one such therapeutic approach might be to enhance
the normal physiologic process of intestinal adaptation
by administering substances that are trophic to the
bowel and/or directly or indirectly influence nutrient
absorption.
Received for publication, August 8,1994.
Intestinal growth and adaptation are mediated in part
Accepted for publication, November 30,1994.
by factors extrinsic to the gastrointestinal tract (eg,
Correspondence and reprint requests: Douglas W. Wilmore, MD, Brigham
growth hormone and thyroxine) and in part by local
& Women's Hospital 75 Francis Street, Boston, MA 02115.
Extensive loss or dysfunction of the intestinal
absorptive surface area results in the short bowel
syndrome. This symptom complex is characterized by
diarrhea, dehydration, electrolyte disturbances, malabsorption, and progressive malnutrition. The severity of
this disorder depends upon the length, location, and
absorptive function of the remaining bowel and its ability
to accommodate the reduced absorptive surface area.1
The compensatory process may occur for 1 to 2 years
before adaptation is maximal and during this period
parenteral nutrition is frequently required. In patients
with very short segments of jejunum or ileum (< 60
cm), sufficient adaptation of the remnant bowel to
support the individual by enteral feedings is unlikely,
and dependence on parenteral nutrition may be perma-
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factors brought into play by the provision of enteral
feedings (eg, exposure of the mucosa to specific
nutrients, pancreatic-biliary secretions, or enteric hormones).6 The amino acid glutamine is a primary energy
source for the gastrointestinal tract;7 it exerts trophic
effects on the bowel8 and stimulates nutrient absorption.910 Similarly, fiber is a specific component of the
diet that may enhance bowel adaptation by promoting
bowel growth and cell proliferation11 by slowing
gastrointestinal transit time.12,13 Although previous pilot
studies investigating the effect of growth hormone or
glutamine alone on nutrient absorption in patients with
short bowel syndrome produced minor biochemical
changes, no significant clinical effects were observed.
Others studies have shown that simple dietary manipulation (eg, restricting fat or increasing carbohydrate
intake) fails to significantly enhance nutrient absorption.14"16 Because a single treatment modality is unlikely
to induce all the adaptive changes that occur within
the resected gastrointestinal tract, we hypothesized that
the co-administration of trophic substances such as
growth hormone and supplemental glutamine in combination with a low-fat, high-carbohydrate, fiber-containing
diet would significantly enhance nutrient absorption
from the remnant bowel of patients who had undergone
massive intestinal resection.
METHODS

Patients
Ten patients (5 females, 5 males, mean age 43 i 4 years) with
severe short bowel syndrome were admitted to the Clinical Research
Center of the Brigham and Women's Hospital, Boston, MA. All patients
had undergone extensive small bowel resection with or without colonic
resection. The lengths of the remaining gut structures were determined
from operative reports and confirmed by perioperative radiographs
(Table I). Patients were ambulatory and clinically stable and without
evidence of uncontrolled infection or active inflammatory bowel
disease. In addition, they had no extradigestive organ failure, were
free of cancer, and did not have a history of cancer. All patients
were able to tolerate an ad libitum diet; however, without parenteral
support they were unable to adequately maintain hydration and/or
nutritional status. The protocol was approved by the Hospital's
Committee for the Protection of Human Subjects from Research Risks,
and informed consent was obtained.

Study Design
• The patients were admitted to the Clinical Research Center for a
2&day stay. The first week served as a control period during which
the patients' nutritional (parenteral and enteral feedings and ad libitum
oral intake) and medical management (antidiarrheal agents, etc)
simulated their usual home therapy. Patients were instructed to
consume the quantity and type of foods and beverages that best
represented their usual earing habits and food preferences. Only food
and beverages of known nutrient composition were provided. Meals
and snacks were made available six times per day. Self-selected
beverages were made available 24 h/d. The supplemental enteral tube
feeding that two patients received at home before admission was
provided and administered at the same rate and concentration. During
the control period, the infusion of parenteral nutrients and fluid
volumes was matched to those that had been prescribed by the
patient's primary-care physician before the research protocol. The
nutrient solutions were prepared daily in the hospital pharmacy as
previously described." Electrolytes were added daily to the nutrient
solution in quantities necessary to maintain normal serum concentrations. •.
Daring the remaining 3 weeks, all patients received a diet that
wis high in complex carbohydrates and low in fat, but nearly isocatoric
and lspnitzogenous to that which the patient received during the

control period. The diet was designed to provide approximately
of total calories from carbohydrate, 20% from fat, and 20% 1
protein. Total dietary fiber (defined as the sum of insoluble fib
soluble fiber) intake increased as complex carbohydrates repl;
simple sugars. In addition, a soluble fiber supplement (Apple p<
powder, Solgar, Lynbrook, NY) was added to specific food item
tolerated. Calories and protein were distributed into six feedings
served throughout the day. Near-isotonic fluids containing glu
and sodium (Gatorade, The Gatorade Company, Chicago, IL,
Pedialyte, Ross Laboratories, Columbus, OH) replaced both hypohyperosmolar fluids and served as the primary source of em
hydration. Two of the 10 patients were treated with this mod
oral diet alone (Diet).
In addition to the modified diet, eight patients received recombt
methionyi-growth hormone (Protropin, Genentech Inc, South
Francisco, CA) at a dose of .14 mg/kg per day by parent
administration. They also received supplemental parenteral an
enteral L-glutamine (Ajinomoto USA, Raleigh, NO) (GH+GLN+D
During the 3-week treatment period, parenteral protein requirem
were provided by administering a commercially available amino
solution rich in essential amino acids (Renamine, Baxter Health <
Corporation, McGraw Park, IL) supplemented with crystalline h
tamine (average parenteral dose = .42 g/kg per day). The glutam
supplemented amino acid mixture was combined with hypext
glucose and fat emulsion to provide an isocaloric and isonitroger
infusion that was comparable to that received during the cor
period. Vitamin and trace elements were added to the glutamine
riched solution as had been prescribed during the control pei
and electrolytes continued to be adjusted to maintain normal bl
concentration. For those patients not receiving parenterally inft
nutrients, i^glutamine powder was provided enterally at an avei
dose .63 g/kg per day, which was slightly higher than the parent
dose because it was assumed that a portion of enterally administe
glutamine would be malabsorbed.
Throughout the entire 28-day study period, all enteral intake
stool output were weighed, and the calorie, nitrogen, fat, water,
sodium contents were determined. Nutrient balance and net absorpi
were then calculated from the measured enteral intake and si
losses. Weight was recorded daily. Twenty-four hour urinary creatir
was measured daily during the control period to identify the deg
of skeletal muscle mass depletion. Blood samples were analy
biweekly to monitor response to therapy.

Details of the Study

Determination of nutrient intake. All enteral diets were provi*
by the Clinical Research Center's metabolic kitchen. Over the en
28-day study period, all administered food was weighed and fl
measured before consumption. The total daily intake of profc
carbohydrate, fat, sodium, and water (including the water content
all food and beverages) was determined by a computer prog!
(GCRC Diet Planner, Version 2.03, Clinical Study <3enter, Unrvei!
of California, San Francisco, CA), which translated the gram wei
of intake into nutrient composition. For food sources not listed
the computer program, nutrient values were determined either fr
product information or from Bowes and Church's Food Values
Portions Commonly Used u The nutrient composition of all tube feedii
was determined from the manufacturer's specifications. On rand
days of the study, duplicate patient trays were prepared and fc
analyses confirmed the nitrogen, fat, and sodium content of the di
Daily caloric intake was expressed as the gross energy content
the diet (ie, the heat of combustion) rather than metabolizable enei
(heat of combustion minus fecal and urinary calories).* The calculal
values were then confirmed by actual food analysis determined '
bomb calorimetxy (Hazelton Laboratories America, Inc., Madison, W
The total and soluble dietary fiber content of the control and treatm*
diets was calculated from standard tables.**1 Supplemental solul
fiber dose was determined by weighing a proportioned serving at f
beginning and the end of each 24-hour study period.
Measurement of nutrient losses. All stool was collected for consecuti
24-hour periods between 7:30 AM and 7:30 AM beginning on the morni
after admission and continuing until completion of the study. Sampl
were frozen at -20°C. At the end of the study, the samples w«
thawed; liquid stool was blended and known quantities of distill
water added to semi-solid stool before blending. The homogenir
stool samples were then analyzed for calories, nitrogen, and Cat
previously described." Stool nitrogen (grams) was converted to stc
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protein (grams) by multiplying by 6.25. Calories (kcai) derived from averaged 6 ± 1 years. Mean jejunal-ileal length was 37
stool protein were determined by multiplying the gram quantity of cm (range 8 to 90 cm) for the GH+GLN+Diet-treatec
stool protein by 5.65 (23.64 kJ).* Stool fat calories (kcai) were
determined by multiplying the quantity of stool fat (grams) by 9.35 patients. The jejunal-ileal length of the two patients treatec
(39.12 kJ)." Stool carbohydrate calories were determined by subtracting with Diet alone ranged from 65 to 120 cm. In all patients
the sum of stool protein and fat calories from the total stool calories. the remnant of small intestine was in continuity with the
The gram quantity of stool carbohydrate was then estimated by remaining colon Before admission, six patients receivec
dividing stool carbohydrate calories (kcai) by 4.2 (17.57 kJ).** The
sodium concentration of the stool was determined by use of a flame parenteral nutrition at home 6 to 7 d/wk. Two patienfc
photometer (Instrumentation Laboratory, Lexington, MA). Stool wet (#2 and #7) were unable to receive IV nutrient infusion*
and dry weights were determined by weighing the samples before due to central vein thrombosis and received daih
and after 72 hours of drying in a 90°C oven (Precision Scientific Co, administration of elemental or semi-elemental entera
Chicago, EL). Stool water was defined as the difference between the
tube feedings; these patients were severely undemour
wet and dry weight of the stool.
Nutritional assessment and patient monitoring. Body weight was ished when their weight and CHI were compared witl
recorded each morning to the nearest .1 kg using a leveled platform healthy individuals (Table I). Two additional patient
scale (model SR2MI01, Acme Scale, Oakland, CA). Ideal body weight (#5 and #10) were maintained at home on an oral die
was determined from standard tables.0 All blood chemical and urine
analyses were determined using standard hospital analytical techniques. supplemented occasionally with infusion of isotonic
Creatinine height index (CHI) was calculated from the mean 24-hour fluids and electrolytes to maintain normal hydration anc
urinary creatinine excretion rate during the control period. Actual serum electrolyte concentrations; these patients wen
excretion was compared with the expected excretion rate for an also less than optimally nourished (Table I).
individual of similar height, frame size, and sex, and the values were
At the time of admission, body weight was 87 ± 49
expressed as a percent of the standard.0 A radioimmunoassay technique
22
was used to determine the plasma concentration of insulin-like growth of ideal body weight Creatinine height index was 79.<
23
factor-one (IGF-1).*
± 5.9% of normal. All patients remained clinicall:
Calculations of nutrient absorption. The net absorption of nitrogen,stable throughout the study period. Weight gain ove
fat, carbohydrate, calories, sodium, and water was calculated by
subtracting the quantity present in the stool from the enteral intake the 28-day admission period averaged 5.4 ± 1.2 kg
for each 24-hour period. The efficiency of nutrient absorption (percent Blood concentrations of urea nitrogen, creatinine
of intake absorbed) was calculated by dividing the quantity absorbed glucose, aspartate-aminotransferase,
alkaline phos
by nutrient intake and multiplying the result by one hundred. The phatase, and total bilirubin did not vary significant!;
ability to absorb food weight was determined by subtracting 24-hour
stool weight from the total weight of all food and beverages consumed throughout the study. Treatment with GH+GLN+Die
during that 24-hour period. The percent of food weight absorbed was resulted in a significant increase in plasma concentration
calculated by dividing the quantity absorbed by the total weight of of IGF-1 (110 ± 25 \Lg/L at baseline to 478 ± 112 \vgfi
intake and multiplying the result by one hundred.
by the end of the fourth week, p ^ .01). Serun

Statistical Analysis
Data were analyzed using standard statistical software (StatView
No. 512, Abacus Concepts, Inc, Berkeley, CA) on a Macintosh SE
personal computer (Apple Computer, Cupertino, CA). Paired Students
t tests were used to determine differences between the control period
and the final week of study. Non-paired Student's t tests were used
to identify differences in nutrient intake between the GH+GLN+Diettreated patients and those treated with the modified Diet alone. Simple
linear regression analysis was used to describe the relationship between
dependent and independent variables. A p value s .05 was considered
statistically significant. Results are expressed as means ± SEM.

concentrations of IGF-1 remained relatively stable fo
the patients treated with Diet alone (152 ± 7.5 jig/L a
baseline to 184 ± 23.5 u.g/L by the end of the fourti
week).
Nutrient Intake

Average daily enteral intake during the control perio*
and the final week of treatment is provided in Tab!
n. For the GH+GLN+Diet-treated patients, the compc
sition
of the enteral diet consumed during the contrc
RESULTS
period consisted of 51.7 ± 4.8% of total caloric intak
The clinical characteristics of the patients are provided as carbohydrate, 29.6 ± 4.3% as fat, and 18.7 ± 1.4S
in Table L The time elapsed since the last surgical resection as protein. Total dietary fiber intake averaged 1 g pe
TABLE I

Patient characteristics
Remaining bowel
Pa tient group

GH + GLN + Diet
1
2
3
4
5
6
7
8
Diet
9
10

Sex

Age
(y)

Diagnosis

M
M
F
F
F
F
M
F

51
68
44
37
28
31
45
42

Small bowel volvulus
SMA thrombosis
Crohn's disease
SMA thrombosis
Trauma to SMA
Venous ectatic disease
SMA thrombosis
Small bowel volvulus

M
M

52
34

Small bowel volvulus
Crohn's disease

Yean since
resection

Jejunum/
(cm)

0.5
8
9
7
6
5
7
11
1
5

Ileocecal
valve

Colon/
rectum

Ideal body weight
(percent of ideal)

Creatinine
height index
(percent of normal)

+

All
TDK
TDR
TDR
TDR
SCR
TDR
TDR

74.3
69.9
95.2
113.0
93.9
89.6
77.1
94.3

54.5
61.9
89.7
100.0
90.1
77.7
50.7
96.2

All
TDR

80.1
81.6

75.1
100.0

65
30
90
30
15
24
30
8

-

65
>120

-

—i

+
or«o

Nutritional status

i,*A «w%L\n

mr\A

nreMnt: - . absent / / ,
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-220 kcal (921 kJ\ Soluble fiber provided approximately
20% of total fiber intake. The composition of the baseline
enteral intake of the two patients treated with Diet
alone was similar to the other patients: 48.6 ± 3.4% of
total caloric intake from carbohydrate, 30.1 ± 2.3% from
fat, and 21.4 ± 1.0% from protein. Total dietary fiber
intake averaged 1 g per -180 kcal (753 kJ) with soluble
fiber providing approximately 19% of total fiber intake.
During the control period, food weight, water, and
sodium intakes were also similar among all patients.
For the GH+GLN+Diet-treated patients, the percent
of total calories derived from carbohydrate increased
significantly to provide 61.3 ± 4.1% of total caloric
intake (p ^ .03 vs the control period); percent fat intake
decreased significantly to 17.9 ± 3.1% (p < .01 vs the
control period), and protein intake remained relatively
constant at 20.8 ± 1.7%. There was a tendency for
caloric intake to decrease as dietary fat was replaced
with carbohydrate and fiber-containing foods, which
provided greater food volume. Total dietary fiber intake
increased to provide 1 g of fiber per -100 kcal (p < .002
vs control period). Soluble fiber intake also increased
significantly (from 2.47 g/d during the control period to
5.58 ± 1.37 g/d by the fourth week of study, p < .05)
and provided -24% of the totalfiberintake. The composition
of the modified enteral intake of the two patients treated
with Diet alone was similar to the other patients: 60.6
± .8% carbohydrate, 20.0 ± .6% fat, and 19.4 ± .3% protein.
Both total and soluble fiber intake was similar to that
which was consumed by the GH+GLN+Diet-treated
patients during their final week of treatment For all
patients, food weight and the mean intakes of water
and sodium were well matched to that which was
consumed during the control period (Table II).
For the GH+GLN+Diet-treated patients, parenteral
nutrition provided 26 ± 4 kcal/kg per day (109 ± 17
kJ/kg per day) and 1.2 ± .2 g of protein/kg per day
during the control period. These values did not differ
significantly from the calories or protein infused during
the final week of study, 23 ± 6 kcal/kg per day (96
± 25 kJ/kg per day) and 1.1 ± 2 g of protein/kg per
day. For the patients treated with Diet alone, parenteral
nutrition provided 29 ± 7 kcal/kg per day (121 ± 30
kJ/kg per day) during the control period and 25 ± 6

29

kcal/kg per day (105 ± 25 kJ/kg per day) during th<
final week of treatment. Because the Diet-treated patient
tended to consume a greater quantity of enteral protein
IV protein was provided at a slightly lower dose thai
that which was administered to the GH+GLN+Diet
treated patients (0.8 ± .2 g/kg per day during the contro
penod and .7 ± .2 g/kg per day during the final weel
of treatment). Total protein intake (enteral + parenteral
during the control period (2.4 ± .2 g/kg per daj
GH+GLN+Diet vs 2.8 g/kg per day Diet alone) and th(
final week of treatment (2.4 ± .2 g/kg per da]
GH+GLN+Diet vs 2.5 ± .3 g/kg per day Diet alone) die
not differ between the two groups.
Nutrient Absorption
Stool output of the GH+GLN+Diet-treated patients wa<
1,783 ± 414 g/d during the control period and decreasec
to 1,308 ± 404 g/d (p < .05) during the fourth week oi
study. This decrease in stool output was associated with
significant increases in the ability to absorb food weight
(p < .0001), calories (p < .003), protein (p < 0.006)
carbohydrate (p ^ .02), water (p s .002), and sodium
(p < .04) (Table HI). The efficiency of fat absorption did
not change (61.0 ± 5.3% to 60.3 ± 7.9%, p = NS).
However, fat absorption was inversely correlated with the
change in soluble fiber intake (r = .80, p ^ .02).
Stool output of the two patients treated with Diet
increased from 1,117 ± 329 to 1,334 ± 503 g/d. Treatment with Diet alone did not influence the ability to
absorb food weight, calories, protein, fat, carbohydrate,
water, or sodium (Table III).
The percent changes in the efficiency of nutrient
absorption from baseline to the final week of study for
the GH+GLN+Diet-treated patients are shown in Figures
1 and 2 for the patients treated with Diet alone. The
percent changes in stool volumes are also shown.
DISCUSSION

Upon admission, the patients in this study were unable
to maintain adequate hydration or nutritional status with
enteral intake and thus required the parenteral administration of nutrients. Body weight was less than optimal
and the baseline determination of CHI identified
moderate-to-severe skeletal muscle depletion. Although

TABLE II

Enteral intake
Control
Weight (g/d)
Calories (kcal/d)*
Protein (g/d)
Fat (g/d)
Carbohydrate (g/d)
Total fiber (g/d)
Soluble fiber (g/d)
Water (L/d)
Sodium (mEq/d)||
•1 kcal = 4.184 kJ.
\p ^ .03 as control period.
tp ^ .002 vs control period.
§t> ^ .05 vs control iveriod.

GH + GLN + Diet
3352 ± 464
2692 ± 520
88.6 ± 18.6
96.1 ± 26.0
307.9 ± 51.2
12.42 ± 1.99
2.47 ± 0.44
2.826 ± 0.392
151.4 ± 24.4

Week 4
Diet
3368 ± 351
3553 ± 483
135.2 ± 24.6
115.6 ± 24.5
406.9 ± 27.5
19.7 ± 0.15
3.69 ± 0.05
2.439 ± 0.143
185.3 ± 21.1

GH + GLN + Diet
3540 ± 414
2367 ± 374
86.7 ± 15.1
44.9 ± 9.3t
347.0 ± 54.9
23.6 ± 3.5*
5.58 ± 1.37§
2.900 ± 0.368
162.3 ± 23.4

Diet
3913 ± 803
3433 ± 612
117.5 ± 19.4
73.0 ± 11.0
497.0 ± 95.2
24.7 ± 5.6
4.35 ± 0.9
2 840 ± 0.366
202.7 ± 35.5

Ucl
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TABLE III

Weight and nutrient absorption
Control
GH + GLN + Diet
(percent absorbed)

Weight (g/d)
Calories (kcal/d)t
Protein (g/d)
Fat (g/d)
Carbohydrate (g/d)
Water (L/d)
Sodium (mEq/d)ti

50.6
60.1
48.8
61.0
60.0
45.7
49.0

±
±
±
±
±
±
±

6.5
6.0
4.8
5.3
9.8
6.7
9.8

Week 4
Diet
(percent absorbed)

66.3
84.5
73.9
91.3
84.8
57.6
54.9

±
±
±
±
±
±
±

GH + GLN + Diet
(percent absorbed)

4.9
5.0
4.0§
4.2§
6.0
8A
20.3

68.2
74.3
63.0
60.3
81.5
65.0
69.6

±
±
±
±
±
i
±

Diet
(percent absorbed)

7.1*
5.0t
5.4?
7.9
5.3**
7.3tt
6.5§§

67.14
81.6
68.9
81.6
85.5
56.6
56.7

±
±
±
±
±
±
±

6.08
4.25
8.2
10.2
1.2
11.2
22.6

*p < .0001 ts control period.
t l k c a l = 4.184 kJ.
Xp ^ .003 «s control period.
§/> < .04 w G H + GLN + Diet.
\p < .006 t* control period.
**p < .02 is control period.
ftp ^ .002 us control period.
t t = 1 mEq = 1 mmol.
§§p < .04 «s control period.

patients with the short bowel syndrome are frequently
encouraged to increase enteral food intake in an attempt
to decrease dependency on parenteral nutrition, the
patients in this study had failed to adapt to the provision
of enteral nutrients.
The exogenous administration of growth hormone (or
its analogue) has been shown to influence bowel
adaptation by enhancing mucosal hyperplasia after
extensive intestinal resection in animals.25*26 Growth
hormone is also known to increase colonic mass and
biomechanical strength;27 these effects may enhance the
reservoir function of the colon or influence peristalsis,
thus prolonging transit time. In addition, IGF-1 production, which is regulated by growth hormone, has been
shown to enhance bowel hyperplasia and hypertrophy
in rats after extensive jejuno-ileal resection.28 Furthermore, exogenous growth hormone increases water and
sodium absorption in the small intestine and in the
colon29 and appears to regulate amino acid absorption.30
Glutamine is a primary fuel source for both the
enterocytes and the colonocytes and serves as an
essential precursor for purine and pyrimidine biosynthesis.7 Supplemental glutamine has been shown to
accelerate postresection hyperplasia,8 prevent intestinal
atrophy in humans receiving parenteral nutrition,31 and
enhance glucose9 and sodium absorption.10
Growth hormone in combination with glutamine may
exert an additive effect on bowel morphology and
function. IGF-1 induces ornithine decarboxylase,32 the
rate-limiting enzyme in the biosynthesis of polyamines,
which play a central role in intestinal cell growth and
proliferation.33 Glutamine is a required substrate for
ornithine decarboxylase and an essential precursor for
nucleotide biosynthesis. Animal studies have demonstrated that the inhibition of ornithine decarboxylase
prevents enhanced cellularity in residual bowel after
intestinal resection,34 whereas glutamine-supplemented
nutrition administered in combination with IGF-1 enhances protein deposition in the residual mucosa after
small bowel resection compared with trophic effects of
glutamine or IGF-1 alone.36 Furthermore, both growth
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FIG. 1. Changes in the efficiency of nutrient absorption and stool output
with growth hormone, glutamine, and diet Treatment with
GH+GLN+Diet produced significant changes in the efficiency of nutrient absorption. These changes resulted in a significant decrease in stool
output •/> < .0003, Xp ^ .03, Xp < .009, §/> < .008, \p < .01.
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Fte. 2. Changes in the efficiency of nutrient absorption and stool output
with diet alone. Treatment with Diet alone produced no change in the
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processes that may be enhanced by the provision of
bowel-specific fuels such as glutamine.
In addition to growth hormone and glutamine, the patients
in this study received a high-carbohydrate, low-fat diet
supplemented with fiber. Although controversy exists over
the role of diet in the management of the short bowel
syndrome, several studies have demonstrated that dietary
manipulation (eg, restricting fat) does not significantly
influence nutrient absorption.14"16 These authors argue that
clinicians should adopt a more liberal attitude regarding
the enteral diets of these patients. Others, however,
recommend diets restricted in fat,35-37 but high in
carbohydrate38 and specific fibers.39 A recent report has
documented that a high-carbohydrate, low-fat diet provided
for a 4-day period can decrease the fecal loss of calories
in short bowel patients with normal colons.38
The rationale for providing an increased carbohydrate
or fiber-containing diet to patients with short bowel
syndrome is that the malabsorbed carbohydrates and
nondigestible fibers pass into the colon, where they can
be fermented by bacteria to produce short-chain fatty
acids. These organic acids are rapidly absorbed by the
colonic mucosa and can be used for energy;40 thus,
some of the carbohydrate calories that would have
otherwise been lost because of upper-intestinal malabsorption can be salvaged by this process.41 Furthermore,
short-chain fatty acids are known to enhance sodium
and water absorption42 and exert trophic effects both
in the small intestine and in the colon.43 In addition to
their role in the production of short-chain fatty acids,
specific soluble fibers have been shown to prolong
gastrointestinal transit time1213 and elicit stimulatory
effects on small and large bowel mucosal growth and
cell proliferation.11,44 Thus, because all patients in our
study had colonic remnants, a high-carbohydrate, low-fat
diet supplemented with fiber was provided in an attempt
to enhance nutrient absorption. However, the provision
of this diet without glutamine or growth hormone failed
to alter nutrient absorption in two subjects.
Three weeks of combined therapy (GH+GLN+Diet)
significantly enhanced calorie, protein, carbohydrate,
water, and sodium absorptive efficiency. The effect of
this therapy on total caloric absorption was somewhat
blunted by the adverse effect of soluble fiber on fat
absorption. However, despite the addition of these
fermentable soluble fibers and other insoluble fibers
that typically increase stool bulk and weight,46 stool
output decreased 33.0 ± 10.0% (p < .01). These adaptive
changes were achieved in all GH+GLN+Diet-treated
patients, even though seven of the eight individuals had
undergone resection 5 to 11 years before participation
in the study.
Additional studies are now underway to determine if
this therapy can allow for a reduction or an elimination
in parenteral nutrient requirements. In addition, a
follow-up program is in progress to assess the long-term
effects of this therapy on nutritional status, body
composition, and liver and kidney function. Additional
studies are needed both to determine whether such
treatment would exert greater effects shortly after
resection and to better define the optimal diet,

particularly the type and quantity of fiber to admin
The use of this therapy in patients with high-o
ostomies has not been systematically evaluated
would most likely require further dietary modifies
In summary, the combined administration of e;
nous growth hormone, glutamine and a diet hit
complex carbohydrates and fiber and low in fat enha
nutrient absorption from the remnant bowel after m$
intestinal resection. These functional changes occ
after 3 weeks of therapy in a group of patients whe
previously failed to adapt to the provision of ei
nutrients. Additional study is needed to determine t
therapy can offer an alternative to long-term depenc
on total parenteral nutrition or intestinal transplant
for patients with the severe short bowel syndrome,
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